{
  "mri-denial": {
    "slug": "mri-denial",
    "title": "Appealing MRI Denials",
    "default_procedure": "MRI Scan",
    "tagline": "Insurance often denies MRIs as 'not medically necessary'—here’s how to overturn it.",
    "hero_h1": "Appeal Your MRI Denial",
    "hero_subhead": "Don’t let \"not medically necessary\" stop you from getting real answers.",
    "intro": "MRIs get denied all the time — usually because the insurer wants cheaper imaging first or claims your symptoms don’t justify the scan. But if your doctor ordered it, there’s a strong chance you can overturn the denial with a clear appeal explaining why the MRI is clinically necessary.",
    "common_denial_reasons": [
      "Not medically necessary",
      "Try X-ray or PT first",
      "Insufficient documentation of symptoms",
      "Out-of-network imaging provider"
    ],
    "how_we_help": "We help you explain your symptoms, clinical history, and physician recommendations in a way insurers actually respond to. Upload your denial and we’ll generate a polished appeal letter you can submit today.",
    "cta": "Start your MRI appeal — it takes about 3 minutes.",
    "faq": [
      {
        "question": "Can I appeal an MRI denial if I already had the scan done?",
        "answer": "Yes. Even if the MRI already happened, you can still appeal the denial and ask the insurer to cover it. Your appeal will focus on why the scan was medically necessary at the time it was ordered."
      },
      {
        "question": "Do I need my doctor to write a letter for my MRI appeal?",
        "answer": "It helps a lot. Our letter generator can work with what you have, but a short note from your doctor explaining why the MRI was necessary can significantly strengthen your appeal."
      },
      {
        "question": "What if my insurer says I should have tried an X-ray first?",
        "answer": "Many guidelines support going straight to MRI when symptoms or red flags are serious enough. Your appeal should explain your symptoms, risks, and why an MRI was the appropriate first test."
      }
    ],
    "evidence_snippets": [
      "Clinical guidelines support MRI when there are neurologic deficits, red-flag symptoms, or failure of conservative treatment.",
      "Delays in appropriate imaging can lead to missed or worsened diagnoses, increased morbidity, and higher downstream costs.",
      "The requested MRI is consistent with evidence-based practice and standard of care for this clinical presentation."
    ],
    "pubmed_search_terms": [
      "MRI appropriateness criteria low back pain red flags",
      "evidence-based guidelines MRI neurologic symptoms",
      "impact of delayed MRI diagnosis outcomes"
    ]
  },
  "ct-scan-denial": {
    "slug": "ct-scan-denial",
    "title": "Appealing CT Scan Denials",
    "default_procedure": "CT Scan",
    "tagline": "Step-by-step help appealing CT scan denials, especially for urgent or diagnostic cases.",
    "hero_h1": "Appeal Your CT Scan Denial",
    "hero_subhead": "When your doctor orders it, insurers shouldn’t second-guess them.",
    "intro": "CT scans are often denied because insurers think the issue isn’t urgent or could be diagnosed another way. A strong appeal clarifies why your doctor chose a CT and why delay could harm your health.",
    "common_denial_reasons": [
      "Not medically necessary",
      "Alternate imaging recommended first",
      "No documentation of urgent symptoms"
    ],
    "how_we_help": "We help you articulate the clinical urgency and rationale behind your CT order, backed by your doctor’s notes and your symptoms.",
    "cta": "Start your CT scan appeal.",
    "faq": [
      {
        "question": "Why did my insurer deny my CT scan?",
        "answer": "Common reasons include claiming your condition isn't urgent, preferring another test first, or saying your symptoms weren’t clearly documented. Your appeal should address each of those points directly."
      },
      {
        "question": "Do I need ER or urgent care notes for my CT appeal?",
        "answer": "They help. If you have records from an ER or urgent visit, including them can show why your doctor felt a CT scan was needed quickly."
      },
      {
        "question": "Can I still appeal if I went ahead and got the CT scan anyway?",
        "answer": "Yes. You can appeal after the fact and ask for coverage, especially if your results showed something significant or matched the doctor’s concerns."
      }
    ],
    "evidence_snippets": [
      "CT imaging is recommended in many guidelines when serious pathology is suspected and rapid diagnosis affects management.",
      "Timely CT scans can reduce morbidity and mortality in conditions such as suspected stroke, pulmonary embolism, or abdominal emergencies.",
      "The requested CT is consistent with standard of care and clinical decision rules for this presentation."
    ],
    "pubmed_search_terms": [
      "CT scan emergency department diagnostic yield",
      "guidelines CT imaging acute abdominal pain",
      "clinical decision rules CT imaging"
    ]
  },
  "sleep-study-denial": {
    "slug": "sleep-study-denial",
    "title": "Appealing Sleep Study Denials",
    "default_procedure": "Sleep Study (Polysomnography or Home Study)",
    "tagline": "Insurers frequently require a home test first—learn how to appeal this and win.",
    "hero_h1": "Appeal Your Sleep Study Denial",
    "hero_subhead": "Whether in-lab or at home, testing for sleep disorders shouldn’t be a battle.",
    "intro": "Sleep studies are denied constantly — often because insurers want a home test first or don’t see enough documented symptoms. Your appeal can fix this.",
    "common_denial_reasons": [
      "Must complete home sleep test first",
      "Insufficient symptoms documented",
      "Repeat test not covered"
    ],
    "how_we_help": "We help you clarify symptoms like snoring, apnea episodes, daytime sleepiness, and medical risks, all of which support medical necessity.",
    "cta": "Start your sleep study appeal.",
    "faq": [
      {
        "question": "What symptoms should I mention in my sleep study appeal?",
        "answer": "Include loud snoring, witnessed apneas, gasping, morning headaches, daytime sleepiness, trouble focusing, and any work or driving safety concerns."
      },
      {
        "question": "Can I appeal if I need an in-lab study instead of a home test?",
        "answer": "Yes. You can explain why an in-lab study is safer or more accurate in your case, such as other medical conditions or prior inconclusive home tests."
      },
      {
        "question": "Do I have to wait for another denial to appeal?",
        "answer": "No. You usually have the right to file an internal appeal after the first denial. Check your plan’s deadline and file as soon as you can."
      }
    ],
    "evidence_snippets": [
      "Polysomnography is the standard diagnostic tool for obstructive sleep apnea and related disorders.",
      "Untreated sleep apnea is associated with cardiovascular disease, metabolic disorders, and increased accident risk.",
      "Early diagnosis and treatment of sleep disorders reduce long-term healthcare costs and improve quality of life."
    ],
    "pubmed_search_terms": [
      "polysomnography obstructive sleep apnea guidelines",
      "untreated sleep apnea cardiovascular risk",
      "home sleep apnea testing vs polysomnography"
    ],
    "advocacy_resources": [
      {
        "name": "American Sleep Apnea Association",
        "url": "https://www.sleepapnea.org/",
        "description": "Patient advocacy organization with A.W.A.K.E. support network and CPAP assistance program."
      },
      {
        "name": "Alliance of Sleep Apnea Partners",
        "url": "https://www.apneapartners.org/",
        "description": "National nonprofit advocacy organization for sleep-disordered breathing."
      }
    ]
  },
  "cpap-denial": {
    "slug": "cpap-denial",
    "title": "Appealing CPAP Denials",
    "default_procedure": "CPAP Machine or Supplies",
    "default_condition": "Sleep Apnea",
    "tagline": "Helpful for OSA patients denied CPAP devices or replacement supplies.",
    "hero_h1": "Appeal Your CPAP Denial",
    "hero_subhead": "Insurers often deny CPAP coverage despite your doctor's prescription.",
    "intro": "Insurers regularly deny CPAP machines and supplies, often claiming test results don't meet criteria or that compliance wasn’t proven.",
    "common_denial_reasons": [
      "Doesn’t meet AHI thresholds",
      "Non-compliant usage",
      "Home sleep study insufficient",
      "Replacement schedule not allowed"
    ],
    "how_we_help": "We help you appeal by asking questions and helping you explain symptoms, severity, diagnostic testing, or medical need for supplies or equipment replacement.",
    "cta": "Start your CPAP appeal.",
    "faq": [
      {
        "question": "What if my AHI is just below their cutoff?",
        "answer": "Your appeal can emphasize symptoms, comorbid conditions, and functional impairment. Many guidelines support treatment even at moderate AHI when symptoms are significant."
      },
      {
        "question": "How do I address a \"non-compliance\" denial?",
        "answer": "Explain barriers you faced, how you’ve addressed them, and include any updated compliance data from your device if available."
      },
      {
        "question": "Can I appeal denials for CPAP supplies and replacement parts?",
        "answer": "Yes. Supplies are part of keeping treatment effective. Your appeal can explain why replacements are needed to maintain therapy."
      }
    ],
    "evidence_snippets": [
      "Medical literature supports CPAP as a standard treatment option for obstructive sleep apnea when prescribed by a physician.",
      "Coverage continuity helps patients maintain the treatment plan their doctor has established.",
      "Many guidelines recognize CPAP as an appropriate treatment for patients who meet clinical criteria."
    ],
    "pubmed_search_terms": [
      "CPAP therapy outcomes obstructive sleep apnea",
      "cost effectiveness CPAP cardiovascular",
      "adherence CPAP treatment health outcomes"
    ],
    "advocacy_resources": [
      {
        "name": "American Sleep Apnea Association",
        "url": "https://www.sleepapnea.org/",
        "description": "Patient advocacy organization with A.W.A.K.E. support network and CPAP assistance program."
      },
      {
        "name": "Alliance of Sleep Apnea Partners",
        "url": "https://www.apneapartners.org/",
        "description": "National nonprofit advocacy organization for sleep-disordered breathing."
      }
    ]
  },
  "pt-ot-st-denial": {
    "slug": "pt-ot-st-denial",
    "title": "Appealing Physical/Occupational/Speech Therapy Denials",
    "default_procedure": "Physical / Occupational / Speech Therapy",
    "tagline": "Appeal visit-limit denials and claims insurers mark as 'maintenance only.'",
    "hero_h1": "Appeal Your Physical, Occupational, or Speech Therapy Denial",
    "hero_subhead": "Movement, recovery, and communication aren’t optional.",
    "intro": "Insurers often deny therapy by calling it \"maintenance care\" or limiting visit counts. Your appeal can correct that.",
    "common_denial_reasons": [
      "Maintenance only, not restorative",
      "Exceeded allowed visit limit",
      "Insufficient documentation of functional deficits"
    ],
    "how_we_help": "We help you explain your functional goals, progress, and clinician recommendations clearly — things insurers typically overlook.",
    "cta": "Start your therapy appeal.",
    "faq": [
      {
        "question": "What counts as \"medical necessity\" for therapy?",
        "answer": "Showing that therapy improves or prevents decline in mobility, strength, speech, or daily activities usually supports medical necessity."
      },
      {
        "question": "Can I appeal if I’ve hit the plan’s visit limit?",
        "answer": "Yes. Many plans allow exceptions when continued therapy is medically necessary. Your appeal can include progress notes and updated goals."
      },
      {
        "question": "Should my therapist provide documentation?",
        "answer": "Absolutely. Progress notes, functional assessments, and a short letter from your therapist can significantly strengthen your appeal."
      }
    ],
    "evidence_snippets": [
      "Rehabilitation therapies improve function, reduce disability, and can prevent more costly interventions or institutional care.",
      "Continuing therapy beyond arbitrary visit limits may be necessary when measurable gains are still being made.",
      "Therapy is considered medically necessary when it is expected to result in significant, sustained improvement in function."
    ],
    "pubmed_search_terms": [
      "physical therapy functional outcomes chronic conditions",
      "occupational therapy activities of daily living improvement",
      "speech therapy effectiveness communication disorders"
    ],
    "advocacy_resources": [
      {
        "name": "American Physical Therapy Association",
        "url": "https://www.apta.org/",
        "description": "Professional organization advocating for physical therapy access and patient rights."
      }
    ]
  },
  "mental-health-denial": {
    "slug": "mental-health-denial",
    "title": "Appealing Mental Health Care Denials",
    "default_procedure": "Psychiatry / Therapy Services",
    "tagline": "Mental health parity laws exist — let’s make insurers follow them.",
    "hero_h1": "Appeal Your Mental Health Care Denial",
    "hero_subhead": "Mental health care is real health care.",
    "intro": "Therapy and psychiatric care get denied for absurd reasons like \"not medically necessary\" or \"not enough impairment.\" Many of these denials violate mental health parity laws.",
    "common_denial_reasons": [
      "Not medically necessary",
      "Too frequent or insufficient symptoms",
      "Provider out-of-network"
    ],
    "how_we_help": "We can help you explain your symptoms, risks, impact on daily life, and your clinician’s treatment plan — which often turns denials around quickly.",
    "cta": "Start your mental health appeal.",
    "faq": [
      {
        "question": "What are mental health parity laws?",
        "answer": "Parity laws generally require insurers to cover mental health and substance use care on equal terms with medical and surgical care. Denials based on stricter rules may violate these laws."
      },
      {
        "question": "Can I appeal if my insurer reduced my therapy frequency?",
        "answer": "Yes. You can appeal a reduction or limit by showing that your current frequency is medically necessary and supported by your therapist or psychiatrist."
      },
      {
        "question": "Do I need to share very personal details in my appeal?",
        "answer": "You can focus on symptoms and how they affect work, school, relationships, and self-care. It should be honest but doesn’t require every personal detail."
      }
    ],
    "evidence_snippets": [
      "Evidence-based psychotherapy and psychiatric medication reduce symptoms, relapse risk, and overall healthcare utilization.",
      "Under-treatment of mental health conditions is associated with increased emergency visits, hospitalizations, and disability.",
      "Parity regulations support coverage of mental health treatment consistent with standards of care."
    ],
    "pubmed_search_terms": [
      "mental health treatment outcomes psychotherapy medication",
      "parity law impact insurance coverage mental health",
      "under-treatment depression healthcare utilization"
    ],
    "advocacy_resources": [
      {
        "name": "NAMI - National Alliance on Mental Illness",
        "url": "https://www.nami.org/",
        "description": "Nation's largest grassroots mental health organization with 500+ local affiliates."
      },
      {
        "name": "Mental Health America",
        "url": "https://mhanational.org/",
        "description": "Nation's leading community-based nonprofit addressing mental health needs."
      }
    ]
  },
  "infusion-therapy-denial": {
    "slug": "infusion-therapy-denial",
    "title": "Appealing Infusion Therapy Denials",
    "default_procedure": "Infusion Therapy",
    "tagline": "Covers IVIG, chemo, biologics, and more.",
    "hero_h1": "Appeal Your Infusion Therapy Denial",
    "hero_subhead": "When your doctor orders infusion therapy, insurers shouldn't stand in the way.",
    "intro": "Insurers deny infusions due to cost, preferred site-of-care, or claims of \"non-medical necessity.\" A strong appeal can reverse this.",
    "common_denial_reasons": [
      "Not medically necessary",
      "Wrong site-of-care (home vs hospital)",
      "Step therapy required first"
    ],
    "how_we_help": "We help you explain your diagnosis, risks of delaying treatment, and why the ordered site-of-care is necessary.",
    "cta": "Start your infusion appeal.",
    "faq": [
      {
        "question": "What is \"site-of-care\" and why does it matter?",
        "answer": "Insurers sometimes require infusions at certain locations, like outpatient centers instead of hospitals. Your appeal can explain why the chosen setting is safer or medically necessary."
      },
      {
        "question": "Can I appeal if they want me to switch to a different drug?",
        "answer": "Yes. Your appeal can explain why the prescribed medication is clinically appropriate and why alternatives may be less effective or riskier in your case."
      },
      {
        "question": "What if delaying infusion could make my condition worse?",
        "answer": "Make that explicit. Appeals are stronger when they clearly describe the risks of delay, including organ damage, flare-ups, or hospitalizations."
      }
    ],
    "evidence_snippets": [
      "Timely administration of infusion therapies reduces disease activity and prevents irreversible organ damage in many conditions.",
      "Site-of-care should be determined based on clinical safety and stability, not solely cost.",
      "Step therapy policies should not override evidence-based prescribing when prior treatments have failed or are contraindicated."
    ],
    "pubmed_search_terms": [
      "infusion therapy outcomes autoimmune",
      "site-of-care infusion safety home vs hospital",
      "step therapy impact biologic treatment delays"
    ],
    "alternatives": [
      "Some infused medications have subcutaneous versions that may have different coverage status.",
      "Ask your provider about biosimilars which may be on a preferred tier with your insurer.",
      "Home infusion vs. hospital/clinic infusion may have different coverage — discuss options with your provider."
    ],
    "assistance_programs": [
      {
        "name": "EntyvioConnect (Entyvio)",
        "url": "https://www.entyvio.com/copay-support",
        "description": "Eligible patients may pay as little as $5 per dose. Max $20,000/year benefit for commercial insurance."
      },
      {
        "name": "Janssen CarePath (Remicade, Simponi Aria)",
        "url": "https://www.jnjwithme.com/",
        "description": "Copay assistance and patient assistance programs for J&J infused medications."
      },
      {
        "name": "Genentech Access Solutions (Rituxan, Ocrevus)",
        "url": "https://www.genentech-access.com/",
        "description": "Copay assistance and patient assistance for Genentech infused therapies."
      },
      {
        "name": "Immune Deficiency Foundation Resources",
        "url": "https://primaryimmune.org/living-primary-immunodeficiency/get-support/find-other-support",
        "description": "Comprehensive list of manufacturer programs and independent foundations for infusion assistance."
      }
    ],
    "advocacy_resources": [
      {
        "name": "Global Healthy Living Foundation",
        "url": "https://www.ghlf.org/",
        "description": "Nonprofit advocating for patients with chronic conditions requiring infusion therapy."
      }
    ]
  },
  "ivig-denial": {
    "slug": "ivig-denial",
    "title": "Appealing IVIG Denials",
    "default_procedure": "IVIG Infusion",
    "tagline": "IVIG denials are common but often successfully appealed with proper documentation.",
    "hero_h1": "Appeal Your IVIG Denial",
    "hero_subhead": "IVIG denials are extremely common — but often reversible.",
    "intro": "IVIG denials often happen because insurers don't understand the exact diagnostic criteria or disease progression.",
    "common_denial_reasons": [
      "Insufficient documentation of autoimmune diagnosis",
      "Other treatments must be tried first",
      "Home infusion only"
    ],
    "how_we_help": "We help you explain diagnostic markers, prior treatments, symptom history, and clinical risks of delaying IVIG.",
    "cta": "Start your IVIG appeal.",
    "faq": [
      {
        "question": "Why is IVIG so commonly denied?",
        "answer": "IVIG is expensive, so insurers scrutinize it heavily. Denials often focus on technical criteria, missing labs, or step therapy requirements."
      },
      {
        "question": "What documentation should I include for IVIG appeals?",
        "answer": "Include lab results, biopsy findings, prior treatment history, neurologic or rheumatologic exams, and your specialist's notes."
      },
      {
        "question": "Can I appeal if they want me to try cheaper treatments again?",
        "answer": "Yes. Your appeal can show what you've already tried, why it failed, and why repeating it is unlikely to help and may be harmful."
      }
    ],
    "evidence_snippets": [
      "Professional medical guidelines include IVIG as a treatment option for various conditions when prescribed by a specialist.",
      "Your specialist's documentation of diagnosis and treatment rationale is essential for a successful appeal.",
      "Coverage determinations should follow disease-specific criteria rather than blanket cost-based denials."
    ],
    "pubmed_search_terms": [
      "IVIG autoimmune neuropathy guidelines",
      "IVIG treatment outcomes immune thrombocytopenia",
      "evidence-based indications for intravenous immunoglobulin"
    ],
    "alternatives": [
      "Subcutaneous immunoglobulin (SCIG) may be an alternative with different coverage criteria for some conditions.",
      "For some conditions, plasma exchange may be covered differently while you appeal.",
      "Ask your provider about different IVIG brands, as formulary coverage varies by manufacturer."
    ],
    "assistance_programs": [
      {
        "name": "Grifols Patient Assistance (Gamunex-C)",
        "url": "https://www.gamunex-c.com/patient-resources",
        "description": "Help with deductibles, copays, and coinsurance. Call 1-888-MYGAMUNEX (1-888-694-2686)."
      },
      {
        "name": "CSL Behring Patient Support (Privigen, Hizentra)",
        "url": "https://www.cslbehring.com/patients",
        "description": "Patient assistance for uninsured/underinsured. Copay support for commercially insured."
      },
      {
        "name": "Octapharma Copay Program (Octagam, Panzyga)",
        "url": "https://www.octapharmausa.com/patients",
        "description": "Eligible patients may pay as little as $0 per treatment with commercial insurance."
      },
      {
        "name": "Immune Deficiency Foundation Resources",
        "url": "https://primaryimmune.org/living-primary-immunodeficiency/get-support/find-other-support",
        "description": "Comprehensive list of manufacturer programs and independent foundations for IVIG assistance."
      },
      {
        "name": "GBS/CIDP Foundation Financial Resources",
        "url": "https://www.gbs-cidp.org/support/resources/financial-assistance-resources/",
        "description": "Financial assistance resources specifically for GBS and CIDP patients needing IVIG."
      }
    ],
    "advocacy_resources": [
      {
        "name": "Immune Deficiency Foundation",
        "url": "https://primaryimmune.org/",
        "description": "Leading nonprofit supporting patients with primary immunodeficiency diseases."
      },
      {
        "name": "GBS/CIDP Foundation International",
        "url": "https://www.gbs-cidp.org/",
        "description": "Support and advocacy for patients with Guillain-Barré syndrome and CIDP."
      }
    ]
  },
  "biologic-denial": {
    "slug": "biologic-denial",
    "title": "Appealing Biologic Medication Denials",
    "default_procedure": "Biologic Medication",
    "tagline": "Help appealing biologic denials for conditions like RA, Crohn's, and psoriasis.",
    "hero_h1": "Appeal Your Biologic Medication Denial",
    "hero_subhead": "Humira, Skyrizi, Stelara, Entyvio, and others are routinely denied.",
    "intro": "Biologics for RA, Crohn's, psoriasis and more are often denied for step therapy or \"insufficient severity.\"",
    "common_denial_reasons": [
      "Must try cheaper medications first",
      "Condition not severe enough",
      "Off-label use not covered"
    ],
    "how_we_help": "We help you articulate clinical severity, treatment failures, diagnostic evidence, and medical rationale that insurers need to see.",
    "cta": "Start your biologic appeal.",
    "faq": [
      {
        "question": "What is \"step therapy\" and how do I fight it?",
        "answer": "Step therapy means the insurer wants you to fail cheaper drugs first. Your appeal can show that you've already tried and failed them, or that they're unsafe or inappropriate for you."
      },
      {
        "question": "What if my biologic is off-label for my condition?",
        "answer": "Some off-label uses are still supported by strong evidence. Your appeal can cite studies and guidelines that support the prescription."
      },
      {
        "question": "Should my specialist be involved in my appeal?",
        "answer": "Yes, ideally. A short letter from your specialist explaining why this biologic is necessary can make a big difference."
      }
    ],
    "evidence_snippets": [
      "Professional guidelines include biologics as treatment options for various autoimmune conditions when prescribed by a specialist.",
      "Your rheumatologist, gastroenterologist, or dermatologist's treatment plan is key evidence for your appeal.",
      "Documentation of prior treatment attempts and their outcomes strengthens appeals for biologic coverage."
    ],
    "pubmed_search_terms": [
      "biologic therapy rheumatoid arthritis treat-to-target",
      "biologic agents inflammatory bowel disease guidelines",
      "delayed biologic treatment outcomes autoimmune"
    ],
    "alternatives": [
      "While fighting your denial, ask your provider about biosimilar options which may have different coverage status.",
      "Some conditions may respond to conventional DMARDs (like methotrexate) as a bridge while appealing.",
      "Different biologics with similar mechanisms may have better formulary status with your insurer."
    ],
    "assistance_programs": [
      {
        "name": "myAbbVie Assist (Humira, Skyrizi, Rinvoq)",
        "url": "https://www.abbvie.com/patients/patient-support/patient-assistance.html",
        "description": "Free medication for qualifying uninsured/underinsured patients. Income limits apply."
      },
      {
        "name": "HUMIRA Complete Savings Card",
        "url": "https://www.humira.com/humira-complete/cost-and-copay",
        "description": "Commercially insured patients may pay as little as $0/month. Not for government insurance."
      },
      {
        "name": "Skyrizi Complete Savings Card",
        "url": "https://www.skyrizi.com/skyrizi-complete/save-on-skyrizi-costs",
        "description": "Eligible commercially insured patients may pay as little as $0 per dose. Max $14,000/year benefit."
      },
      {
        "name": "Janssen CarePath (Stelara)",
        "url": "https://www.jnjwithme.com/patient/stelara/cost-support/",
        "description": "Eligible patients pay $5 per dose with commercial insurance. Patient assistance also available."
      },
      {
        "name": "EntyvioConnect (Entyvio)",
        "url": "https://www.entyvio.com/copay-support",
        "description": "Eligible patients may pay as little as $5 per dose. Max $20,000/year benefit for commercial insurance."
      },
      {
        "name": "COSENTYX Connect",
        "url": "https://www.cosentyx.com/all/treatment-cost",
        "description": "84% of eligible patients paid $0 out of pocket. Up to 2 years free while appealing denials."
      },
      {
        "name": "Enbrel Co-Pay Program",
        "url": "https://www.enbrel.com/support",
        "description": "Eligible commercially insured patients may pay as little as $0 per dose."
      }
    ],
    "advocacy_resources": [
      {
        "name": "Global Healthy Living Foundation",
        "url": "https://www.ghlf.org/",
        "description": "Patient advocacy for chronic disease including biologic medication access."
      }
    ]
  },
  "oxygen-therapy-denial": {
    "slug": "oxygen-therapy-denial",
    "title": "Appealing Oxygen Therapy Denials",
    "default_procedure": "Home Oxygen Therapy",
    "tagline": "Help appealing oxygen therapy denials when your doctor has prescribed it.",
    "hero_h1": "Appeal Your Oxygen Therapy Denial",
    "hero_subhead": "COPD and pulmonary patients are denied oxygen far too often.",
    "intro": "Oxygen therapy is frequently denied over narrow testing thresholds or documentation gaps.",
    "common_denial_reasons": [
      "O2 saturation not low enough",
      "Home oxygen setup not justified",
      "Equipment replacement too soon"
    ],
    "how_we_help": "We help you explain symptoms, functional limits, risks, and test results to support medical necessity.",
    "cta": "Start your oxygen therapy appeal.",
    "faq": [
      {
        "question": "Do I need a specific oxygen saturation number for coverage?",
        "answer": "Many plans use specific thresholds, but your appeal can explain your real-world symptoms, desaturations with activity, and other risk factors."
      },
      {
        "question": "Can I appeal replacement denials for oxygen equipment?",
        "answer": "Yes. Your appeal can document wear, malfunction, and safety issues with old equipment."
      },
      {
        "question": "Should I include my pulmonary function tests?",
        "answer": "If you have them, yes. PFTs, six-minute walk tests, and oximetry reports can all support your appeal."
      }
    ],
    "evidence_snippets": [
      "Your pulmonologist's prescription and clinical documentation are the foundation of a strong appeal.",
      "Medical guidelines support oxygen therapy for patients who meet specific clinical criteria determined by their physician.",
      "Coverage decisions should consider your physician's assessment of functional impairment and documented test results."
    ],
    "pubmed_search_terms": [
      "long term oxygen therapy survival COPD",
      "oxygen therapy chronic hypoxemia guidelines",
      "home oxygen functional outcomes pulmonary disease"
    ],
    "advocacy_resources": [
      {
        "name": "Pulmonary Fibrosis Foundation",
        "url": "https://www.pulmonaryfibrosis.org/",
        "description": "Advocates for oxygen access and has resources on the SOAR Act for Medicare oxygen coverage."
      },
      {
        "name": "COPD Foundation",
        "url": "https://www.copdfoundation.org/",
        "description": "National nonprofit supporting COPD patients with education, advocacy, and research."
      }
    ]
  },
  "wheelchair-denial": {
    "slug": "wheelchair-denial",
    "title": "Appealing Wheelchair or Mobility Aid Denials",
    "default_procedure": "Wheelchair / Mobility Device",
    "tagline": "Mobility is a medical necessity — not a luxury.",
    "hero_h1": "Appeal Your Wheelchair or Mobility Aid Denial",
    "hero_subhead": "Wheelchairs and mobility aids get denied constantly for bad reasons.",
    "intro": "Insurers often deny mobility devices due to coding issues, documentation gaps, or \"not medically necessary\" claims.",
    "common_denial_reasons": [
      "Not medically necessary",
      "Cheaper device required",
      "Insufficient documentation of mobility limitation"
    ],
    "how_we_help": "We help you present clear functional limitations, clinician recommendations, and why the specific device is medically required.",
    "cta": "Start your mobility appeal.",
    "faq": [
      {
        "question": "What should I say about my daily activities?",
        "answer": "Explain how walking or standing affects you, including pain, falls, fatigue, and whether you can safely get around at home or in the community without a device."
      },
      {
        "question": "Can I appeal for a power chair instead of a manual one?",
        "answer": "Yes. Your appeal should explain why you cannot effectively use a manual chair, such as limited arm strength or endurance."
      },
      {
        "question": "Should my PT or OT help with the appeal?",
        "answer": "If you have a mobility evaluation from PT or OT, including it with your appeal can be very persuasive."
      }
    ],
    "evidence_snippets": [
      "Appropriate mobility devices reduce fall risk, maintain independence, and can prevent institutionalization.",
      "Choosing the correct type of wheelchair based on functional needs is cost-effective over time.",
      "Coverage determinations should consider safety, independence, and long-term outcomes."
    ],
    "pubmed_search_terms": [
      "wheelchair prescription functional outcomes",
      "mobility aids fall risk reduction elderly",
      "power wheelchair cost effectiveness independence"
    ],
    "advocacy_resources": [
      {
        "name": "United Spinal Association",
        "url": "https://unitedspinal.org/",
        "description": "Leading nonprofit dedicated to empowering people with spinal cord injuries and disabilities."
      },
      {
        "name": "Amputee Coalition",
        "url": "https://amputee-coalition.org/",
        "description": "Advocates for mobility device access for the limb loss community."
      }
    ]
  },
  "surgery-denial": {
    "slug": "surgery-denial",
    "title": "Appealing Surgery Denials",
    "default_procedure": "Surgery",
    "tagline": "When your doctor says it’s necessary, insurers shouldn’t overrule them.",
    "hero_h1": "Appeal Your Surgery Denial",
    "hero_subhead": "Surgery denials often rely on outdated or incorrect standards.",
    "intro": "Surgeries get denied because insurers think conservative care hasn’t been exhausted or symptoms aren’t severe enough.",
    "common_denial_reasons": [
      "Conservative treatments not completed",
      "Insufficient imaging or clinical documentation",
      "Procedure considered elective"
    ],
    "how_we_help": "We help you document severity, prior treatments, imaging findings, and medical necessity.",
    "cta": "Start your surgery appeal.",
    "faq": [
      {
        "question": "What does \"conservative care\" mean in surgery denials?",
        "answer": "Insurers usually mean treatments like medication, physical therapy, or injections. Your appeal should show what you’ve tried and why surgery is now appropriate."
      },
      {
        "question": "Can I appeal if they called my surgery \"elective\"?",
        "answer": "Yes. Your appeal can explain the medical consequences of delaying surgery, including pain, disability, or progression of disease."
      },
      {
        "question": "Do I need my surgeon to help with the appeal?",
        "answer": "A short letter from your surgeon outlining the medical necessity, risks of delay, and expected benefits of surgery can be very helpful."
      }
    ],
    "evidence_snippets": [
      "For many conditions, timely surgery improves pain, function, and long-term outcomes compared to prolonged conservative care.",
      "Delaying indicated surgery may lead to irreversible damage or more complex procedures later.",
      "Coverage determinations should account for specialist recommendations and evidence-based surgical indications."
    ],
    "pubmed_search_terms": [
      "timing of surgery outcomes orthopedic",
      "conservative management vs surgery comparative effectiveness",
      "elective vs medically necessary surgery insurance"
    ]
  },
  "implantable-device-denial": {
    "slug": "implantable-device-denial",
    "title": "Appealing Implantable Device Denials",
    "default_procedure": "Implantable Device or Medical Implant",
    "tagline": "Implants can be life-changing — insurers shouldn’t deny them lightly.",
    "hero_h1": "Appeal Your Implantable Device Denial",
    "hero_subhead": "Spinal stimulators, cardiac devices, and pain pumps are often denied for cost reasons.",
    "intro": "Insurers often deny implants due to cost, labeling them \"experimental\" or requiring unnecessary steps.",
    "common_denial_reasons": [
      "Experimental or investigational",
      "Not medically necessary",
      "Alternative treatment recommended"
    ],
    "how_we_help": "We help you outline clinical justification, symptom history, and why non-implant treatments were insufficient.",
    "cta": "Start your implant appeal.",
    "faq": [
      {
        "question": "Why did they call my implant \"experimental\"?",
        "answer": "Insurers sometimes use older policy language that doesn’t reflect current evidence. Your appeal can cite up-to-date studies and guidelines."
      },
      {
        "question": "What if I’ve already tried other treatments?",
        "answer": "Your appeal should list each prior treatment, how long you tried it, and why it failed or caused side effects."
      },
      {
        "question": "Should my specialist provide device-specific information?",
        "answer": "Yes. Manufacturer and clinical data, plus your specialist’s letter, can directly counter \"experimental\" or \"not necessary\" claims."
      }
    ],
    "evidence_snippets": [
      "Implantable devices such as spinal cord stimulators have demonstrated efficacy in reducing pain and improving function in selected patients.",
      "Cardiac devices like ICDs and pacemakers reduce mortality in appropriately selected populations.",
      "Implant coverage decisions should align with FDA indications and specialty society guidelines."
    ],
    "pubmed_search_terms": [
      "spinal cord stimulation chronic pain outcomes",
      "implantable cardioverter defibrillator mortality benefit",
      "guidelines implantable medical devices indications"
    ]
  },
  "pain-management-denial": {
    "slug": "pain-management-denial",
    "title": "Appealing Pain Management Denials",
    "default_procedure": "Pain Management Treatment",
    "tagline": "Help appealing denials for pain procedures your doctor has recommended.",
    "hero_h1": "Appeal Your Pain Management Treatment Denial",
    "hero_subhead": "Pain care gets denied constantly — we can help reverse that.",
    "intro": "Pain treatments get denied because insurers love to call them \"experimental\" or require weeks of PT first.",
    "common_denial_reasons": [
      "Experimental / investigational",
      "Conservative care required first",
      "Not enough clinical documentation"
    ],
    "how_we_help": "We help you articulate diagnosis, severity, prior treatments, and clinical justification for your pain plan.",
    "cta": "Start your pain management appeal.",
    "faq": [
      {
        "question": "Why do they say my injections are \"experimental\"?",
        "answer": "Many interventional pain procedures have guideline support. Your appeal can reference those guidelines and your past treatment failures."
      },
      {
        "question": "Do I have to keep doing PT before getting pain procedures?",
        "answer": "Not always. If you’ve already tried PT or cannot tolerate it, your appeal should explain that and why procedures are now appropriate."
      },
      {
        "question": "Should I describe how pain affects my daily life?",
        "answer": "Yes. Include how pain limits walking, work, sleep, caregiving, and other activities. That helps show why treatment is medically necessary."
      }
    ],
    "evidence_snippets": [
      "Interventional pain procedures can reduce pain scores, improve function, and decrease reliance on systemic medications.",
      "For some patients, procedures provide safer, targeted relief than chronic opioid therapy.",
      "Coverage decisions should follow pain society guidelines and individualized treatment planning."
    ],
    "pubmed_search_terms": [
      "epidural steroid injection chronic back pain outcomes",
      "radiofrequency ablation facet joint pain effectiveness",
      "interventional pain management guidelines"
    ],
    "advocacy_resources": [
      {
        "name": "American Chronic Pain Association",
        "url": "https://www.theacpa.org/",
        "description": "Peer support and education for people living with chronic pain."
      },
      {
        "name": "U.S. Pain Foundation",
        "url": "https://uspainfoundation.org/",
        "description": "Nonprofit connecting people with pain to resources, support, and advocacy."
      }
    ]
  },
  "prenatal-denial": {
    "slug": "prenatal-denial",
    "title": "Appealing Prenatal Care Denials",
    "default_procedure": "Prenatal Care / Ultrasound",
    "tagline": "Pregnancy care should never be a fight.",
    "hero_h1": "Appeal Your Prenatal Care Denial",
    "hero_subhead": "Ultrasounds and prenatal monitoring are essential care.",
    "intro": "Prenatal care often gets denied due to coding errors or nonsense \"not medically necessary\" claims.",
    "common_denial_reasons": [
      "Too many ultrasounds",
      "Screening not medically necessary",
      "Provider out of network"
    ],
    "how_we_help": "We help you clarify risks, symptoms, and physician recommendations.",
    "cta": "Start your prenatal care appeal.",
    "faq": [
      {
        "question": "Why did they say I had too many ultrasounds?",
        "answer": "Some plans only expect a small number of scans. Your appeal can explain high-risk factors or complications that justified additional imaging."
      },
      {
        "question": "Can I appeal if they denied prenatal labs?",
        "answer": "Yes. Many labs are standard of care in pregnancy. Your appeal can reference guidelines and any risk factors you have."
      },
      {
        "question": "What if my OB is out-of-network?",
        "answer": "You can appeal in some cases, especially if there is limited access to in-network providers or continuity of care concerns."
      }
    ],
    "evidence_snippets": [
      "Adequate prenatal care and appropriate fetal monitoring are associated with better maternal and neonatal outcomes.",
      "High-risk pregnancies often require more frequent imaging or testing than uncomplicated pregnancies.",
      "Coverage should reflect obstetric guidelines and individualized risk factors, not a fixed number of visits or scans."
    ],
    "pubmed_search_terms": [
      "prenatal care outcomes maternal neonatal",
      "high risk pregnancy ultrasound frequency guidelines",
      "antenatal testing evidence-based recommendations"
    ],
    "advocacy_resources": [
      {
        "name": "March of Dimes",
        "url": "https://www.marchofdimes.org/",
        "description": "Leading nonprofit fighting for the health of all moms and babies."
      }
    ]
  },
  "breast-imaging-denial": {
    "slug": "breast-imaging-denial",
    "title": "Appealing Breast Imaging Denials",
    "default_procedure": "Mammogram / Breast MRI / Ultrasound",
    "tagline": "Early detection saves lives — denials shouldn’t stand in the way.",
    "hero_h1": "Appeal Your Breast Imaging Denial",
    "hero_subhead": "High-risk screening often gets denied — your appeal can fix that.",
    "intro": "Mammograms, ultrasounds, and breast MRIs can be denied when insurers claim you're not \"high-risk enough.\"",
    "common_denial_reasons": [
      "High-risk criteria not met",
      "Routine screening too early",
      "Diagnostic imaging not justified"
    ],
    "how_we_help": "We help you explain risk factors, symptoms, and why additional imaging was recommended.",
    "cta": "Start your breast imaging appeal.",
    "faq": [
      {
        "question": "What counts as \"high risk\" for extra breast imaging?",
        "answer": "Family history, genetic mutations, prior chest radiation, and certain biopsy results can all count. Your appeal should list your risk factors clearly."
      },
      {
        "question": "Can I appeal if they denied a diagnostic mammogram or MRI?",
        "answer": "Yes. Your appeal can explain your symptoms, prior imaging findings, and why your clinician ordered diagnostic testing instead of routine screening."
      },
      {
        "question": "Does age matter for my appeal?",
        "answer": "Many guidelines allow earlier or more frequent imaging for high-risk people. Your appeal can cite these exceptions."
      }
    ],
    "evidence_snippets": [
      "Appropriate breast imaging reduces late-stage cancer diagnoses and improves survival.",
      "High-risk populations benefit from supplemental imaging such as MRI in addition to mammography.",
      "Coverage decisions should consider individual risk rather than a one-size-fits-all age cutoff."
    ],
    "pubmed_search_terms": [
      "breast cancer screening high risk MRI",
      "supplemental breast MRI outcomes",
      "breast imaging guidelines high risk women"
    ],
    "advocacy_resources": [
      {
        "name": "National Breast Cancer Coalition",
        "url": "https://www.stopbreastcancer.org/",
        "description": "Grassroots advocacy organization dedicated to ending breast cancer through research and policy."
      },
      {
        "name": "Susan G. Komen",
        "url": "https://www.komen.org/",
        "description": "Leading breast cancer organization funding research and providing patient support."
      }
    ]
  },
  "ffs-denial": {
    "slug": "ffs-denial",
    "title": "Appealing Facial Feminization Surgery (FFS) Denials",
    "default_procedure": "Facial Feminization Surgery (FFS)",
    "default_condition": "Gender Dysphoria",
    "tagline": "Insurers often incorrectly classify FFS as cosmetic — appeals can change that.",
    "hero_h1": "Appeal Your FFS Denial",
    "hero_subhead": "Insurers often deny FFS incorrectly as \"cosmetic\" — your appeal can address this.",
    "intro": "FFS is frequently denied by insurers who misclassify it as cosmetic. Appeals succeed when they clearly document your diagnosis, your provider's clinical recommendations, and alignment with WPATH standards.",
    "common_denial_reasons": [
      "Incorrectly deemed cosmetic",
      "Insufficient documentation of gender dysphoria",
      "Missing mental health evaluation notes",
      "Provider out-of-network or no contract for FFS"
    ],
    "how_we_help": "We help you document dysphoria, functional impairments, safety concerns, and WPATH-consistent medical necessity. We also help present your provider’s clinical support in a way insurers respond to.",
    "cta": "Start your FFS appeal.",
    "faq": [
      {
        "question": "Why did my insurer call FFS \"cosmetic\"?",
        "answer": "Many plans use outdated language that ignores current medical and professional guidance. Your appeal can explain how FFS treats gender dysphoria and improves safety, not appearance for its own sake."
      },
      {
        "question": "Do I need letters from therapists or mental health providers?",
        "answer": "Often yes. Including letters that diagnose gender dysphoria and support FFS as medically necessary can significantly strengthen your appeal."
      },
      {
        "question": "Can I appeal if only some FFS procedures were denied?",
        "answer": "Yes. You can appeal specific components and explain how each one affects your dysphoria, safety, or ability to be perceived as your correct gender."
      }
    ],
    "evidence_snippets": [
      "Your provider's documentation of diagnosis and treatment recommendations is essential for your appeal.",
      "WPATH Standards of Care address facial gender-affirming procedures as part of comprehensive care.",
      "Professional guidelines can be cited in appeals to counter insurer claims that FFS is purely cosmetic."
    ],
    "pubmed_search_terms": [
      "facial feminization surgery quality of life gender dysphoria",
      "gender affirming facial surgery mental health outcomes",
      "WPATH facial gender affirming surgery medical necessity"
    ],
    "advocacy_resources": [
      {
        "name": "National Center for Transgender Equality",
        "url": "https://transequality.org/",
        "description": "Nation's leading social justice advocacy organization for transgender people."
      },
      {
        "name": "Transgender Law Center",
        "url": "https://transgenderlawcenter.org/",
        "description": "Legal organization advocating for transgender rights and providing legal resources."
      },
      {
        "name": "WPATH",
        "url": "https://www.wpath.org/",
        "description": "World Professional Association for Transgender Health - promotes evidence-based care and standards."
      }
    ]
  },
  "top-surgery-masc-denial": {
    "slug": "top-surgery-masc-denial",
    "title": "Appealing Transmasculine Top Surgery Denials",
    "default_procedure": "Chest Reconstruction (Top Surgery)",
    "default_condition": "Gender Dysphoria",
    "tagline": "If your provider recommended top surgery, we can help you appeal the denial.",
    "hero_h1": "Appeal Your Top Surgery Denial",
    "hero_subhead": "Insurers often demand outdated or unnecessary requirements — we help you push back.",
    "intro": "Top surgery denials typically rely on outdated guidelines or incorrect criteria. A strong appeal focuses on your provider's recommendations and alignment with current standards of care.",
    "common_denial_reasons": [
      "Not medically necessary",
      "BMI requirements or arbitrary weight rules",
      "Requests for excessive therapy letters",
      "Incorrectly labeled cosmetic"
    ],
    "how_we_help": "We help you cite WPATH standards, document dysphoria and functional limitations, and present your provider’s letter in a format insurers can’t easily ignore.",
    "cta": "Start your top surgery appeal.",
    "faq": [
      {
        "question": "Do I have to meet a specific BMI to get coverage?",
        "answer": "Many insurers use arbitrary BMI cutoffs that don’t reflect individualized risk. Your appeal can address safety planning without using BMI as an absolute barrier."
      },
      {
        "question": "Can I appeal if they want more therapy letters than WPATH suggests?",
        "answer": "Yes. You can point to WPATH standards and explain that excessive gatekeeping is not clinically justified."
      },
      {
        "question": "Should I talk about binding in my appeal?",
        "answer": "Yes, if it’s relevant. You can describe pain, skin damage, breathing issues, and functional problems from binding, which support medical necessity for surgery."
      }
    ],
    "evidence_snippets": [
      "Your provider's documentation and letters supporting the surgery are the foundation of a strong appeal.",
      "WPATH Standards of Care can be cited in appeals to counter arbitrary insurer requirements.",
      "Professional guidelines address criteria for chest reconstruction that your appeal can reference."
    ],
    "pubmed_search_terms": [
      "gender affirming chest surgery mental health outcomes",
      "top surgery transmasculine quality of life",
      "chest binding physical health effects"
    ],
    "advocacy_resources": [
      {
        "name": "National Center for Transgender Equality",
        "url": "https://transequality.org/",
        "description": "Nation's leading social justice advocacy organization for transgender people."
      },
      {
        "name": "Transgender Law Center",
        "url": "https://transgenderlawcenter.org/",
        "description": "Legal organization advocating for transgender rights and providing legal resources."
      },
      {
        "name": "WPATH",
        "url": "https://www.wpath.org/",
        "description": "World Professional Association for Transgender Health - promotes evidence-based care and standards."
      }
    ]
  },
  "top-surgery-fem-denial": {
    "slug": "top-surgery-fem-denial",
    "title": "Appealing Transfeminine Breast Augmentation Denials",
    "default_procedure": "Breast Augmentation (Gender-Affirming)",
    "default_condition": "Gender Dysphoria",
    "tagline": "Breast augmentation for transfeminine people is gender-affirming care, not cosmetic.",
    "hero_h1": "Appeal Your Breast Augmentation Denial",
    "hero_subhead": "Many insurers rely on outdated criteria — appeals often succeed with proper documentation.",
    "intro": "Gender-affirming breast augmentation is frequently denied as \"cosmetic,\" even when medically necessary. A proper appeal reframes the request according to WPATH and clinical needs.",
    "common_denial_reasons": [
      "Incorrectly deemed cosmetic",
      "Claim that hormones should be continued longer first",
      "Insufficient dysphoria documentation",
      "Provider out-of-network"
    ],
    "how_we_help": "We help you build a strong appeal documenting medical necessity, dysphoria reduction aligned with WPATH SOC8.",
    "cta": "Start your appeal.",
    "faq": [
      {
        "question": "How long do I have to be on hormones before appealing?",
        "answer": "Insurers sometimes require a minimum hormone duration, but this should be individualized. Your appeal can explain your actual development and ongoing dysphoria. Many plans reference the WPATH standards of care which have changed so checking the version in your plan documents can help."
      },
      {
        "question": "Should I include photos in my appeal?",
        "answer": "Most appeals focus on dysphoria, physical development, and mental health impact rather than photos."
      },
      {
        "question": "Can I appeal if I’m nonbinary or not fully out?",
        "answer": "Yes. The key is documenting your gender dysphoria, your goals, and your provider’s support, not a specific label or coming-out timeline."
      }
    ],
    "evidence_snippets": [
      "Gender-affirming breast procedures are associated with improved body image and mental health in transfeminine patients.",
      "Breast augmentation can reduce misgendering and social anxiety, improving daily functioning.",
      "Guidelines increasingly support chest procedures as medically necessary components of gender-affirming care."
    ],
    "pubmed_search_terms": [
      "gender affirming breast augmentation outcomes transfeminine",
      "chest surgery body image transgender women",
      "WPATH chest surgery medical necessity transfeminine"
    ],
    "advocacy_resources": [
      {
        "name": "National Center for Transgender Equality",
        "url": "https://transequality.org/",
        "description": "Nation's leading social justice advocacy organization for transgender people."
      },
      {
        "name": "Transgender Law Center",
        "url": "https://transgenderlawcenter.org/",
        "description": "Legal organization advocating for transgender rights and providing legal resources."
      },
      {
        "name": "WPATH",
        "url": "https://www.wpath.org/",
        "description": "World Professional Association for Transgender Health - promotes evidence-based care and standards."
      }
    ]
  },
  "electrolysis-denial": {
    "slug": "electrolysis-denial",
    "title": "Appealing Electrolysis & Gender-Affirming Hair Removal Denials",
    "default_procedure": "Electrolysis / Laser Hair Removal (Gender-Affirming)",
    "default_condition": "Gender Dysphoria",
    "tagline": "Hair removal is often required for surgeries — insurers still deny it as cosmetic.",
    "hero_h1": "Appeal Your Electrolysis Denial",
    "hero_subhead": "Gender-affirming hair removal is medically necessary for many people, especially pre-op.",
    "intro": "Electrolysis and laser hair removal are often necessary before genital surgeries and to reduce dysphoria. Insurers still deny them as cosmetic despite clear surgical guidelines.",
    "common_denial_reasons": [
      "Incorrectly classified as cosmetic",
      "Not deemed medically necessary for surgery prep",
      "Insufficient documentation or referral",
      "Claim that it is purely aesthetic"
    ],
    "how_we_help": "We help you show medical necessity and when applicable clarify surgical requirements that can help turn these denials around.",
    "cta": "Start your electrolysis appeal.",
    "faq": [
      {
        "question": "Why do surgeons require hair removal before some surgeries?",
        "answer": "Pre-op hair removal can prevent complications like hair growth where it shouldn’t be and reduce infection risk. Your appeal can cite your surgeon’s requirements."
      },
      {
        "question": "Can I appeal if I’m not having surgery but still need hair removal?",
        "answer": "Yes. Hair removal can still be medically necessary to treat severe dysphoria or safety concerns even when surgery isn’t planned."
      },
      {
        "question": "Do I need a referral from a surgeon or endocrinologist?",
        "answer": "It helps. A letter stating hair removal is medically necessary for your gender-affirming care can strengthen your appeal."
      }
    ],
    "evidence_snippets": [
      "Hair removal is a standard preoperative requirement in many genital reconstruction protocols.",
      "Gender-affirming hair removal can reduce dysphoria and improve mental health and social functioning.",
      "Classifying medically necessary hair removal as purely cosmetic is inconsistent with contemporary guidelines for gender-affirming care."
    ],
    "pubmed_search_terms": [
      "hair removal preoperative vaginoplasty protocol",
      "gender affirming hair removal mental health outcomes",
      "WPATH hair removal medical necessity transgender"
    ],
    "advocacy_resources": [
      {
        "name": "National Center for Transgender Equality",
        "url": "https://transequality.org/",
        "description": "Nation's leading social justice advocacy organization for transgender people."
      },
      {
        "name": "Transgender Law Center",
        "url": "https://transgenderlawcenter.org/",
        "description": "Legal organization advocating for transgender rights and providing legal resources."
      },
      {
        "name": "WPATH",
        "url": "https://www.wpath.org/",
        "description": "World Professional Association for Transgender Health - promotes evidence-based care and standards."
      }
    ]
  },
  "voice-therapy-denial": {
    "slug": "voice-therapy-denial",
    "title": "Appealing Voice Therapy Denials",
    "default_procedure": "Voice Therapy (Gender-Affirming)",
    "default_condition": "Gender Dysphoria",
    "tagline": "Voice therapy is medically necessary gender-affirming care — not elective.",
    "hero_h1": "Appeal Your Voice Therapy Denial",
    "hero_subhead": "Insurers often misclassify voice work as cosmetic or elective — which is incorrect.",
    "intro": "Gender-affirming voice therapy reduces dysphoria, improves safety, and supports communication. Denials often rely on outdated coverage policies.",
    "common_denial_reasons": [
      "Considered cosmetic",
      "No speech pathology notes provided",
      "Insufficient documentation of dysphoria or vocal strain",
      "Provider out-of-network"
    ],
    "how_we_help": "We help you explain clinical necessity, communication limitations, and dysphoria impacts — key elements insurers often overlook.",
    "cta": "Start your voice therapy appeal.",
    "faq": [
      {
        "question": "Why does my insurer think voice therapy is cosmetic?",
        "answer": "Old policies treat voice only as appearance-related. Your appeal can explain how misgendering, safety concerns, and vocal strain make therapy medically necessary."
      },
      {
        "question": "Do I need an evaluation from a speech-language pathologist?",
        "answer": "It’s very helpful. An SLP’s assessment of your current voice, goals, and any strain or pain can support medical necessity."
      },
      {
        "question": "Can I appeal if I’ve already started voice therapy and they won’t cover more sessions?",
        "answer": "Yes. Your appeal can show progress made so far and why continued sessions are needed to reach safe, sustainable vocal patterns. However, retroactive coverage for sessions already paid for may be more difficult to achieve if \"prior authorization\" is required."
      }
    ],
    "evidence_snippets": [
      "Gender-affirming voice therapy improves vocal satisfaction, reduces dysphoria, and can decrease vocal strain.",
      "Voice training can reduce misgendering and associated anxiety, improving daily functioning and mental health.",
      "Professional groups recognize gender-affirming voice therapy as a legitimate scope of speech-language pathology practice."
    ],
    "pubmed_search_terms": [
      "gender affirming voice therapy transgender outcomes",
      "voice therapy transgender women satisfaction dysphoria",
      "speech language pathology gender affirming voice care"
    ],
    "advocacy_resources": [
      {
        "name": "National Center for Transgender Equality",
        "url": "https://transequality.org/",
        "description": "Nation's leading social justice advocacy organization for transgender people."
      },
      {
        "name": "Transgender Law Center",
        "url": "https://transgenderlawcenter.org/",
        "description": "Legal organization advocating for transgender rights and providing legal resources."
      },
      {
        "name": "WPATH",
        "url": "https://www.wpath.org/",
        "description": "World Professional Association for Transgender Health - promotes evidence-based care and standards."
      }
    ]
  },
  "voice-surgery-denial": {
    "slug": "voice-surgery-denial",
    "title": "Appealing Voice Surgery Denials",
    "default_procedure": "Vocal Feminization / Masculinization Surgery",
    "default_condition": "Gender Dysphoria",
    "tagline": "Voice surgery is medically necessary for many trans people, not cosmetic.",
    "hero_h1": "Appeal Your Voice Surgery Denial",
    "hero_subhead": "Insurers frequently deny voice surgeries due to outdated criteria.",
    "intro": "Voice surgeries are life-changing and medically necessary for many trans people. Insurers often deny them as cosmetic despite evidence to the contrary.",
    "common_denial_reasons": [
      "Incorrectly labeled cosmetic",
      "Must complete voice therapy first",
      "Insufficient documentation of dysphoria",
      "Provider out-of-network"
    ],
    "how_we_help": "We help you build a WPATH-consistent appeal explaining why surgery is required and how conservative treatments were insufficient.",
    "cta": "Start your voice surgery appeal.",
    "faq": [
      {
        "question": "Do I have to do voice therapy before surgery for coverage?",
        "answer": "Some insurers require it, but your appeal can explain what you’ve tried, how effective it was, and why surgery is still necessary."
      },
      {
        "question": "Is voice surgery really considered medically necessary?",
        "answer": "For many people, yes. It can significantly reduce dysphoria and safety risks. Your appeal should connect the surgery directly to your health and functioning."
      },
      {
        "question": "Should I talk about misgendering in my appeal?",
        "answer": "Yes. Explain how your voice leads to misgendering, harassment, or avoidance of daily activities, which supports medical necessity."
      }
    ],
    "evidence_snippets": [
      "Gender-affirming voice surgery can produce durable pitch changes and improved gender congruence.",
      "Patients often report reduced dysphoria and improved social comfort after voice surgery.",
      "When voice therapy alone is insufficient, surgery is an evidence-supported next step for some patients."
    ],
    "pubmed_search_terms": [
      "gender affirming voice surgery outcomes pitch",
      "vocal feminization surgery satisfaction transgender women",
      "voice surgery transgender patients quality of life"
    ],
    "advocacy_resources": [
      {
        "name": "National Center for Transgender Equality",
        "url": "https://transequality.org/",
        "description": "Nation's leading social justice advocacy organization for transgender people."
      },
      {
        "name": "Transgender Law Center",
        "url": "https://transgenderlawcenter.org/",
        "description": "Legal organization advocating for transgender rights and providing legal resources."
      },
      {
        "name": "WPATH",
        "url": "https://www.wpath.org/",
        "description": "World Professional Association for Transgender Health - promotes evidence-based care and standards."
      }
    ]
  },
  "hrt-denial": {
    "slug": "hrt-denial",
    "title": "Appealing Hormone Therapy (HRT) Denials",
    "default_procedure": "Gender-Affirming Hormone Therapy",
    "default_condition": "Gender Dysphoria",
    "tagline": "When your doctor prescribes hormone therapy, denials can often be appealed.",
    "hero_h1": "Appeal Your Hormone Therapy Denial",
    "hero_subhead": "Denials often rely on outdated guidelines or incorrect coding.",
    "intro": "Hormone therapy denials often stem from coding errors, documentation issues, or outdated insurer requirements. A well-documented appeal can address these issues.",
    "common_denial_reasons": [
      "Not medically necessary",
      "Plan claims it doesn't cover hormone therapy",
      "Missing diagnosis codes (gender dysphoria ICD-10)",
      "Duration of therapy requirements"
    ],
    "how_we_help": "We help you fix coding issues, document dysphoria, and demonstrate clear medical necessity supported by WPATH and Endocrine Society guidelines.",
    "cta": "Start your HRT appeal.",
    "faq": [
      {
        "question": "Do I need a specific diagnosis code for HRT coverage?",
        "answer": "Often yes. Appeals are stronger when they clearly reference a diagnosis like gender dysphoria or gender incongruence plus your clinician's treatment plan."
      },
      {
        "question": "What if my plan says it doesn't cover gender-affirming hormones at all?",
        "answer": "Your appeal can argue that excluding medically necessary gender-affirming care is discriminatory and conflicts with current medical standards."
      },
      {
        "question": "Can I appeal dose or formulation changes they denied?",
        "answer": "Yes. Your appeal can explain why your current or requested dose and route are clinically appropriate and monitored by your provider."
      }
    ],
    "evidence_snippets": [
      "Your provider's prescription and documentation are the foundation of a strong HRT appeal.",
      "WPATH and Endocrine Society guidelines can be cited in appeals to support your provider's treatment plan.",
      "Proper diagnosis coding (ICD-10) is often key to successful hormone therapy appeals."
    ],
    "pubmed_search_terms": [
      "gender affirming hormone therapy mental health outcomes",
      "endocrine society clinical practice guideline gender dysphoria",
      "transgender hormone therapy quality of life"
    ],
    "alternatives": [
      "Generic formulations of estradiol and testosterone are often significantly cheaper and may have better coverage.",
      "Different delivery methods (pills vs patches vs injections) may have different coverage status with your insurer.",
      "GoodRx and similar discount programs can significantly reduce out-of-pocket costs for hormone prescriptions."
    ],
    "assistance_programs": [
      {
        "name": "Point of Pride HRT Access Fund",
        "url": "https://www.pointofpride.org/hrt-access-fund",
        "description": "Provides 18 months of HRT-related care including visits, labs, and prescriptions for qualifying trans individuals."
      },
      {
        "name": "FOLX HRT Care Fund",
        "url": "https://www.folxhealth.com/hrt-care-fund",
        "description": "Year-long grants covering hormone therapy, clinical visits, and lab work through FOLX telehealth."
      },
      {
        "name": "Plume (with Trans Lifeline discount)",
        "url": "https://getplume.co/",
        "description": "Telehealth HRT provider. Trans Lifeline members receive discounted rates. Accepts some insurance."
      },
      {
        "name": "GoodRx Prescription Savings",
        "url": "https://www.goodrx.com/",
        "description": "Free discount card that can significantly reduce costs for generic estradiol and testosterone at pharmacies."
      }
    ],
    "advocacy_resources": [
      {
        "name": "National Center for Transgender Equality",
        "url": "https://transequality.org/",
        "description": "Nation's leading social justice advocacy organization for transgender people."
      },
      {
        "name": "Transgender Law Center",
        "url": "https://transgenderlawcenter.org/",
        "description": "Legal organization advocating for transgender rights and providing legal resources."
      },
      {
        "name": "WPATH",
        "url": "https://www.wpath.org/",
        "description": "World Professional Association for Transgender Health - promotes evidence-based care and standards."
      }
    ]
  },
  "puberty-blocker-denial": {
    "slug": "puberty-blocker-denial",
    "title": "Appealing Puberty Blocker Denials",
    "default_procedure": "Puberty Blockers (GnRH Analogues)",
    "default_condition": "Gender Dysphoria",
    "tagline": "When your provider prescribes puberty blockers, denials can often be appealed.",
    "hero_h1": "Appeal Your Puberty Blocker Denial",
    "hero_subhead": "Puberty blocker denials often require strong appeals with proper documentation.",
    "intro": "Insurers often deny puberty blockers due to age requirements, documentation issues, or outdated policies. Your appeal should focus on your provider's recommendations and clinical guidelines.",
    "common_denial_reasons": [
      "Considered experimental",
      "Age requirements",
      "Missing mental health documentation",
      "Plan exclusion for gender affirming care"
    ],
    "how_we_help": "We help you align documentation with WPATH and pediatric endocrine guidelines to overturn these denials.",
    "cta": "Start your puberty blocker appeal.",
    "faq": [
      {
        "question": "Are puberty blockers really evidence-based?",
        "answer": "Yes. Puberty blockers have been used for decades and are included in multiple professional guidelines for treating early puberty and gender dysphoria."
      },
      {
        "question": "Do we need a mental health evaluation for coverage?",
        "answer": "Most insurers want documentation of gender dysphoria and a mental health professional's support. Your appeal can highlight those records."
      },
      {
        "question": "Can we appeal if the plan has a blanket exclusion?",
        "answer": "You can still appeal and argue that excluding medically necessary gender-affirming care is discriminatory and conflicts with current medical standards. The success of these arguments often depends on who the plans regulator is."
      }
    ],
    "evidence_snippets": [
      "Your provider's documentation and treatment plan are essential for a successful puberty blocker appeal.",
      "Professional guidelines from WPATH and pediatric endocrine societies can be cited in your appeal.",
      "GnRH analogues have been used for decades for various conditions and are included in clinical guidelines."
    ],
    "pubmed_search_terms": [
      "puberty suppression gender dysphoria outcomes",
      "GnRH analogue treatment transgender youth",
      "guidelines puberty blockers gender incongruence"
    ],
    "alternatives": [
      "Different GnRH analogue formulations (monthly vs. 3-month vs. implant) may have different coverage status.",
      "Ask your provider about which specific medication has the best formulary status with your insurer."
    ],
    "assistance_programs": [
      {
        "name": "Lupron Depot-PED Copay Assistance",
        "url": "https://www.lupronpedpro.com/",
        "description": "Eligible commercially insured patients may pay as little as $10 per prescription. Max $4,000-$7,000/year benefit."
      },
      {
        "name": "Abbott Patient Assistance Foundation (Lupron)",
        "url": "https://www.rxassist.org/pap-info/company-detail?CmpId=1",
        "description": "Free Lupron Depot for patients experiencing financial difficulties who meet eligibility criteria."
      },
      {
        "name": "Endo Pharmaceuticals PAP (Supprelin LA)",
        "url": "https://www.supprelinla.com/",
        "description": "Patient assistance program providing free medication to eligible uninsured/underinsured patients."
      },
      {
        "name": "Point of Pride HRT Access Fund",
        "url": "https://www.pointofpride.org/hrt-access-fund",
        "description": "While primarily for HRT, may assist with gender-affirming care navigation for trans youth (18+)."
      }
    ],
    "advocacy_resources": [
      {
        "name": "National Center for Transgender Equality",
        "url": "https://transequality.org/",
        "description": "Nation's leading social justice advocacy organization for transgender people."
      },
      {
        "name": "Transgender Law Center",
        "url": "https://transgenderlawcenter.org/",
        "description": "Legal organization advocating for transgender rights and providing legal resources."
      },
      {
        "name": "WPATH",
        "url": "https://www.wpath.org/",
        "description": "World Professional Association for Transgender Health - promotes evidence-based care and standards."
      }
    ]
  },
  "grs-denial": {
    "slug": "grs-denial",
    "title": "Appealing Gender-Affirming Genital Surgery Denials",
    "default_procedure": "Gender-Affirming Genital Surgery (GRS)",
    "default_condition": "Gender Dysphoria",
    "tagline": "When your provider recommends genital surgery, denials can often be appealed.",
    "hero_h1": "Appeal Your Genital Surgery Denial",
    "hero_subhead": "Insurers deny GRS using outdated, incorrect, or discriminatory criteria.",
    "intro": "Insurers frequently deny gender-affirming genital surgery coverage based on obsolete guidelines or arbitrary requirements. A strong appeal focuses on your provider's recommendations and WPATH criteria.",
    "common_denial_reasons": [
      "Considered cosmetic or elective",
      "Insufficient therapy letters",
      "Genital surgery exclusions",
      "Provider out-of-network or limited network"
    ],
    "how_we_help": "We help you document dysphoria, prior treatments, safety concerns, and World Professional Association for Transgender Health(WPATH) Standards of Care (SOC) criteria to strengthen your appeal.",
    "cta": "Start your genital surgery appeal.",
    "faq": [
      {
        "question": "Do I need to meet exact WPATH criteria to appeal?",
        "answer": "Your appeal can show how you meet or reasonably align with those criteria, and why additional gatekeeping isn’t clinically justified."
      },
      {
        "question": "Can I appeal exclusions that say genital surgery is never covered?",
        "answer": "You can argue that blanket exclusions conflict with current medical standards and may be discriminatory. Some plans reconsider after internal and external review."
      },
      {
        "question": "Should I discuss safety and mental health in my appeal?",
        "answer": "This is a personal choice, but explaining how surgery relates to your mental health, safety, and ability to function in daily life can be helpful."
      }
    ],
    "evidence_snippets": [
      "Your surgeon's and mental health provider's documentation are essential for a successful GRS appeal.",
      "WPATH Standards of Care criteria can be cited in appeals to counter arbitrary insurer requirements.",
      "Professional medical organization positions can be referenced to counter claims that GRS is elective or cosmetic."
    ],
    "pubmed_search_terms": [
      "gender affirming genital surgery outcomes quality of life",
      "vaginoplasty satisfaction transgender women mental health",
      "phalloplasty transgender men outcomes dysphoria"
    ],
    "advocacy_resources": [
      {
        "name": "National Center for Transgender Equality",
        "url": "https://transequality.org/",
        "description": "Nation's leading social justice advocacy organization for transgender people."
      },
      {
        "name": "Transgender Law Center",
        "url": "https://transgenderlawcenter.org/",
        "description": "Legal organization advocating for transgender rights and providing legal resources."
      },
      {
        "name": "WPATH",
        "url": "https://www.wpath.org/",
        "description": "World Professional Association for Transgender Health - promotes evidence-based care and standards."
      }
    ]
  },
  "fertility-preservation-denial": {
    "slug": "fertility-preservation-denial",
    "title": "Appealing Fertility Preservation Denials",
    "default_procedure": "Fertility Preservation Prior to treatment",
    "default_condition": "Gender Dysphoria",
    "tagline": "Many insurers must cover this when medically indicated — appeals often win.",
    "hero_h1": "Appeal Your Fertility Preservation Denial",
    "hero_subhead": "Egg or sperm preservation before gender-affirming, oncology, and other care can be medically necessary.",
    "intro": "Fertility preservation is critical for many trans people before starting HRT or undergoing surgery. Insurers frequently deny coverage due to outdated or discriminatory policies.",
    "common_denial_reasons": [
      "Not medically necessary",
      "Considered elective",
      "Plan excludes fertility services generally",
      "Incorrect coding for gender-affirming context"
    ],
    "how_we_help": "We help you reframe the request as medically necessary and supported by major medical societies, not elective.",
    "cta": "Start your fertility preservation appeal.",
    "faq": [
      {
        "question": "Why should fertility preservation be covered?",
        "answer": "Gender-affirming treatments can affect fertility. Preserving eggs or sperm beforehand is a medically recommended way to keep future family-building options open."
      },
      {
        "question": "What if my plan excludes all fertility treatment?",
        "answer": "Your appeal can argue that preserving fertility before medically necessary treatment is different from elective fertility treatment and should be considered part of comprehensive care."
      },
      {
        "question": "Do guidelines actually support fertility counseling and preservation?",
        "answer": "Many guidelines recommend discussing fertility options before starting treatments that can reduce fertility, including HRT and oncology."
      }
    ],
    "evidence_snippets": [
      "Clinical guidelines recommend discussing and offering fertility preservation options before treatments that may impair fertility.",
      "Transgender individuals often regret loss of fertility options when this is not addressed prior to treatment.",
      "Fertility preservation in this context is preventive care related to medically necessary treatment, not purely elective fertility enhancement."
    ],
    "pubmed_search_terms": [
      "fertility preservation transgender individuals guidelines",
      "counseling fertility options before gender affirming hormones",
      "fertility preservation oncology analogy standard of care"
    ],
    "advocacy_resources": [
      {
        "name": "National Center for Transgender Equality",
        "url": "https://transequality.org/",
        "description": "Nation's leading social justice advocacy organization for transgender people."
      },
      {
        "name": "Transgender Law Center",
        "url": "https://transgenderlawcenter.org/",
        "description": "Legal organization advocating for transgender rights and providing legal resources."
      },
      {
        "name": "WPATH",
        "url": "https://www.wpath.org/",
        "description": "World Professional Association for Transgender Health - promotes evidence-based care and standards."
      }
    ]
  },
  "glp1-denial": {
    "slug": "glp1-denial",
    "title": "Appealing GLP-1 Medication Denials",
    "default_procedure": "GLP-1 Medication (Ozempic, Wegovy, Mounjaro, etc.)",
    "tagline": "Weight and diabetes meds are not vanity drugs when they treat real disease.",
    "hero_h1": "Appeal Your GLP-1 Medication Denial",
    "hero_subhead": "Whether for diabetes or obesity, GLP-1s are often medically necessary — not optional extras.",
    "intro": "GLP-1 medications like semaglutide and tirzepatide are frequently denied because insurers say your diagnosis does not qualify, you have not tried enough alternatives, or your plan excludes weight-loss drugs entirely. But for many people with diabetes and obesity-related conditions, these medications are key to preventing serious complications.",
    "common_denial_reasons": [
      "Plan excludes weight-loss medications",
      "Patient does not meet BMI or comorbidity criteria",
      "Has not tried metformin or other oral agents first",
      "Dose or formulation not on formulary",
      "Off-label use not covered"
    ],
    "how_we_help": "We help you explain your medical history, prior treatments, and obesity or diabetes-related complications in a way that shows this medication is medically necessary, not cosmetic. We also help you respond to step-therapy requirements and plan exclusions.",
    "cta": "Start your GLP-1 appeal in a few minutes.",
    "faq": [
      {
        "question": "Can I appeal if my plan excludes weight-loss drugs?",
        "answer": "Yes. You can argue that your GLP-1 is treating serious health conditions like diabetes, sleep apnea, or cardiovascular risk rather than purely cosmetic weight loss. Your appeal can emphasize comorbidities, functional limits, and guideline support for using GLP-1s in high-risk patients."
      },
      {
        "question": "What if I have already tried other diabetes medications?",
        "answer": "List every medication you have tried, how long you used it, and what happened. If you had side effects, poor control, or complications, your appeal should connect those experiences to why a GLP-1 is now medically appropriate."
      },
      {
        "question": "Can I appeal if my A1c is not extremely high?",
        "answer": "Yes. Your appeal can highlight other risk factors like obesity, cardiovascular disease, kidney disease, or prior complications. GLP-1s are often used to reduce long-term risk, not only to fix very high A1c values."
      }
    ],
    "evidence_snippets": [
      "GLP-1 receptor agonists improve glycemic control and promote clinically meaningful weight loss in many patients with type 2 diabetes and obesity.",
      "Large outcome trials show some GLP-1 medications reduce cardiovascular events in people at high risk.",
      "Treating obesity and diabetes aggressively can prevent downstream complications such as heart disease, kidney failure, and disability."
    ],
    "pubmed_search_terms": [
      "GLP-1 receptor agonist cardiovascular outcomes trial",
      "semaglutide weight loss obesity randomized study",
      "tirzepatide type 2 diabetes glycemic control"
    ],
    "advocacy_resources": [
      {
        "name": "Obesity Action Coalition",
        "url": "https://www.obesityaction.org/",
        "description": "National nonprofit empowering those affected by obesity through advocacy, education and support."
      }
    ]
  },
  "migraine-med-denial": {
    "slug": "migraine-med-denial",
    "title": "Appealing Migraine Medication Denials",
    "default_procedure": "Migraine Medications (CGRP Inhibitors, Gepants, Triptans)",
    "tagline": "When migraines steal your life, treatment is not optional.",
    "hero_h1": "Appeal Your Migraine Medication Denial",
    "hero_subhead": "CGRP meds, gepants, and triptans are often denied until you push back.",
    "intro": "Newer migraine medications are frequently denied as too expensive, not medically necessary, or reserved for people who have failed a long list of older drugs. Even older triptans may be limited to a tiny number of pills per month. A good appeal tells your story clearly and aligns it with headache guidelines.",
    "common_denial_reasons": [
      "Must fail multiple older preventive medications first",
      "Quantity limits on acute migraine medications",
      "Condition not documented as chronic or severe enough",
      "Off-label use or non-formulary medication"
    ],
    "how_we_help": "We help you explain how often you have migraines, how they affect work and daily life, which medications you have tried before, and why your prescriber chose this treatment. We turn that into a structured appeal that speaks the insurer's language.",
    "cta": "Start your migraine appeal now.",
    "faq": [
      {
        "question": "What should I include about my migraine history?",
        "answer": "Include how many days per month you have headaches, how many are disabling, what symptoms you experience, and how they affect work, school, or caregiving. If you have an official diagnosis of chronic migraine, make sure that is clearly stated."
      },
      {
        "question": "How do I respond to step-therapy requirements?",
        "answer": "Your appeal should list all preventives and acute medications you have already tried, including side effects and treatment failures. If a required medication is unsafe or inappropriate for you, your doctor can explain why it should be skipped."
      },
      {
        "question": "Can I appeal quantity limits on triptans or gepants?",
        "answer": "Yes. You can appeal by showing how many migraines you actually have per month, how you currently ration medication, and how inadequate quantities lead to ER visits, urgent care, or missed work."
      }
    ],
    "evidence_snippets": [
      "CGRP-targeting therapies reduce monthly migraine days and improve quality of life in patients with episodic and chronic migraine.",
      "Effective migraine prevention can reduce the need for emergency visits and hospitalizations.",
      "Treating migraine adequately lowers disability and improves work productivity and daily functioning."
    ],
    "pubmed_search_terms": [
      "calcitonin gene related peptide monoclonal antibody migraine trial",
      "gepants acute migraine randomized controlled",
      "chronic migraine prevention guidelines"
    ],
    "advocacy_resources": [
      {
        "name": "American Migraine Foundation",
        "url": "https://americanmigrainefoundation.org/",
        "description": "Leading resource for migraine education, support, and advocacy."
      },
      {
        "name": "National Headache Foundation",
        "url": "https://headaches.org/",
        "description": "Promotes headache awareness and education, and provides patient resources."
      },
      {
        "name": "Alliance for Headache Disorders Advocacy",
        "url": "https://allianceforheadacheadvocacy.org/",
        "description": "Advocates for equitable policies for people with headache disorders."
      }
    ]
  },
  "asthma-biologic-denial": {
    "slug": "asthma-biologic-denial",
    "title": "Appealing Asthma Biologic Denials",
    "default_procedure": "Severe Asthma Biologic (Dupilumab, Omalizumab, etc.)",
    "tagline": "For severe asthma, biologics can be the difference between stability and the ICU.",
    "hero_h1": "Appeal Your Asthma Biologic Denial",
    "hero_subhead": "If inhalers and steroids are not enough, insurers should not stand in the way of the next step.",
    "intro": "Biologic medications for severe asthma, such as omalizumab, dupilumab, and others, are often denied because insurers say you have not met exact lab criteria, have not failed enough inhalers, or your asthma is not severe enough. These denials ignore how dangerous uncontrolled asthma can be.",
    "common_denial_reasons": [
      "Does not meet blood eosinophil or IgE thresholds",
      "Insufficient trial of high-dose inhaled corticosteroids and other controllers",
      "Asthma not documented as severe or uncontrolled",
      "Non-formulary biologic requested when a different one is preferred"
    ],
    "how_we_help": "We help you explain your asthma history, ER visits, oral steroid bursts, and test results so that an appeal clearly shows you meet guideline-based criteria for a biologic and that ongoing uncontrolled asthma is unsafe and costly.",
    "cta": "Start your asthma biologic appeal.",
    "faq": [
      {
        "question": "What counts as severe or uncontrolled asthma in an appeal?",
        "answer": "Frequent symptoms, night awakenings, multiple ER or urgent care visits, hospitalizations, or repeated steroid bursts are all signs of uncontrolled asthma. Your appeal should list these events and any limitations on daily activities."
      },
      {
        "question": "Do I need specific lab results for a biologic?",
        "answer": "Many biologics require lab values such as eosinophil counts or IgE levels. If you have those results, include them and have your doctor explain how they match the criteria. If results are borderline, your doctor can still explain why treatment is appropriate."
      },
      {
        "question": "Can I appeal if the insurer wants me to use a different biologic?",
        "answer": "Yes. Your clinician can explain why the prescribed biologic is the best choice for you, based on your phenotype, comorbidities, prior response, or side effects with others."
      }
    ],
    "evidence_snippets": [
      "Biologic therapies for severe asthma reduce exacerbation rates and oral steroid use in appropriately selected patients.",
      "Uncontrolled asthma is associated with frequent ER visits, hospitalizations, and impaired quality of life.",
      "Guidelines recommend escalation to biologic therapy when high-dose inhaled therapies do not adequately control disease."
    ],
    "pubmed_search_terms": [
      "severe asthma biologic therapy randomized trial",
      "omalizumab dupilumab mepolizumab exacerbation reduction",
      "GINA guideline severe asthma biologics"
    ],
    "advocacy_resources": [
      {
        "name": "Asthma and Allergy Foundation of America",
        "url": "https://aafa.org/",
        "description": "Leading patient advocacy organization for asthma and allergies, certified by National Health Council."
      },
      {
        "name": "Allergy & Asthma Network",
        "url": "https://allergyasthmanetwork.org/",
        "description": "Nonprofit patient outreach, education, advocacy and research organization."
      }
    ]
  },
  "eczema-biologic-denial": {
    "slug": "eczema-biologic-denial",
    "title": "Appealing Eczema Biologic Denials",
    "default_procedure": "Biologic or Targeted Therapy for Atopic Dermatitis",
    "tagline": "Severe eczema is not just dry skin — it is a serious inflammatory disease.",
    "hero_h1": "Appeal Your Eczema Biologic Denial",
    "hero_subhead": "When topical creams fail, insurers often fight advanced therapies. You can fight back.",
    "intro": "For moderate-to-severe atopic dermatitis, biologic drugs and targeted therapies can dramatically reduce itching, skin breakdown, and infections. Insurers frequently deny them as too expensive, not medically necessary, or not tried long enough after topical treatments.",
    "common_denial_reasons": [
      "Topical therapies and phototherapy not tried long enough",
      "Disease severity not documented as moderate-to-severe",
      "Non-formulary drug requested when another is preferred",
      "Off-label dosing or age not covered"
    ],
    "how_we_help": "We help you tell the story of your eczema: how much of your body is affected, how often your skin flares, any infections or hospital visits, and what treatments you have already tried. We structure this into an appeal that aligns with dermatology guidelines.",
    "cta": "Start your eczema biologic appeal.",
    "faq": [
      {
        "question": "How do I show that my eczema is severe enough?",
        "answer": "Describe how many areas of your body are affected, how often your skin cracks or bleeds, any infections or hospital visits, and how itching disrupts sleep, work, or school. Dermatology notes and photographs can also help demonstrate severity."
      },
      {
        "question": "Do I have to fail every cream and phototherapy first?",
        "answer": "Not always. Your appeal can explain what you have already used, why some treatments were not tolerated or practical, and why moving to a biologic is now appropriate based on guidelines and your dermatologist's judgment."
      },
      {
        "question": "Can children or adolescents be covered for eczema biologics?",
        "answer": "Yes, many biologics have pediatric indications. Your appeal should note the patient's age, prior therapies, pediatric dosing recommendations, and the impact of uncontrolled eczema on growth, sleep, and development."
      }
    ],
    "evidence_snippets": [
      "Biologic therapies for atopic dermatitis improve skin clearance, reduce itching, and enhance quality of life compared to standard topical treatments alone.",
      "Uncontrolled atopic dermatitis is associated with sleep disturbance, infections, and significant psychosocial burden.",
      "Guidelines support escalating to systemic or biologic treatments when topical therapies are insufficient for moderate-to-severe disease."
    ],
    "pubmed_search_terms": [
      "dupilumab atopic dermatitis randomized controlled trial",
      "systemic therapy moderate severe atopic dermatitis guidelines",
      "quality of life atopic dermatitis biologic therapy"
    ],
    "advocacy_resources": [
      {
        "name": "National Eczema Association",
        "url": "https://nationaleczema.org/",
        "description": "Largest patient advocacy organization serving Americans with eczema."
      }
    ]
  },
  "insulin-pump-cgm-denial": {
    "slug": "insulin-pump-cgm-denial",
    "title": "Appealing Insulin Pump and CGM Denials",
    "default_procedure": "Insulin Pump or Continuous Glucose Monitor",
    "tagline": "For many people with diabetes, diabetes tech is not a luxury — it is survival.",
    "hero_h1": "Appeal Your Insulin Pump or CGM Denial",
    "hero_subhead": "Insurers often set narrow criteria for diabetes technology. Your real-world data can change their minds.",
    "intro": "Insulin pumps and continuous glucose monitors (CGMs) help people with diabetes keep blood sugar in a safer range and avoid life-threatening highs and lows. Insurers often deny them for not meeting strict eligibility rules, being on the wrong diagnosis code, or preferring older, less effective approaches.",
    "common_denial_reasons": [
      "Diagnosis code or type of diabetes does not meet policy criteria",
      "Not enough documented episodes of hypoglycemia or hyperglycemia",
      "Failure to document multiple daily injections and frequent glucose testing",
      "Device not on the formulary or out-of-network supplier"
    ],
    "how_we_help": "We ask you questions to help provide information about A1c trends, episodes of severe lows or highs, and prior treatment history so your appeal shows why a pump or CGM is medically necessary, not just convenient.",
    "cta": "Start your insulin pump or CGM appeal.",
    "faq": [
      {
        "question": "What information should I include from my glucose records?",
        "answer": "Include examples of frequent lows, wide swings, or persistent high readings despite following your regimen. Downloaded reports from meters or existing CGMs can show patterns that justify advanced technology."
      },
      {
        "question": "Can people with type 2 diabetes ever get pumps or CGMs covered?",
        "answer": "Yes. Many policies allow coverage when there is intensive insulin use, high risk of hypoglycemia, or complications. Your appeal should highlight these factors and show why structured finger-stick testing is insufficient."
      },
      {
        "question": "What if the insurer wants a different brand of device?",
        "answer": "You can appeal by having your prescriber explain why a specific device is medically preferable for you, such as integration with your pump, alarm features, vision or dexterity issues, or prior problems with other brands."
      }
    ],
    "evidence_snippets": [
      "Continuous glucose monitoring reduces time spent in hypoglycemia and improves overall glycemic control compared with traditional self-monitoring alone.",
      "Insulin pump therapy can improve flexibility and glycemic outcomes in selected patients, especially those with type 1 diabetes.",
      "Better glycemic control reduces the risk of long-term complications such as kidney disease, neuropathy, and retinopathy."
    ],
    "pubmed_search_terms": [
      "continuous glucose monitoring randomized trial hypoglycemia",
      "insulin pump therapy type 1 diabetes outcomes",
      "technology-assisted diabetes care quality of life"
    ],
    "advocacy_resources": [
      {
        "name": "American Diabetes Association",
        "url": "https://diabetes.org/",
        "description": "Nation's leading voluntary health organization fighting diabetes through advocacy, research, and education."
      },
      {
        "name": "Beyond Type 1",
        "url": "https://beyondtype1.org/",
        "description": "Global diabetes community providing education, advocacy, and support for people with diabetes."
      }
    ]
  },
  "prosthetic-denial": {
    "slug": "prosthetic-denial",
    "title": "Appealing Prosthetic Limb Denials",
    "default_procedure": "Prosthetic Limb or Advanced Prosthetic Component",
    "tagline": "Mobility, independence, and work are not cosmetic goals.",
    "hero_h1": "Appeal Your Prosthetic Limb Denial",
    "hero_subhead": "When insurers push the cheapest option, you can push back with function and safety.",
    "intro": "People who use prosthetic limbs often face denials for new devices, replacements, or advanced components like microprocessor knees. Insurers may argue that a lower-level device is sufficient or that advanced features are not medically necessary.",
    "common_denial_reasons": [
      "Cheaper or more basic prosthetic considered adequate",
      "Replacement requested too soon according to policy",
      "Insufficient documentation of activity level or goals",
      "Advanced components labeled as convenience or luxury"
    ],
    "how_we_help": "We help you describe your daily activities, work demands, fall risks, and medical conditions in a way that shows why the prescribed device level is necessary for safe ambulation and independence.",
    "cta": "Start your prosthetic appeal.",
    "faq": [
      {
        "question": "How do I show that I need an advanced component?",
        "answer": "Describe your typical day, walking surfaces, job tasks, and any history of falls or near-falls. Your prosthetist can explain why a basic device cannot safely support those activities and how advanced components reduce risk."
      },
      {
        "question": "What if my insurer says my current prosthetic should last longer?",
        "answer": "Your appeal can include documentation of wear, fit problems, changes in limb shape, or activity level increases that make a replacement medically necessary even if arbitrary time limits have not been reached."
      },
      {
        "question": "Can I appeal if they only approve a device suited for limited indoor walking?",
        "answer": "Yes. If you need to walk outdoors, at work, or on uneven surfaces, your prosthetist can explain that your functional level requires a device designed for that activity, not a purely basic indoor limb."
      }
    ],
    "evidence_snippets": [
      "Appropriate prosthetic prescription is associated with improved mobility, reduced fall risk, and better participation in work and community life.",
      "Under-prescription of prosthetic technology can increase long-term costs by contributing to falls, injuries, and loss of independence.",
      "Prosthetic selection should be based on functional level, comorbidities, and goals rather than lowest upfront cost."
    ],
    "pubmed_search_terms": [
      "prosthetic limb functional outcomes microprocessor knee",
      "amputee mobility falls risk prosthesis",
      "cost effectiveness advanced prosthetic components"
    ],
    "advocacy_resources": [
      {
        "name": "Amputee Coalition",
        "url": "https://amputee-coalition.org/",
        "description": "National organization with 350+ support groups and peer support for limb loss community."
      }
    ]
  },
  "hearing-aid-denial": {
    "slug": "hearing-aid-denial",
    "title": "Appealing Hearing Aid and Cochlear Implant Denials",
    "default_procedure": "Hearing Aids or Cochlear Implant",
    "tagline": "Communication is a health need, not a luxury.",
    "hero_h1": "Appeal Your Hearing Aid or Cochlear Implant Denial",
    "hero_subhead": "Even when policies are restrictive, you may still be able to win coverage for medically necessary hearing devices.",
    "intro": "Many plans exclude hearing aids entirely or only cover very limited devices for certain ages. Cochlear implants may be denied for not meeting audiologic criteria. Appeals can focus on the health, safety, and developmental impact of untreated hearing loss.",
    "common_denial_reasons": [
      "Plan excludes hearing aids as a benefit",
      "Hearing loss not severe enough by plan criteria",
      "Age limits or frequency limits on devices",
      "Cochlear implant criteria not fully met"
    ],
    "how_we_help": "We help you present your reports, speech and language impacts, workplace communication needs, safety concerns, and developmental risks so your appeal shows why a hearing device is medically necessary.",
    "cta": "Start your hearing device appeal.",
    "faq": [
      {
        "question": "Can I appeal if my plan excludes hearing aids?",
        "answer": "You can still appeal by emphasizing that untreated hearing loss affects safety, mental health, and ability to work or learn. Success varies by plan, but a strong appeal can sometimes lead to exceptions or partial coverage."
      },
      {
        "question": "What documentation should I include?",
        "answer": "Include audiograms, speech discrimination scores, notes from audiologists or ENT specialists, and descriptions of how hearing loss affects daily life, school, or work. For children, include information about speech and language development."
      },
      {
        "question": "What about cochlear implant denials?",
        "answer": "Your appeal should address each criterion in the policy, include updated audiology testing, and have your implant team explain why an implant is necessary to achieve functional hearing despite hearing aids."
      }
    ],
    "evidence_snippets": [
      "Untreated hearing loss is associated with social isolation, depression, and cognitive decline in adults.",
      "Early access to amplification or cochlear implantation improves language and educational outcomes in children with significant hearing loss.",
      "Hearing devices can reduce safety risks related to environmental awareness, such as hearing alarms and traffic."
    ],
    "pubmed_search_terms": [
      "hearing aid outcomes quality of life adult hearing loss",
      "cochlear implant speech language development children",
      "hearing loss cognitive decline association"
    ],
    "advocacy_resources": [
      {
        "name": "Hearing Loss Association of America",
        "url": "https://www.hearingloss.org/",
        "description": "Nation's leading organization for people with hearing loss, with 200 local chapters."
      }
    ]
  },
  "genetic-testing-denial": {
    "slug": "genetic-testing-denial",
    "title": "Appealing Genetic Testing Denials",
    "default_procedure": "Genetic or Genomic Testing",
    "tagline": "Genetic answers can change treatment, screening, and family planning.",
    "hero_h1": "Appeal Your Genetic Testing Denial",
    "hero_subhead": "When testing could change your care, insurers should not dismiss it as unnecessary.",
    "intro": "Genetic and genomic tests are often denied as experimental, not medically necessary, or not covered for your specific indication. For many conditions, however, test results directly affect treatment choices, cancer screening, or family risk.",
    "common_denial_reasons": [
      "Test considered experimental or investigational",
      "Patient does not meet narrow family history criteria",
      "Gene panel larger than policy allows",
      "Testing ordered by non-specialist provider"
    ],
    "how_we_help": "We help you show how test results will change management, summarize relevant family history, and map your situation to guideline-based indications for testing.",
    "cta": "Start your genetic testing appeal.",
    "faq": [
      {
        "question": "How do I show that genetic testing will change my care?",
        "answer": "Have your clinician explain how positive, negative, or uncertain results would affect medication choice, surveillance imaging, surgery, or recommendations for relatives. Appeals are strongest when the link between results and action is clear."
      },
      {
        "question": "What if my family history is complicated or incomplete?",
        "answer": "Your appeal can still describe known relatives with relevant cancers or conditions, and explain any barriers to obtaining more information. Genetic counselors are skilled at working with incomplete pedigrees and can support testing when risk is still elevated."
      },
      {
        "question": "Can I appeal broad gene panel denials?",
        "answer": "Yes. Your clinician or genetic counselor can justify why a panel is more appropriate than single-gene testing, especially when multiple syndromes could explain your or your family's history."
      }
    ],
    "evidence_snippets": [
      "Genetic testing for hereditary cancer syndromes can guide screening, prophylactic surgery, and targeted therapy.",
      "Identifying pathogenic variants allows cascade testing of at-risk relatives, enabling early detection and prevention.",
      "Professional guidelines support genetic evaluation when personal or family history suggests an inherited risk."
    ],
    "pubmed_search_terms": [
      "hereditary cancer genetic testing guidelines BRCA Lynch",
      "clinical utility multigene panel testing oncology",
      "cascade genetic testing prevention outcomes"
    ],
    "advocacy_resources": [
      {
        "name": "National Society of Genetic Counselors",
        "url": "https://www.nsgc.org/",
        "description": "Professional society advocating for genetic counseling and testing access."
      },
      {
        "name": "FORCE: Facing Our Risk of Cancer Empowered",
        "url": "https://www.facingourrisk.org/",
        "description": "Advocacy for hereditary cancer testing and support."
      }
    ]
  },
  "pet-scan-denial": {
    "slug": "pet-scan-denial",
    "title": "Appealing PET Scan Denials",
    "default_procedure": "Positron Emission Tomography (PET) Scan",
    "tagline": "When staging or restaging cancer, the right scan matters.",
    "hero_h1": "Appeal Your PET Scan Denial",
    "hero_subhead": "PET scans are often key for cancer staging and treatment decisions — and often denied on cost grounds.",
    "intro": "PET scans are widely used in oncology and some neurologic and cardiac conditions, but insurers frequently deny them as not medically necessary, outside of policy indications, or unnecessary compared with CT alone.",
    "common_denial_reasons": [
      "PET not on policy list for this cancer type or stage",
      "Alternative imaging considered sufficient",
      "Repeat PET within restricted time window",
      "Non-oncologic use considered experimental"
    ],
    "how_we_help": "We help explain how PET results will affect treatment decisions, show that your situation matches guideline-based indications, and address concerns about repeated or off-label use.",
    "cta": "Start your PET scan appeal.",
    "faq": [
      {
        "question": "When is a PET scan usually considered medically necessary?",
        "answer": "Many cancer guidelines recommend PET for initial staging, assessing treatment response, or evaluating suspected recurrence in specific cancers. Your appeal should reference those guidelines and your exact clinical question."
      },
      {
        "question": "Can I appeal a denial for a repeat PET scan?",
        "answer": "Yes. Your appeal can explain why new symptoms, lab changes, or treatment milestones make a repeat scan important now, and how results will alter the treatment plan."
      },
      {
        "question": "What about PET scans for non-cancer conditions?",
        "answer": "Some neurologic or cardiac PET scans have established roles. Your specialist can cite evidence and explain why PET, and not another test, is needed for accurate diagnosis or risk assessment."
      }
    ],
    "evidence_snippets": [
      "PET imaging improves staging accuracy in many cancers, which can change surgical and systemic treatment decisions.",
      "PET scans are useful in assessing metabolic response to therapy and detecting residual or recurrent disease.",
      "Guidelines specify indications where PET is preferred or recommended over conventional imaging alone."
    ],
    "pubmed_search_terms": [
      "PET CT oncology staging treatment decisions",
      "FDG PET response assessment cancer outcomes",
      "PET indications guideline tumor staging"
    ]
  },
  "bariatric-surgery-denial": {
    "slug": "bariatric-surgery-denial",
    "title": "Appealing Bariatric Surgery Denials",
    "default_procedure": "Metabolic or Bariatric Surgery",
    "default_condition": "Obesity",
    "tagline": "Bariatric surgery treats a disease — it is not a cosmetic shortcut.",
    "hero_h1": "Appeal Your Bariatric Surgery Denial",
    "hero_subhead": "When obesity is harming your health, surgery may be the evidence-based treatment.",
    "intro": "Bariatric surgery is one of the most effective treatments for severe obesity and related conditions, yet many plans deny coverage based on BMI thresholds, documentation technicalities, or blanket exclusions for weight-loss procedures.",
    "common_denial_reasons": [
      "BMI or comorbidity criteria not met on paper",
      "Insufficient documentation of supervised weight-loss attempts",
      "Plan excludes bariatric surgery as a benefit",
      "Required evaluations or classes not documented"
    ],
    "how_we_help": "We help you gather weight history, comorbid conditions, prior supervised programs, and multidisciplinary evaluations to show that bariatric surgery is medically necessary and consistent with major guidelines.",
    "cta": "Start your bariatric surgery appeal.",
    "faq": [
      {
        "question": "What if I have not completed a long supervised diet program?",
        "answer": "Your appeal can explain attempts you have made to lose weight, including structured and unstructured efforts, and why further delay would worsen health risks. Your surgeon can also explain how rigid program requirements may not reflect current evidence."
      },
      {
        "question": "How do I document obesity-related health problems?",
        "answer": "Include diagnoses such as diabetes, sleep apnea, hypertension, fatty liver disease, joint disease, and any hospitalizations or limitations caused by weight. Laboratory results and sleep studies can be helpful."
      },
      {
        "question": "Can I appeal a plan exclusion on bariatric surgery?",
        "answer": "You can argue that excluding evidence-based treatment for a chronic disease is inconsistent with modern medical standards. Success depends on plan type and state law, but strong appeals sometimes lead employers or plans to make exceptions."
      }
    ],
    "evidence_snippets": [
      "Bariatric surgery leads to substantial and sustained weight loss and can induce remission of type 2 diabetes in many patients.",
      "Surgery reduces long-term risks of cardiovascular disease, mortality, and obesity-related complications compared with non-surgical management for eligible patients.",
      "Professional societies consider bariatric surgery medically necessary treatment for selected individuals with severe obesity and comorbid conditions."
    ],
    "pubmed_search_terms": [
      "bariatric surgery long term outcomes mortality",
      "gastric bypass diabetes remission randomized",
      "metabolic surgery guidelines obesity treatment"
    ],
    "advocacy_resources": [
      {
        "name": "Obesity Action Coalition",
        "url": "https://www.obesityaction.org/",
        "description": "National nonprofit empowering those affected by obesity through advocacy, education and support."
      }
    ]
  },
  "substance-use-treatment-denial": {
    "slug": "substance-use-treatment-denial",
    "title": "Appealing Substance Use Treatment Denials",
    "default_procedure": "Substance Use Disorder Treatment (Inpatient, IOP, MAT)",
    "default_condition": "Substance Use Disorder",
    "tagline": "Addiction is a chronic medical condition — treatment should be covered like any other.",
    "hero_h1": "Appeal Your Substance Use Treatment Denial",
    "hero_subhead": "When your life or your loved one's life is at stake, coverage denials are not acceptable.",
    "intro": "Detox, rehab, medication-assisted treatment, and intensive outpatient programs for substance use disorders are often denied or cut short, even though mental health parity laws require comparable coverage to medical conditions.",
    "common_denial_reasons": [
      "Lower level of care deemed sufficient",
      "Length of stay considered longer than medically necessary",
      "Medication-assisted treatment limited or not covered",
      "Plan claims no benefit for residential or certain program types"
    ],
    "how_we_help": "We help you explain the relapse risk, withdrawal history, co-occurring conditions, and safety concerns so your appeal shows why the recommended level of care and duration are medically necessary.",
    "cta": "Start your substance use treatment appeal.",
    "faq": [
      {
        "question": "How does mental health parity help my appeal?",
        "answer": "Parity laws generally require that insurers use comparable criteria for mental health and substance use treatment as for medical care. Your appeal can point out if stricter limits or different rules are being applied to addiction treatment."
      },
      {
        "question": "What should my provider include in their letter?",
        "answer": "They should describe your diagnosis, prior treatment attempts, overdose history, medical and psychiatric comorbidities, home environment, and why a specific level of care (inpatient, residential, IOP, or MAT) is needed now."
      },
      {
        "question": "Can I appeal denial of medication-assisted treatment?",
        "answer": "Yes. Your appeal can explain how medications like buprenorphine, methadone, or naltrexone reduce overdose risk and support recovery, and why discontinuing or restricting them is dangerous."
      }
    ],
    "evidence_snippets": [
      "Medication-assisted treatment for opioid use disorder reduces overdose deaths and improves retention in care.",
      "Higher levels of care are often required after relapse, overdose, or failed lower-intensity treatment.",
      "Parity regulations support equitable coverage for substance use disorder treatment compared with other medical conditions."
    ],
    "pubmed_search_terms": [
      "medication assisted treatment opioid use disorder mortality",
      "inpatient versus outpatient substance use treatment outcomes",
      "mental health parity substance use insurance coverage"
    ],
    "advocacy_resources": [
      {
        "name": "Faces & Voices of Recovery",
        "url": "https://facesandvoicesofrecovery.org/",
        "description": "National advocacy organization for addiction recovery."
      },
      {
        "name": "Shatterproof",
        "url": "https://www.shatterproof.org/",
        "description": "National nonprofit fighting addiction through prevention, treatment access, and advocacy."
      }
    ]
  },
  "emergency-room-denial": {
    "slug": "emergency-room-denial",
    "title": "Appealing Emergency Room Visit Denials",
    "default_procedure": "Emergency Department Visit",
    "tagline": "If it felt like an emergency at the time, the law is usually on your side.",
    "hero_h1": "Appeal Your ER Visit Denial",
    "hero_subhead": "Insurers often second-guess emergencies after the fact — appeals can force them to apply the prudent layperson standard.",
    "intro": "Some insurers deny emergency department claims by saying your condition was not an emergency after all. This ignores the reality that patients must decide based on symptoms in the moment, not final diagnoses.",
    "common_denial_reasons": [
      "Condition judged non-emergent in hindsight",
      "Care could have been provided at urgent care or primary care",
      "Out-of-network emergency facility charges denied",
      "Observation vs. inpatient status disputes tied to the ER visit"
    ],
    "how_we_help": "We help you describe what you were experiencing before you went to the ER, connect those symptoms to reasonable fears of serious harm, and point to laws that require insurers to use the prudent layperson standard.",
    "cta": "Start your ER visit appeal.",
    "faq": [
      {
        "question": "What is the prudent layperson standard?",
        "answer": "It is a legal standard that requires emergency coverage if a reasonable person with your symptoms would think they might have a serious medical problem, even if the final diagnosis turns out to be minor."
      },
      {
        "question": "What should I include in my appeal about the ER visit?",
        "answer": "Describe your symptoms before going to the ER, any prior calls to nurse lines or doctors, why you thought it was serious, and what treatments or tests were done there. Include the ER doctor's notes if possible."
      },
      {
        "question": "Can I appeal out-of-network emergency bills?",
        "answer": "Yes. Many laws require emergency care to be covered at in-network cost sharing even if the hospital or clinician is out of network. Your appeal can reference these protections and ask for a corrected claim."
      }
    ],
    "evidence_snippets": [
      "Emergency patients must make care decisions without knowing the final diagnosis, which is why coverage rules focus on presenting symptoms.",
      "Delays in seeking emergency care can worsen outcomes in conditions such as heart attack, stroke, and sepsis.",
      "Regulations generally prohibit insurers from denying emergency claims solely because the final diagnosis appears non-urgent."
    ],
    "pubmed_search_terms": [
      "prudent layperson standard emergency department insurance",
      "emergency room visit denial insurance appeals",
      "delay in seeking emergency care outcomes"
    ]
  },
  "ambulance-transport-denial": {
    "slug": "ambulance-transport-denial",
    "title": "Appealing Ambulance Transport Denials",
    "default_procedure": "Ground or Air Ambulance Transport",
    "tagline": "If it was not safe to drive, ambulance care was not optional.",
    "hero_h1": "Appeal Your Ambulance Bill Denial",
    "hero_subhead": "Ambulance denials often ignore the safety and urgency that existed at the time.",
    "intro": "Ambulance rides are frequently denied as not medically necessary or out-of-network, leaving patients with large bills. Appeals should focus on why you could not safely travel by private car and how the situation met emergency criteria.",
    "common_denial_reasons": [
      "Transport judged non-emergent",
      "Patient considered stable for private vehicle",
      "Out-of-network ambulance provider",
      "No prior authorization"
    ],
    "how_we_help": "We help you explain the symptoms, risks, and scene circumstances that made ambulance transport the only safe option, and we help you reference protections for emergency transport where they apply.",
    "cta": "Start your ambulance transport appeal.",
    "faq": [
      {
        "question": "What counts as medically necessary ambulance transport?",
        "answer": "Situations where you could worsen or harm yourself by traveling in a private vehicle, such as chest pain, breathing difficulty, altered mental status, severe injuries, or when monitoring and interventions are needed during transport."
      },
      {
        "question": "Can I appeal if the ambulance was out of network?",
        "answer": "Yes. Your appeal can argue that in an emergency you could not shop for in-network transport and that emergency protections should limit your financial responsibility."
      },
      {
        "question": "Should I include the EMS run sheet?",
        "answer": "If you can obtain it, yes. The run sheet documents your vital signs, symptoms, and treatments in the field, which can strongly support medical necessity."
      }
    ],
    "evidence_snippets": [
      "EMS transport provides monitoring and interventions en route that are not available in private vehicles.",
      "Timely ambulance transport can improve outcomes in conditions such as stroke, trauma, and acute coronary syndromes.",
      "Emergency care protections are intended to prevent financial penalties for calling 911 in good faith."
    ],
    "pubmed_search_terms": [
      "emergency medical services transport outcomes",
      "ambulance use medical necessity criteria",
      "out of network ambulance surprise billing"
    ]
  },
  "glp1-denial-semaglutide-ozempic-denial": {
    "slug": "glp1-denial-semaglutide-ozempic-denial",
    "title": "Appealing Ozempic (Semaglutide) Denials",
    "default_procedure": "Ozempic (Semaglutide)",
    "default_condition": "Type 2 Diabetes",
    "tagline": "Ozempic treats more than blood sugar — it helps prevent serious complications.",
    "hero_h1": "Appeal Your Ozempic Denial",
    "hero_subhead": "If your clinician prescribed Ozempic, chances are there’s a strong medical reason.",
    "intro": "Ozempic (semaglutide) is often denied because insurers say your A1c is not high enough, you have not failed enough other medications, or they consider it too expensive. But Ozempic can be medically necessary to control diabetes, reduce complications, and address obesity-related risk.",
    "common_denial_reasons": [
      "Not meeting A1c or diagnosis criteria for coverage",
      "Plan requires failure of multiple cheaper diabetes medications first",
      "Dose or pen strength not on formulary",
      "Use for weight reduction considered non-covered"
    ],
    "how_we_help": "We help you list prior medications, side effects, comorbidities, and complication risks so your appeal shows why Ozempic is the right next step—not a cosmetic option.",
    "cta": "Start your Ozempic appeal.",
    "faq": [
      {
        "question": "What should I include about my diabetes history?",
        "answer": "Include your A1c trend, episodes of highs and lows, other conditions like kidney disease, neuropathy, or sleep apnea, and all medications you have tried. Make it clear that Ozempic is part of preventing further damage, not just lowering a number on paper."
      },
      {
        "question": "Can I appeal if my insurer says I must stay on older drugs?",
        "answer": "Yes. Your appeal can explain how you used those medications, why they did not work well enough or caused side effects, and why your prescriber chose Ozempic instead."
      }
    ],
    "evidence_snippets": [
      "Semaglutide improves glycemic control and promotes clinically meaningful weight loss in adults with type 2 diabetes.",
      "GLP-1 receptor agonists like semaglutide have shown cardiovascular benefit in high-risk patients.",
      "Aggressive management of type 2 diabetes reduces long-term complications such as kidney failure, neuropathy, and cardiovascular events."
    ],
    "pubmed_search_terms": [
      "semaglutide Ozempic type 2 diabetes cardiovascular outcomes",
      "semaglutide GLP-1 receptor agonist glycemic control",
      "GLP-1 agonist weight loss diabetes complications"
    ],
    "assistance_programs": [
      {
        "name": "Ozempic Savings Card",
        "url": "https://www.ozempic.com/savings-and-resources/save-on-ozempic.html",
        "description": "Pay as little as $25/month for up to 48 months with commercial insurance. Not for government programs."
      },
      {
        "name": "NovoCare - Ozempic",
        "url": "https://www.novocare.com/diabetes/products/ozempic.html",
        "description": "Savings offers, patient assistance program for eligible uninsured patients, and support resources."
      },
      {
        "name": "Novo Nordisk Patient Assistance Program",
        "url": "https://www.novocare.com/diabetes/help-with-costs/pap.html",
        "description": "Free medication for qualifying patients at or below 400% federal poverty level without insurance."
      }
    ],
    "advocacy_resources": [
      {
        "name": "American Diabetes Association",
        "url": "https://diabetes.org/",
        "description": "Nation's leading voluntary health organization fighting diabetes through advocacy, research, and education."
      },
      {
        "name": "Beyond Type 1",
        "url": "https://beyondtype1.org/",
        "description": "Global diabetes community providing education, advocacy, and support for people with diabetes."
      }
    ]
  },
  "glp1-denial-semaglutide-wegovy-denial": {
    "slug": "glp1-denial-semaglutide-wegovy-denial",
    "title": "Appealing Wegovy (Semaglutide) Denials",
    "default_procedure": "Wegovy (Semaglutide for Obesity)",
    "default_condition": "Obesity",
    "tagline": "Wegovy is obesity treatment, not vanity medicine.",
    "hero_h1": "Appeal Your Wegovy Denial",
    "hero_subhead": "When weight is damaging your health, Wegovy can be medically necessary care.",
    "intro": "Wegovy is frequently denied because plans exclude weight-loss drugs, require very specific BMI thresholds, or ignore obesity-related complications. Appeals can reframe Wegovy as treatment for a chronic disease that is harming your health, not a cosmetic choice.",
    "common_denial_reasons": [
      "Plan excludes anti-obesity medications entirely",
      "BMI criteria or comorbidity rules not met on paper",
      "Insufficient documentation of prior weight-loss attempts",
      "Dose strength not on formulary"
    ],
    "how_we_help": "We help you present your BMI history, obesity-related conditions, prior supervised and unsupervised weight-loss efforts, and functional limitations to show Wegovy is medically necessary obesity treatment.",
    "cta": "Start your Wegovy appeal.",
    "faq": [
      {
        "question": "How do I show Wegovy is more than cosmetic?",
        "answer": "Describe specific health issues—such as diabetes, sleep apnea, hypertension, joint damage, or fatty liver—and how weight worsens them. Explain how weight affects your ability to work, parent, or perform daily tasks."
      },
      {
        "question": "What if my plan says it never covers weight-loss drugs?",
        "answer": "You can still appeal by emphasizing that obesity is a chronic disease and Wegovy is evidence-based treatment for high-risk patients. Some employers or plans grant exceptions when the medical risk is clear."
      }
    ],
    "evidence_snippets": [
      "Once-weekly semaglutide for obesity results in substantial and sustained weight loss compared with lifestyle interventions alone.",
      "Weight reduction in people with obesity improves blood pressure, glycemic control, and cardiovascular risk factors.",
      "Obesity is recognized as a chronic disease requiring long-term management, not a short-term cosmetic issue."
    ],
    "pubmed_search_terms": [
      "semaglutide Wegovy obesity randomized controlled trial",
      "GLP-1 receptor agonist weight loss cardiovascular risk",
      "pharmacologic treatment obesity guidelines semaglutide"
    ],
    "assistance_programs": [
      {
        "name": "Wegovy Savings Card",
        "url": "https://www.wegovy.com/coverage-and-savings/save-on-wegovy.html",
        "description": "Pay as little as $0/month with commercial insurance coverage (up to $225 off per fill). Not for government programs."
      },
      {
        "name": "NovoCare - Wegovy",
        "url": "https://www.novocare.com/obesity/products/wegovy/savings-offer.html",
        "description": "Savings offers and support for Wegovy patients, including $349/month self-pay option."
      },
      {
        "name": "NovoCare Pharmacy",
        "url": "https://www.novocare.com/eligibility/wegovy-savings-card.html",
        "description": "Home delivery option for self-pay patients with access to savings programs."
      }
    ],
    "advocacy_resources": [
      {
        "name": "Obesity Action Coalition",
        "url": "https://www.obesityaction.org/",
        "description": "National nonprofit empowering those affected by obesity through advocacy, education and support."
      }
    ]
  },
  "glp1-denial-tirzepatide-mounjaro-denial": {
    "slug": "glp1-denial-tirzepatide-mounjaro-denial",
    "title": "Appealing Mounjaro (Tirzepatide) Denials",
    "default_procedure": "Mounjaro (Tirzepatide for Type 2 Diabetes)",
    "default_condition": "Type 2 Diabetes",
    "tagline": "Tirzepatide is a powerful tool for high-risk diabetes, not an optional upgrade.",
    "hero_h1": "Appeal Your Mounjaro Denial",
    "hero_subhead": "If prior regimens failed, denying Mounjaro can be unsafe and short-sighted.",
    "intro": "Mounjaro is often denied because it is newer, more expensive, and requires strict criteria. Insurers may demand failure of multiple other drugs or limit use to narrow subsets of people with type 2 diabetes.",
    "common_denial_reasons": [
      "Not enough prior medication failures documented",
      "Use for weight reduction rather than documented diabetes",
      "Dose or titration schedule not on formulary",
      "Plan prefers a different GLP-1/GIP agent"
    ],
    "how_we_help": "We help you document your full diabetes regimen history, comorbidities, and any complications so your appeal shows why Mounjaro is clinically appropriate and not easily substituted.",
    "cta": "Start your Mounjaro appeal.",
    "faq": [
      {
        "question": "What makes Mounjaro medically necessary in my case?",
        "answer": "Explain your current A1c, prior therapies, side effects, weight-related risk, and any complications. Your prescriber can explain why tirzepatide’s mechanism and potency are especially helpful for your situation."
      },
      {
        "question": "Can I appeal if I am also hoping for weight loss benefits?",
        "answer": "Yes. You can acknowledge weight loss benefits while emphasizing that the primary goal is better diabetes control and reduced risk of cardiovascular and metabolic complications."
      }
    ],
    "evidence_snippets": [
      "Tirzepatide significantly lowers A1c and body weight in adults with type 2 diabetes compared with several existing therapies.",
      "Intensive glycemic control in high-risk patients reduces microvascular and, in some groups, macrovascular complications.",
      "Treatments that address both hyperglycemia and obesity can provide synergistic risk reduction."
    ],
    "pubmed_search_terms": [
      "tirzepatide Mounjaro type 2 diabetes randomized trial",
      "dual GIP GLP-1 agonist glycemic control weight",
      "tirzepatide cardiovascular risk factors outcomes"
    ],
    "assistance_programs": [
      {
        "name": "Mounjaro Savings Card",
        "url": "https://www.mounjaro.lilly.com/savings-resources",
        "description": "Pay as little as $25/month with commercial insurance coverage. Up to $150 off per fill."
      }
    ],
    "advocacy_resources": [
      {
        "name": "American Diabetes Association",
        "url": "https://diabetes.org/",
        "description": "Nation's leading voluntary health organization fighting diabetes through advocacy, research, and education."
      },
      {
        "name": "Beyond Type 1",
        "url": "https://beyondtype1.org/",
        "description": "Global diabetes community providing education, advocacy, and support for people with diabetes."
      }
    ]
  },
  "glp1-denial-tirzepatide-zepbound-denial": {
    "slug": "glp1-denial-tirzepatide-zepbound-denial",
    "title": "Appealing Zepbound (Tirzepatide) Denials",
    "default_procedure": "Zepbound (Tirzepatide for Obesity)",
    "default_condition": "Obesity",
    "tagline": "Zepbound is intensive obesity medicine for high-risk patients, not a vanity drug.",
    "hero_h1": "Appeal Your Zepbound Denial",
    "hero_subhead": "When obesity is damaging your health, denying Zepbound can be dangerous.",
    "intro": "Zepbound is commonly denied because anti-obesity medications are excluded or tightly restricted. Appeals can connect Zepbound to concrete health outcomes: fewer complications, fewer hospitalizations, and better function.",
    "common_denial_reasons": [
      "Anti-obesity medications excluded from coverage",
      "BMI and comorbidity criteria not documented correctly",
      "Insufficient evidence of structured weight-loss attempts",
      "Dose or duration limits exceeded"
    ],
    "how_we_help": "We help you compile your BMI history, documented co-morbidities, prior weight-loss programs, and functional impairment so your appeal makes a strong medical case for Zepbound.",
    "cta": "Start your Zepbound appeal.",
    "faq": [
      {
        "question": "How do I document prior weight-loss attempts?",
        "answer": "List supervised programs, diets, medications, and lifestyle changes, including durations and outcomes. If weight was regained, note why, such as medication side effects or mobility limits."
      },
      {
        "question": "Can my doctor's letter make a difference?",
        "answer": "Yes. A concise letter linking Zepbound to reduction in concrete risks—such as diabetes progression, sleep apnea, or heart disease—can be very persuasive."
      },
      {
        "question": "What if my plan is switching to a different GLP-1 medication?",
        "answer": "If you're already stable on Zepbound and your insurer wants you to switch (e.g., CVS Caremark moving to Wegovy in mid-2025), you may have continuity of care rights. You can request a medical exception. Many states also have non-medical switching laws. See our continuity of care page for more information."
      }
    ],
    "evidence_snippets": [
      "Tirzepatide produces substantial weight loss in adults with obesity, often exceeding that of earlier agents.",
      "Weight loss improves cardiometabolic risk factors and can prevent or delay type 2 diabetes in high-risk individuals.",
      "Treating obesity as a chronic disease requires long-term strategies, including medications when appropriate."
    ],
    "pubmed_search_terms": [
      "tirzepatide obesity clinical trial weight loss",
      "pharmacologic treatment obesity tirzepatide",
      "anti-obesity medication cardiometabolic outcomes"
    ],
    "assistance_programs": [
      {
        "name": "Zepbound Savings Card",
        "url": "https://www.zepbound.lilly.com/coverage-savings",
        "description": "Pay as little as $25/month with commercial insurance coverage, or up to $569 off without coverage. Not for government insurance."
      },
      {
        "name": "LillyDirect - Zepbound",
        "url": "https://www.lilly.com/lillydirect/medicines/zepbound",
        "description": "Order Zepbound vials direct from Lilly for $299/month (self-pay option)."
      }
    ],
    "advocacy_resources": [
      {
        "name": "Obesity Action Coalition",
        "url": "https://www.obesityaction.org/",
        "description": "National nonprofit empowering those affected by obesity through advocacy, education and support."
      }
    ]
  },
  "asthma-biologic-denial-dupilumab-denial": {
    "slug": "asthma-biologic-denial-dupilumab-denial",
    "title": "Appealing Dupixent (Dupilumab) Asthma Denials",
    "default_procedure": "Dupixent for Severe Asthma",
    "default_condition": "Severe Asthma",
    "tagline": "Dupixent can calm type 2 inflammation when inhalers alone are not enough.",
    "hero_h1": "Appeal Your Dupixent Asthma Denial",
    "hero_subhead": "If you are still wheezing on high-dose inhalers, biologic therapy may be essential.",
    "intro": "Dupixent is often denied for asthma due to borderline lab criteria, questions about severity, or insurer preference for other biologics. A strong appeal shows that you meet guideline-based criteria and that your asthma remains unsafe without Dupixent.",
    "common_denial_reasons": [
      "Eosinophil count or FeNO not meeting strict thresholds",
      "Asthma not documented as severe or uncontrolled",
      "Insufficient documentation of high-dose inhaler and steroid use",
      "Plan prefers another biologic first"
    ],
    "how_we_help": "We help you and your clinician summarize ER visits, steroid bursts, spirometry, and biomarker data to show why Dupixent specifically is medically appropriate.",
    "cta": "Start your Dupixent asthma appeal.",
    "faq": [
      {
        "question": "What should my doctor highlight about my asthma?",
        "answer": "They should list exacerbations, hospitalizations, oral steroid courses, and how symptoms limit daily life. They should tie these to type 2 inflammation markers that support Dupixent use."
      },
      {
        "question": "Can I appeal if my eosinophil count is borderline?",
        "answer": "Yes. Your appeal can explain your clinical history, FeNO levels if available, and how your pattern fits guideline criteria even if a single lab value is borderline."
      },
      {
        "question": "What if my plan is removing Dupixent from formulary or switching to another biologic?",
        "answer": "If you're already stable on Dupixent and your insurer wants you to switch, you may have continuity of care rights. You can request a medical exception showing that switching biologics may destabilize your condition. See our continuity of care page for more information."
      }
    ],
    "evidence_snippets": [
      "Dupilumab reduces exacerbations and improves lung function in patients with moderate-to-severe asthma with type 2 inflammation.",
      "Biologic therapy can reduce dependence on systemic steroids, lowering the risk of steroid-related side effects.",
      "Guidelines endorse biologics like dupilumab for patients with uncontrolled asthma despite maximal inhaled therapy."
    ],
    "pubmed_search_terms": [
      "dupilumab severe asthma randomized trial",
      "type 2 inflammation asthma biologic dupilumab",
      "GINA guideline biologic therapy dupilumab"
    ],
    "assistance_programs": [
      {
        "name": "DUPIXENT MyWay Copay Card",
        "url": "https://www.dupixent.com/support-savings/copay-card",
        "description": "Pay as little as $0 per fill with commercial insurance. Max $13,000/year benefit."
      },
      {
        "name": "DUPIXENT MyWay Patient Support",
        "url": "https://www.dupixent.com/support-savings/dupixent-my-way",
        "description": "Benefits investigation, prior auth support, and patient assistance for uninsured or coverage gaps."
      }
    ],
    "advocacy_resources": [
      {
        "name": "Asthma and Allergy Foundation of America",
        "url": "https://aafa.org/",
        "description": "Leading patient advocacy organization for asthma and allergies, certified by National Health Council."
      },
      {
        "name": "Allergy & Asthma Network",
        "url": "https://allergyasthmanetwork.org/",
        "description": "Nonprofit patient outreach, education, advocacy and research organization."
      }
    ]
  },
  "asthma-biologic-denial-omalizumab-denial": {
    "slug": "asthma-biologic-denial-omalizumab-denial",
    "title": "Appealing Xolair (Omalizumab) Asthma Denials",
    "default_procedure": "Xolair for Allergic Asthma",
    "default_condition": "Allergic Asthma",
    "tagline": "For allergic asthma, IgE-targeted therapy can be life-changing.",
    "hero_h1": "Appeal Your Xolair Asthma Denial",
    "hero_subhead": "If allergy-driven asthma is out of control, denying Xolair can be dangerous.",
    "intro": "Xolair is often denied for not hitting a narrow IgE range, weight band, or step-therapy path. Appeals that walk through your allergy history and exacerbations can reverse those decisions.",
    "common_denial_reasons": [
      "IgE level or weight not within policy table",
      "Insufficient documentation of perennial allergen sensitization",
      "Asthma not labeled as severe persistent",
      "Insurer prefers alternative therapies"
    ],
    "how_we_help": "We help you assemble allergy testing, exacerbation history, and inhaler use so your appeal clearly shows why Xolair is medically appropriate for your pattern of allergic asthma.",
    "cta": "Start your Xolair asthma appeal.",
    "faq": [
      {
        "question": "What allergy documentation should I include?",
        "answer": "Include skin or blood test results for perennial allergens (like dust mites or animal dander), plus notes connecting exposures to symptom flares."
      },
      {
        "question": "What if I’ve been on high-dose inhalers for years?",
        "answer": "Your appeal should make that clear, including any side effects or ongoing exacerbations despite treatment—this supports escalation to Xolair."
      }
    ],
    "evidence_snippets": [
      "Omalizumab reduces exacerbations and healthcare use in patients with moderate-to-severe allergic asthma.",
      "Targeting IgE can help patients whose asthma is driven by perennial allergen sensitization.",
      "Biologic therapy is recommended when standard inhaled regimens fail to provide adequate control."
    ],
    "pubmed_search_terms": [
      "omalizumab allergic asthma exacerbation reduction",
      "IgE targeted therapy severe persistent asthma",
      "omalizumab guideline severe allergic asthma"
    ],
    "assistance_programs": [
      {
        "name": "Xolair Co-pay Program",
        "url": "https://www.xolaircopay.com/",
        "description": "Pay as little as $0 per injection with commercial insurance. Up to $15,000/year for allergic asthma."
      },
      {
        "name": "Genentech Patient Foundation",
        "url": "https://www.genentech-access.com/patient/brands/xolair/how-we-help-you.html",
        "description": "Free medication for qualifying uninsured or underinsured patients meeting income requirements."
      }
    ],
    "advocacy_resources": [
      {
        "name": "Asthma and Allergy Foundation of America",
        "url": "https://aafa.org/",
        "description": "Leading patient advocacy organization for asthma and allergies, certified by National Health Council."
      },
      {
        "name": "Allergy & Asthma Network",
        "url": "https://allergyasthmanetwork.org/",
        "description": "Nonprofit patient outreach, education, advocacy and research organization."
      }
    ]
  },
  "asthma-biologic-denial-mepolizumab-denial": {
    "slug": "asthma-biologic-denial-mepolizumab-denial",
    "title": "Appealing Nucala (Mepolizumab) Asthma Denials",
    "default_procedure": "Nucala for Eosinophilic Asthma",
    "default_condition": "Eosinophilic Asthma",
    "tagline": "Eosinophilic asthma is high risk—denials often ignore that.",
    "hero_h1": "Appeal Your Nucala Asthma Denial",
    "hero_subhead": "Eosinophilic asthma is high risk—denials often ignore that.",
    "intro": "Nucala is denied when eosinophil counts are questioned, documentation is incomplete, or insurers want a different biologic first. Appeals can show that your eosinophilic asthma remains uncontrolled and at high risk without Nucala.",
    "common_denial_reasons": [
      "Eosinophil counts not documented or not repeated",
      "Asthma not labeled as eosinophilic or severe",
      "Not enough steroid bursts or exacerbations documented",
      "Preference for an alternative eosinophil-targeting biologic"
    ],
    "how_we_help": "We help your clinician pull together lab trends, imaging, lung function, and exacerbation records to show why Nucala is medically necessary.",
    "cta": "Start your Nucala asthma appeal.",
    "faq": [
      {
        "question": "Do I need multiple eosinophil counts?",
        "answer": "Multiple measurements can help. Your appeal can include both historical and recent labs, especially if steroids temporarily lowered counts."
      },
      {
        "question": "How do I show that my asthma is eosinophilic?",
        "answer": "Your clinician can connect lab values, nasal or sinus disease, and response to steroids with the diagnosis of eosinophilic asthma."
      }
    ],
    "evidence_snippets": [
      "Mepolizumab reduces exacerbations and oral steroid use in patients with severe eosinophilic asthma.",
      "Eosinophilic inflammation is a key driver of exacerbations in a subset of asthma patients.",
      "Biologics targeting IL-5 or related pathways are standard options for severe eosinophilic asthma in guideline algorithms."
    ],
    "pubmed_search_terms": [
      "mepolizumab eosinophilic asthma randomized trial",
      "IL-5 inhibition severe eosinophilic asthma outcomes",
      "eosinophilic asthma biologic guideline mepolizumab"
    ],
    "assistance_programs": [
      {
        "name": "NUCALA Copay Program",
        "url": "https://www.nucala.com/nucala-copay-program/",
        "description": "Pay as little as $0 with commercial insurance. Up to $15,000/year benefit."
      },
      {
        "name": "GSK Patient Assistance Foundation",
        "url": "https://gskpaf.org/gsk/prescription-medicine-patient-assistance/nucala-uninsured/",
        "description": "Free medication for qualifying uninsured patients or those with Medicare."
      }
    ],
    "advocacy_resources": [
      {
        "name": "Asthma and Allergy Foundation of America",
        "url": "https://aafa.org/",
        "description": "Leading patient advocacy organization for asthma and allergies, certified by National Health Council."
      },
      {
        "name": "Allergy & Asthma Network",
        "url": "https://allergyasthmanetwork.org/",
        "description": "Nonprofit patient outreach, education, advocacy and research organization."
      }
    ]
  },
  "eczema-biologic-denial-dupilumab-denial": {
    "slug": "eczema-biologic-denial-dupilumab-denial",
    "title": "Appealing Dupixent (Dupilumab) Eczema Denials",
    "default_procedure": "Dupixent for Atopic Dermatitis",
    "default_condition": "Atopic Dermatitis",
    "tagline": "Severe eczema is a systemic disease, not just a rash.",
    "hero_h1": "Appeal Your Dupixent Eczema Denial",
    "hero_subhead": "When skin is cracked, infected, and sleepless, denying Dupixent is not reasonable.",
    "intro": "Dupixent is often denied for atopic dermatitis because severity is under-documented, prior treatments are not listed, or plans prefer to avoid high-cost biologics. Appeals that clearly describe severity can change outcomes.",
    "common_denial_reasons": [
      "Disease not documented as moderate-to-severe",
      "Topical therapies or phototherapy not fully documented",
      "Age or dosing concerns for pediatric patients",
      "Plan questions long-term use"
    ],
    "how_we_help": "We help you document body areas involved, infections, sleep loss, and emotional distress to show Dupixent is medically necessary and guideline-consistent.",
    "cta": "Start your Dupixent eczema appeal.",
    "faq": [
      {
        "question": "How detailed should I be about my symptoms?",
        "answer": "Very detailed. Describe itch, pain, bleeding, infections, missed work or school, and how long flares last. Photos and dermatologist notes help."
      },
      {
        "question": "Can children be approved for Dupixent?",
        "answer": "Yes, many children meet indications. Your appeal should highlight pediatric dosing recommendations and the impact on growth, sleep, and development."
      },
      {
        "question": "What if my plan is removing Dupixent from formulary or switching me to another medication?",
        "answer": "If you're already stable on Dupixent and your insurer wants you to switch, you may have continuity of care rights. Switching biologics or systemic therapies in atopic dermatitis can destabilize skin control. See our continuity of care page for more information."
      }
    ],
    "evidence_snippets": [
      "Dupilumab significantly improves skin clearance and itch in moderate-to-severe atopic dermatitis.",
      "Effective treatment of atopic dermatitis improves sleep, work productivity, and mental health.",
      "Guidelines endorse systemic or biologic therapies when topical treatments are insufficient."
    ],
    "pubmed_search_terms": [
      "dupilumab moderate severe atopic dermatitis trial",
      "biologic therapy atopic dermatitis quality of life",
      "atopic dermatitis guideline systemic therapy dupilumab"
    ],
    "assistance_programs": [
      {
        "name": "DUPIXENT MyWay Copay Card",
        "url": "https://www.dupixent.com/support-savings/copay-card",
        "description": "Pay as little as $0 per fill with commercial insurance. Max $13,000/year benefit."
      },
      {
        "name": "DUPIXENT MyWay Patient Support",
        "url": "https://www.dupixent.com/support-savings/dupixent-my-way",
        "description": "Benefits investigation, prior auth support, and patient assistance for uninsured or coverage gaps."
      }
    ],
    "advocacy_resources": [
      {
        "name": "National Eczema Association",
        "url": "https://nationaleczema.org/",
        "description": "Largest patient advocacy organization serving Americans with eczema."
      }
    ]
  },
  "eczema-biologic-denial-upadacitinib-denial": {
    "slug": "eczema-biologic-denial-upadacitinib-denial",
    "title": "Appealing Rinvoq (Upadacitinib) Eczema Denials",
    "default_procedure": "Rinvoq for Atopic Dermatitis",
    "default_condition": "Atopic Dermatitis",
    "tagline": "When topical and biologic options fail, targeted oral therapy may be necessary.",
    "hero_h1": "Appeal Your Rinvoq Eczema Denial",
    "hero_subhead": "Rinvoq is often reserved for the hardest cases—exactly where appeals matter most.",
    "intro": "Rinvoq is a JAK inhibitor used for moderate-to-severe atopic dermatitis when other options are inadequate. Insurers may deny it as too risky, experimental, or not medically necessary.",
    "common_denial_reasons": [
      "Not enough prior systemic or biologic therapy failures documented",
      "Concerns about JAK inhibitor safety profile without context",
      "Disease severity not clearly documented",
      "Age or comorbidity concerns not addressed"
    ],
    "how_we_help": "We help you and your dermatologist explain prior treatment failures, monitoring plans, and why Rinvoq’s benefits outweigh risks in your case.",
    "cta": "Start your Rinvoq eczema appeal.",
    "faq": [
      {
        "question": "How do we address safety concerns in the appeal?",
        "answer": "Your clinician can describe baseline labs, ongoing monitoring, and why benefits—such as preventing infections from open skin—are clinically important."
      },
      {
        "question": "What if I've already tried Dupixent or other biologics?",
        "answer": "List each prior systemic treatment, how long you used it, and why it was insufficient or intolerable. That strengthens the case for advancing to Rinvoq."
      }
    ],
    "evidence_snippets": [
      "Upadacitinib improves skin clearance and reduces itch in patients with refractory atopic dermatitis.",
      "For some patients, targeted oral therapies are needed after failure of biologic or conventional systemic treatments.",
      "Careful selection and monitoring can mitigate risks associated with JAK inhibitors."
    ],
    "pubmed_search_terms": [
      "upadacitinib atopic dermatitis randomized trial",
      "JAK inhibitor atopic dermatitis safety efficacy",
      "systemic therapy refractory atopic dermatitis upadacitinib"
    ],
    "assistance_programs": [
      {
        "name": "RINVOQ Complete Savings Card",
        "url": "https://www.rinvoq.com/resources/save-on-rinvoq-costs",
        "description": "Pay as little as $0/month with commercial insurance. Up to $14,000/year benefit."
      },
      {
        "name": "RINVOQ Complete Bridge Program",
        "url": "https://www.rinvoq.com/resources/rinvoq-complete",
        "description": "Free medication for up to 24 months while insurance coverage is delayed or denied."
      },
      {
        "name": "myAbbVie Assist",
        "url": "https://www.abbvie.com/patients/patient-assistance.html",
        "description": "Free medication for qualifying uninsured, underinsured, or unemployed patients."
      }
    ],
    "advocacy_resources": [
      {
        "name": "National Eczema Association",
        "url": "https://nationaleczema.org/",
        "description": "Largest patient advocacy organization serving Americans with eczema."
      }
    ]
  },
  "migraine-med-denial-emgality-denial": {
    "slug": "migraine-med-denial-emgality-denial",
    "title": "Appealing Emgality (Galcanezumab) Denials",
    "default_procedure": "Emgality for Migraine Prevention",
    "default_condition": "Migraine",
    "tagline": "Chronic migraines are often under treated by insurance.",
    "hero_h1": "Appeal Your Emgality Denial",
    "hero_subhead": "If chronic migraine is disabling you, denying Emgality is not acceptable.",
    "intro": "Emgality is often denied until patients have failed a long list of older preventives. Appeals can show that you meet criteria and that Emgality is needed to reduce disability and emergency visits.",
    "common_denial_reasons": [
      "Not enough failed preventive medications documented",
      "Migraine frequency not clearly recorded",
      "Insurer prefers a different CGRP antibody",
      "Quantity limits or duration limits"
    ],
    "how_we_help": "We help you document headache days per month, disability, prior medication failures, and ER/urgent care visits to support Emgality coverage.",
    "cta": "Start your Emgality appeal.",
    "faq": [
      {
        "question": "How do I document my migraine burden?",
        "answer": "Use a headache diary or calendar showing number of migraine days, severity, and impact on work or school. Include any ER or urgent care visits."
      },
      {
        "question": "Can I appeal if I had side effects from older preventives?",
        "answer": "Yes. Note the side effects and how they limited use—this supports moving to a better-tolerated option like Emgality."
      }
    ],
    "evidence_snippets": [
      "Galcanezumab reduces monthly migraine days in patients with episodic and chronic migraine.",
      "CGRP monoclonal antibodies are specifically designed for migraine prevention and are often better tolerated than older preventives.",
      "Effective migraine prevention decreases disability and healthcare utilization."
    ],
    "pubmed_search_terms": [
      "galcanezumab Emgality chronic migraine randomized",
      "CGRP monoclonal antibody migraine prevention",
      "migraine disability reduction CGRP therapy"
    ],
    "assistance_programs": [
      {
        "name": "Emgality Savings Card",
        "url": "https://www.emgality.lilly.com/savings-support",
        "description": "Pay as little as $0/month for up to 12 months with commercial insurance. Max $4,900/year savings."
      },
      {
        "name": "Lilly Cares Foundation",
        "url": "https://www.lillycares.com/",
        "description": "Free medication for qualifying patients without commercial insurance and with low income, including some Medicare Part D patients."
      }
    ],
    "advocacy_resources": [
      {
        "name": "American Migraine Foundation",
        "url": "https://americanmigrainefoundation.org/",
        "description": "Leading resource for migraine education, support, and advocacy."
      },
      {
        "name": "National Headache Foundation",
        "url": "https://headaches.org/",
        "description": "Promotes headache awareness and education, and provides patient resources."
      },
      {
        "name": "Alliance for Headache Disorders Advocacy",
        "url": "https://allianceforheadacheadvocacy.org/",
        "description": "Advocates for equitable policies for people with headache disorders."
      }
    ]
  },
  "migraine-med-denial-aimovig-denial": {
    "slug": "migraine-med-denial-aimovig-denial",
    "title": "Appealing Aimovig (Erenumab) Denials",
    "default_procedure": "Aimovig for Migraine Prevention",
    "default_condition": "Migraine",
    "tagline": "Step therapy shouldn't stop you from accessing the care you need.",
    "hero_h1": "Appeal Your Aimovig Denial",
    "hero_subhead": "Aimovig may be appropriate when multiple older preventives have failed.",
    "intro": "Aimovig is often denied due to strict step-therapy rules or incomplete documentation. A focused appeal can show that you meet standard criteria for CGRP therapy.",
    "common_denial_reasons": [
      "Fewer than required trialed preventive drugs documented",
      "Migraine days per month not clearly stated",
      "Insurer prefers a different CGRP agent",
      "Issues with prior authorization timing"
    ],
    "how_we_help": "We help you and your clinician summarize prior preventives, side effects, and migraine burden so Aimovig is seen as medically necessary.",
    "cta": "Start your Aimovig appeal.",
    "faq": [
      {
        "question": "Which prior medications should I mention?",
        "answer": "List beta-blockers, antiepileptics, antidepressants, or other preventives you’ve tried, including dose, duration, and why they failed or were stopped."
      },
      {
        "question": "Can I appeal if I previously used another CGRP drug?",
        "answer": "Yes. Explain response or side effects and why switching to Aimovig is appropriate now."
      }
    ],
    "evidence_snippets": [
      "Erenumab reduces monthly migraine days and improves quality of life in migraine patients.",
      "CGRP-targeted therapies provide a migraine-specific preventive option when older drugs fail.",
      "Long-term data suggest sustained benefit and tolerability for many patients."
    ],
    "pubmed_search_terms": [
      "erenumab Aimovig migraine randomized controlled",
      "CGRP receptor antagonist migraine prevention",
      "long term safety erenumab migraine"
    ],
    "assistance_programs": [
      {
        "name": "Aimovig Copay Card",
        "url": "https://www.aimovig.com/paying-for-aimovig",
        "description": "Pay as little as $5/month with commercial insurance. Up to $3,500 annual benefit."
      },
      {
        "name": "Aimovig Bridge Program",
        "url": "https://www.aimovigcopaycard.com/enroll",
        "description": "Free Aimovig for up to 12 doses while insurance coverage is pending."
      },
      {
        "name": "Amgen Safety Net Foundation",
        "url": "https://www.amgensafetynetfoundation.com/",
        "description": "Free medication for qualifying uninsured patients or those whose insurance excludes Aimovig."
      }
    ],
    "advocacy_resources": [
      {
        "name": "American Migraine Foundation",
        "url": "https://americanmigrainefoundation.org/",
        "description": "Leading resource for migraine education, support, and advocacy."
      },
      {
        "name": "National Headache Foundation",
        "url": "https://headaches.org/",
        "description": "Promotes headache awareness and education, and provides patient resources."
      },
      {
        "name": "Alliance for Headache Disorders Advocacy",
        "url": "https://allianceforheadacheadvocacy.org/",
        "description": "Advocates for equitable policies for people with headache disorders."
      }
    ]
  },
  "migraine-med-denial-ajovy-denial": {
    "slug": "migraine-med-denial-ajovy-denial",
    "title": "Appealing Ajovy (Fremanezumab) Denials",
    "default_procedure": "Ajovy for Migraine Prevention",
    "default_condition": "Migraine",
    "tagline": "Monthly or quarterly dosing can simplify life with migraine.",
    "hero_h1": "Appeal Your Ajovy Denial",
    "hero_subhead": "Ajovy is one of several CGRP antibodies—appeals can justify why it’s the right one for you.",
    "intro": "Ajovy may be denied when insurers want you to try a different CGRP antibody or insist that older preventives are enough. Appeals should highlight your specific needs and prior experiences.",
    "common_denial_reasons": [
      "Failure to use insurer-preferred CGRP agent first",
      "Not meeting threshold for chronic or high-frequency migraine",
      "Incomplete documentation of prior preventive failures",
      "Questions about monthly vs. quarterly dosing"
    ],
    "how_we_help": "We help your clinician explain why Ajovy’s dosing schedule, response in your case, or side-effect profile makes it the most appropriate option.",
    "cta": "Start your Ajovy appeal.",
    "faq": [
      {
        "question": "Does it matter if my migraines are episodic or chronic?",
        "answer": "Yes. Your appeal should specify which pattern you have and reference data showing Ajovy’s benefit in that group."
      },
      {
        "question": "Can dosing schedule matter in an appeal?",
        "answer": "Absolutely. If quarterly dosing improves adherence or reduces burden, your clinician should spell that out."
      }
    ],
    "evidence_snippets": [
      "Fremanezumab reduces migraine frequency in both episodic and chronic migraine.",
      "Flexible monthly or quarterly dosing can support adherence and patient preference.",
      "CGRP monoclonal antibodies are recommended for patients with frequent migraines who fail standard preventives."
    ],
    "pubmed_search_terms": [
      "fremanezumab Ajovy episodic chronic migraine trial",
      "CGRP monoclonal antibody migraine quarterly dosing",
      "migraine guideline CGRP monoclonal antibody fremanezumab"
    ],
    "assistance_programs": [
      {
        "name": "Ajovy Savings Offer",
        "url": "https://www.ajovy.com/savings",
        "description": "Pay as little as $15 per prescription with commercial insurance. Annual limits apply."
      },
      {
        "name": "Teva Cares Foundation",
        "url": "https://www.tevacares.org/",
        "description": "Free medication for qualifying uninsured or underinsured patients meeting income criteria."
      }
    ],
    "advocacy_resources": [
      {
        "name": "American Migraine Foundation",
        "url": "https://americanmigrainefoundation.org/",
        "description": "Leading resource for migraine education, support, and advocacy."
      },
      {
        "name": "National Headache Foundation",
        "url": "https://headaches.org/",
        "description": "Promotes headache awareness and education, and provides patient resources."
      },
      {
        "name": "Alliance for Headache Disorders Advocacy",
        "url": "https://allianceforheadacheadvocacy.org/",
        "description": "Advocates for equitable policies for people with headache disorders."
      }
    ]
  },
  "migraine-med-denial-nurtec-denial": {
    "slug": "migraine-med-denial-nurtec-denial",
    "title": "Appealing Nurtec ODT (Rimegepant) Denials",
    "default_procedure": "Nurtec ODT for Acute and Preventive Migraine Treatment",
    "default_condition": "Migraine",
    "tagline": "Medication for both stopping and helping prevent migraine attacks.",
    "hero_h1": "Appeal Your Nurtec Denial",
    "hero_subhead": "Nurtec is often denied on cost grounds or strict quantity limits.",
    "intro": "Nurtec ODT is a gepant used for acute migraine and, in some cases, prevention. Insurers often impose severe quantity limits or reject coverage entirely.",
    "common_denial_reasons": [
      "Quantity limits inconsistent with patient’s attack frequency",
      "Requirement to fail multiple triptans first",
      "Off-label use for prevention questioned",
      "Plan prefers a different gepant"
    ],
    "how_we_help": "We help you explain migraine frequency, failed triptans, and any contraindications that make Nurtec necessary for you.",
    "cta": "Start your Nurtec appeal.",
    "faq": [
      {
        "question": "How do I appeal quantity limits?",
        "answer": "Show your typical number of attacks per month and how strict limits lead to untreated attacks, ER visits, or missed work."
      },
      {
        "question": "What if I cannot take triptans?",
        "answer": "Have your clinician explain contraindications—such as heart disease or stroke risk—or intolerable side effects from triptans."
      }
    ],
    "evidence_snippets": [
      "Rimegepant provides relief for acute migraine and has evidence for preventive use with regular dosing.",
      "Gepants offer an option for patients who cannot use or do not respond to triptans.",
      "Adequate acute and preventive treatment reduces migraine-related disability."
    ],
    "pubmed_search_terms": [
      "rimegepant Nurtec acute migraine randomized",
      "rimegepant preventive migraine dosing trial",
      "gepant therapy migraine triptan contraindication"
    ],
    "assistance_programs": [
      {
        "name": "Nurtec ODT Copay Card",
        "url": "https://www.nurtec.com/savings",
        "description": "Pay as little as $0 for a 30-day supply with commercial insurance. Max $7,000/year benefit."
      },
      {
        "name": "Pfizer Patient Assistance Program",
        "url": "https://www.pfizerrxpathways.com/",
        "description": "Free medication for qualifying patients at or below 300% federal poverty level."
      }
    ],
    "advocacy_resources": [
      {
        "name": "American Migraine Foundation",
        "url": "https://americanmigrainefoundation.org/",
        "description": "Leading resource for migraine education, support, and advocacy."
      },
      {
        "name": "National Headache Foundation",
        "url": "https://headaches.org/",
        "description": "Promotes headache awareness and education, and provides patient resources."
      },
      {
        "name": "Alliance for Headache Disorders Advocacy",
        "url": "https://allianceforheadacheadvocacy.org/",
        "description": "Advocates for equitable policies for people with headache disorders."
      }
    ]
  },
  "migraine-med-denial-ubrelvy-denial": {
    "slug": "migraine-med-denial-ubrelvy-denial",
    "title": "Appealing Ubrelvy (Ubrogepant) Denials",
    "default_procedure": "Ubrelvy for Acute Migraine Treatment",
    "default_condition": "Migraine",
    "tagline": "When triptans are not an option, gepants can be crucial.",
    "hero_h1": "Appeal Your Ubrelvy Denial",
    "hero_subhead": "Ubrelvy is often denied or heavily restricted, but appeals frequently succeed.",
    "intro": "Ubrelvy is a gepant used acutely to stop migraine attacks. Plans often restrict it to small quantities or deny it unless several triptans have failed.",
    "common_denial_reasons": [
      "Insufficient prior triptan trials",
      "Quantity limits too low for attack frequency",
      "Use in patients with perceived low migraine burden",
      "Preference for formulary alternatives"
    ],
    "how_we_help": "We help you document prior acute treatments, contraindications, and attack frequency to justify Ubrelvy at an appropriate quantity.",
    "cta": "Start your Ubrelvy appeal.",
    "faq": [
      {
        "question": "How many prior medications do I need to document?",
        "answer": "List all acute meds you’ve tried—over-the-counter and prescription—with responses and side effects. The more thorough, the better."
      },
      {
        "question": "Can I appeal even if I still have some triptan benefit?",
        "answer": "Yes. If triptans cause side effects, can’t be used often enough, or are unsafe given your risk factors, that still supports coverage for Ubrelvy."
      }
    ],
    "evidence_snippets": [
      "Ubrogepant is effective for acute treatment of migraine and is generally well tolerated.",
      "Gepants provide an option for patients with cardiovascular risk factors that limit triptan use.",
      "Timely acute treatment reduces the need for emergency care and shortens attack duration."
    ],
    "pubmed_search_terms": [
      "ubrogepant Ubrelvy acute migraine randomized",
      "gepant acute migraine cardiovascular risk",
      "ubrogepant efficacy safety migraine treatment"
    ],
    "assistance_programs": [
      {
        "name": "Ubrelvy Savings Card",
        "url": "https://www.ubrelvy.com/savings",
        "description": "Pay as little as $0/month with commercial insurance. Up to 13 fills per year."
      },
      {
        "name": "myAbbVie Assist",
        "url": "https://www.abbvie.com/patients/patient-assistance.html",
        "description": "Free medication for qualifying patients who have difficulty paying for their medicine."
      }
    ],
    "advocacy_resources": [
      {
        "name": "American Migraine Foundation",
        "url": "https://americanmigrainefoundation.org/",
        "description": "Leading resource for migraine education, support, and advocacy."
      },
      {
        "name": "National Headache Foundation",
        "url": "https://headaches.org/",
        "description": "Promotes headache awareness and education, and provides patient resources."
      },
      {
        "name": "Alliance for Headache Disorders Advocacy",
        "url": "https://allianceforheadacheadvocacy.org/",
        "description": "Advocates for equitable policies for people with headache disorders."
      }
    ]
  },
  "insulin-pump-cgm-denial-dexcom-denial": {
    "slug": "insulin-pump-cgm-denial-dexcom-denial",
    "title": "Appealing Dexcom CGM Denials",
    "default_procedure": "Dexcom Continuous Glucose Monitor",
    "default_condition": "Diabetes",
    "tagline": "Real-time glucose data can prevent dangerous highs and lows.",
    "hero_h1": "Appeal Your Dexcom CGM Denial",
    "hero_subhead": "When finger sticks are not enough, Dexcom can be medically necessary.",
    "intro": "Dexcom CGMs are denied when plans claim that traditional glucose monitoring is sufficient, or that criteria like multiple daily injections are not clearly documented. Appeals can show how Dexcom improves safety and control.",
    "common_denial_reasons": [
      "Not enough documented hypoglycemia episodes",
      "Insufficient evidence of multiple daily insulin injections",
      "Use for type 2 diabetes questioned",
      "Preference for a different CGM"
    ],
    "how_we_help": "We help you compile logs of lows, highs, and variability, plus your insulin regimen, to demonstrate why Dexcom’s continuous data is necessary.",
    "cta": "Start your Dexcom appeal.",
    "faq": [
      {
        "question": "What data should I include?",
        "answer": "Include documented low readings, episodes where you needed help, night-time events, and any ER visits for hypo- or hyperglycemia."
      },
      {
        "question": "Can people with type 2 diabetes qualify?",
        "answer": "Yes, especially on intensive insulin regimens or with high hypoglycemia risk. Your appeal should highlight those factors."
      }
    ],
    "evidence_snippets": [
      "Continuous glucose monitoring reduces hypoglycemia and improves glycemic control compared with finger-stick monitoring alone.",
      "Real-time CGM data allow earlier intervention for rising or falling glucose levels.",
      "Improved glucose control reduces long-term complications and acute events."
    ],
    "pubmed_search_terms": [
      "Dexcom continuous glucose monitoring randomized trial",
      "real time CGM type 1 type 2 diabetes outcomes",
      "continuous glucose monitoring hypoglycemia risk reduction"
    ],
    "assistance_programs": [
      {
        "name": "Dexcom Patient Assistance Program",
        "url": "https://assistance.dexcom.com/",
        "description": "Discounts for qualifying patients, as low as $45 per 90-day supply for Type 1 diabetes patients meeting income criteria."
      },
      {
        "name": "Dexcom Pharmacy Savings Program",
        "url": "https://www.dexcom.com/en-us/savings-center",
        "description": "Save over 50% on standard monthly cash price at participating pharmacies."
      }
    ],
    "advocacy_resources": [
      {
        "name": "American Diabetes Association",
        "url": "https://diabetes.org/",
        "description": "Nation's leading voluntary health organization fighting diabetes through advocacy, research, and education."
      },
      {
        "name": "Beyond Type 1",
        "url": "https://beyondtype1.org/",
        "description": "Global diabetes community providing education, advocacy, and support for people with diabetes."
      }
    ]
  },
  "insulin-pump-cgm-denial-freestyle-libre-denial": {
    "slug": "insulin-pump-cgm-denial-freestyle-libre-denial",
    "title": "Appealing FreeStyle Libre Denials",
    "default_procedure": "FreeStyle Libre Flash Glucose Monitoring",
    "default_condition": "Diabetes",
    "tagline": "Scanning a sensor is not a luxury—it's safer than guessing.",
    "hero_h1": "Appeal Your FreeStyle Libre Denial",
    "hero_subhead": "Libre gives continuous insight without constant finger sticks.",
    "intro": "FreeStyle Libre is often denied as unnecessary when finger-stick testing is available. Appeals can show how sensor data helps prevent severe highs and lows, especially for people on insulin.",
    "common_denial_reasons": [
      "Plan believes standard glucose testing is sufficient",
      "Not enough documented daily testing or insulin use",
      "Use in type 2 diabetes restricted",
      "Supplier or brand not preferred"
    ],
    "how_we_help": "We help you and your clinician show how Libre improves adherence, safety, and control compared with occasional finger-stick checks.",
    "cta": "Start your Libre appeal.",
    "faq": [
      {
        "question": "Should I include my current testing pattern?",
        "answer": "Yes. Show how often you realistically test now and why more frequent data from Libre would improve safety and control."
      },
      {
        "question": "What if I have trouble with finger sticks?",
        "answer": "Note pain, calluses, vision issues, or dexterity limits that make traditional testing difficult—these are strong arguments for Libre."
      }
    ],
    "evidence_snippets": [
      "Flash glucose monitoring improves time in range and reduces hypoglycemia in people with insulin-treated diabetes.",
      "Sensor-based monitoring can increase engagement and adherence to glucose monitoring.",
      "Better glucose data allow more precise insulin adjustments and lifestyle decisions."
    ],
    "pubmed_search_terms": [
      "FreeStyle Libre flash glucose monitoring trial",
      "flash glucose monitoring time in range hypoglycemia",
      "sensor based glucose monitoring insulin treated diabetes"
    ],
    "assistance_programs": [
      {
        "name": "MyFreeStyle Program",
        "url": "https://www.freestyle.abbott/us-en/myfreestyle-freestyle-libre-3.html",
        "description": "Eligible patients can receive one sensor at $0 copay. Free sensor offer for new users."
      },
      {
        "name": "FreeStyle Libre Copay Card",
        "url": "https://www.freestyle.abbott/us-en/support.html",
        "description": "Savings for commercially insured patients. Over 95% of commercial plans cover FreeStyle Libre."
      },
      {
        "name": "Abbott Patient Assistance Foundation",
        "url": "https://www.abbott.com/corpnewsroom/diabetes-care/at-a-crossroads-heres-how-to-get-help-for-diabetes.html",
        "description": "Free or reduced-cost sensors for patients meeting income and insurance criteria."
      }
    ],
    "advocacy_resources": [
      {
        "name": "American Diabetes Association",
        "url": "https://diabetes.org/",
        "description": "Nation's leading voluntary health organization fighting diabetes through advocacy, research, and education."
      },
      {
        "name": "Beyond Type 1",
        "url": "https://beyondtype1.org/",
        "description": "Global diabetes community providing education, advocacy, and support for people with diabetes."
      }
    ]
  },
  "insulin-pump-denial-omnipod-denial": {
    "slug": "insulin-pump-denial-omnipod-denial",
    "title": "Appealing Omnipod Insulin Pump Denials",
    "default_procedure": "Omnipod Insulin Pump System",
    "default_condition": "Diabetes",
    "tagline": "Tubeless pump therapy can be the safest and most realistic option for some people.",
    "hero_h1": "Appeal Your Omnipod Pump Denial",
    "hero_subhead": "If multiple daily injections are not working, Omnipod may be medically necessary.",
    "intro": "Omnipod and other insulin pumps are denied when insurers believe injections are sufficient or another pump should be used. Appeals can show why a tubeless system is necessary for safety, adherence, or disability.",
    "common_denial_reasons": [
      "Not enough documented problems with multiple daily injections",
      "Not meeting criteria for insulin pump therapy",
      "Preference for a different pump brand",
      "Classified as convenience rather than medical necessity"
    ],
    "how_we_help": "We help you describe hypoglycemia risk, dawn phenomenon, injection site issues, and lifestyle factors that make Omnipod safer and more effective than injections.",
    "cta": "Start your Omnipod appeal.",
    "faq": [
      {
        "question": "Why does pump therapy count as medically necessary?",
        "answer": "Your clinician can explain how a pump allows finer dosing, better pattern management, and fewer highs/lows compared with injections."
      },
      {
        "question": "How do I justify Omnipod specifically?",
        "answer": "Mention factors like needle phobia, tubing entanglement risks, work or sports activities, or sensory issues that make tubeless therapy important."
      }
    ],
    "evidence_snippets": [
      "Insulin pump therapy can improve glycemic control and reduce hypoglycemia in selected patients.",
      "Tubeless pump systems may improve quality of life and adherence for some individuals.",
      "Pump therapy is particularly useful for patients requiring flexible basal rates and frequent dose adjustments."
    ],
    "pubmed_search_terms": [
      "insulin pump therapy glycemic control type 1",
      "tubeless insulin pump Omnipod quality of life",
      "insulin pump vs multiple daily injections outcomes"
    ],
    "assistance_programs": [
      {
        "name": "Omnipod Financial Assistance Program",
        "url": "https://www.omnipod.com/is-omnipod-right-for-me/coverage/financial-assistance",
        "description": "Copay card to reduce monthly out-of-pocket costs for commercially insured patients."
      },
      {
        "name": "Omnipod 5 Free Trial",
        "url": "https://www.omnipod.com/what-is-omnipod/omnipod-5",
        "description": "30-day free trial for new patients switching from injections or tubed pumps."
      }
    ],
    "advocacy_resources": [
      {
        "name": "American Diabetes Association",
        "url": "https://diabetes.org/",
        "description": "Nation's leading voluntary health organization fighting diabetes through advocacy, research, and education."
      },
      {
        "name": "Beyond Type 1",
        "url": "https://beyondtype1.org/",
        "description": "Global diabetes community providing education, advocacy, and support for people with diabetes."
      }
    ]
  },
  "pep-denial-hiv-exposure-denial": {
    "slug": "pep-denial-hiv-exposure-denial",
    "title": "Appealing HIV PEP (Post-Exposure Prophylaxis) Denials",
    "default_procedure": "HIV Post-Exposure Prophylaxis (PEP)",
    "default_condition": "HIV Exposure",
    "tagline": "PEP is time-critical emergency prevention — coverage fights come second.",
    "hero_h1": "Appeal Your HIV PEP Denial",
    "hero_subhead": "If you might have been exposed to HIV, getting PEP fast is the emergency — we help you fight the bill after.",
    "intro": "PEP is a course of HIV medicines that should be started as soon as possible after a potential exposure. We encourage you to not wait for insurance and seek out treatment as soon as possible. This page focuses on what to do **after** you’ve gotten care and are facing a denial or a huge bill.",
    "common_denial_reasons": [
      "Insurer claims the exposure was not \"high risk\" enough for PEP",
      "Started PEP close to or slightly beyond a strict 72-hour cutoff",
      "Plan treating PEP as non-emergency pharmacy benefit only (no ER coverage)",
      "Lack of prior authorization even though treatment was urgent",
      "Denial of some components of the 3-drug regimen or follow-up labs"
    ],
    "how_we_help": "We help you explain the exposure, timing, and clinical recommendations in plain language, tie your situation to HIV prevention guidelines, and argue that PEP was urgent post-exposure care — not elective medication. We also help challenge denial of specific drugs or follow-up testing and fix common coding issues.",
    "cta": "Start your HIV PEP appeal.",
    "faq": [
      {
        "question": "What should I do *right now* if I think I’ve been exposed to HIV?",
        "answer": "We do not provide medical advice, but we strongly encourage you to consult a provider as soon as possible as PEP is most effective when started as soon as possible. We strongly encourage you not to wait for an insurance decision to seek care and look into community resources that can help in the meantime."
      },
      {
        "question": "Does it still make sense to appeal if I already finished PEP and only now got the denial?",
        "answer": "Yes. Many people only find out later that their PEP visit or medications weren’t fully covered. Your appeal can explain why PEP was clinically appropriate at the time, how quickly you presented, and what your provider recommended, and ask the plan to reconsider the charges."
      },
      {
        "question": "Can my insurer deny PEP because they think the risk was low?",
        "answer": "Your appeal can describe what actually happened (in terms you’re comfortable with) and reference clinical guidance that supports offering PEP for similar exposures. Plans shouldn’t substitute their own risk guesses for the judgment of clinicians using current guidelines."
      },
      {
        "question": "What if the problem is that different parts of the bill were denied?",
        "answer": "Sometimes the ER visit is covered but the pharmacy isn’t, or vice versa. Your appeal can argue that the visit, medication, and required labs were all part of one medically necessary PEP episode and should be considered together."
      },
      {
        "question": "Are there local resources that can help me besides my insurer?",
        "answer": "Yes. Many cities and states have HIV hotlines, AIDS service organizations, or health department programs that help people access PEP and navigate billing. You can search for \"HIV hotline\" plus your city or state, or call your local health department or an LGBTQ+ community health center to ask about PEP help and financial assistance."
      }
    ],
    "evidence_snippets": [
      "HIV PEP is most effective when started as soon as possible after a potential exposure and must generally be started within 72 hours; earlier is better.",
      "Standard PEP regimens are 3-drug antiretroviral combinations taken for 28 days with follow-up HIV testing.",
      "Clinical guidelines treat HIV exposure as a medical emergency and recommend initiating PEP immediately when indicated, with insurance coverage following standard emergency-care rules."
    ],
    "pubmed_search_terms": [
      "HIV post exposure prophylaxis timing 72 hours 28 days regimen",
      "nonoccupational HIV PEP guidelines United States",
      "emergency HIV exposure prophylaxis clinical outcomes"
    ],
    "assistance_programs": [
      {
        "name": "HIV.gov PEP Access and Assistance",
        "url": "https://www.hiv.gov/hiv-basics/hiv-prevention/using-hiv-medication-to-reduce-risk/post-exposure-prophylaxis/accessing",
        "description": "Overview of how to access PEP quickly and manufacturer patient assistance programs that may provide PEP medications at low or no cost."
      },
      {
        "name": "Gilead Advancing Access",
        "url": "https://www.gileadadvancingaccess.com/",
        "description": "Patient assistance and co-pay support program for certain HIV medications commonly used in PEP regimens."
      },
      {
        "name": "State PrEP/PEP Assistance Programs (NASTAD directory)",
        "url": "https://nastad.org/prepcost-resources/state-prep-assistance-programs",
        "description": "State-level programs that may help with PEP and related lab costs for uninsured or under-insured people."
      }
    ],
    "advocacy_resources": [
      {
        "name": "AIDS Healthcare Foundation",
        "url": "https://www.aidshealth.org/",
        "description": "Global nonprofit providing cutting-edge medicine and advocacy for HIV/AIDS."
      },
      {
        "name": "The Well Project",
        "url": "https://www.thewellproject.org/",
        "description": "Nonprofit focused on HIV/AIDS information and support for women."
      }
    ]
  },
  "doxy-pep-denial": {
    "slug": "doxy-pep-denial",
    "title": "Appealing Doxy-PEP (Doxycycline Post-Exposure Prophylaxis) Denials",
    "default_procedure": "Doxycycline Post-Exposure Prophylaxis (Doxy-PEP) for STIs",
    "default_condition": "STI Prevention",
    "tagline": "Doxy-PEP is guideline-supported STI prevention for some patients — not experimental for everyone.",
    "hero_h1": "Appeal Your Doxy-PEP Denial",
    "hero_subhead": "For some MSM and trans women, taking doxycycline after sex is now part of standard STI prevention.",
    "intro": "Doxycycline post-exposure prophylaxis (doxy-PEP) is a newer STI prevention strategy where certain patients take doxycycline shortly after sex to reduce the risk of syphilis and chlamydia and, in some settings, gonorrhea. Current U.S. guidelines recommend doxy-PEP discussion and prescribing for specific groups, especially men who have sex with men and transgender women with a recent bacterial STI. Plans may deny coverage as \"experimental\" or \"not medically necessary\" even when you’re clearly in the guideline-supported group.",
    "common_denial_reasons": [
      "Classified as experimental or investigational despite guideline support for selected populations",
      "Plan says doxycycline is only covered for infections, not prevention",
      "Risk factors or recent STI history not clearly documented in the chart",
      "Confusion about dosing (e.g., 200 mg within 72 hours after sex) vs standard infection treatment"
    ],
    "how_we_help": "We help your clinician document your risk factors and recent STI history, show that you fall into a guideline-supported group for doxy-PEP, and explain that this is targeted, evidence-based prevention — not casual or indefinite antibiotic use.",
    "cta": "Start your doxy-PEP appeal.",
    "faq": [
      {
        "question": "Who do guidelines say doxy-PEP is appropriate for?",
        "answer": "Current U.S. guidance focuses on men who have sex with men and transgender women who have had a recent bacterial STI like syphilis, chlamydia, or gonorrhea, or who have ongoing high risk of exposure. Your appeal can show that your situation matches those criteria and that the decision was made with shared decision-making."
      },
      {
        "question": "How is doxy-PEP taken?",
        "answer": "Guidelines describe a single dose of doxycycline (often 200 mg) taken within a specified window after condomless sex. Your clinician’s note can clarify your dosing plan and emphasize that this is intermittent, post-exposure prevention — not daily long-term antibiotics."
      },
      {
        "question": "What if my plan is worried about antibiotic resistance or side effects?",
        "answer": "Your appeal can acknowledge these concerns and explain that your clinician is following guideline criteria, monitoring side effects, and periodically re-evaluating whether doxy-PEP is still appropriate, balancing individual and public health considerations."
      },
      {
        "question": "Should I also be getting regular STI screening while on doxy-PEP?",
        "answer": "Yes. Doxy-PEP is designed to complement, not replace, regular STI testing and other prevention strategies. Your appeal can mention that you’re in ongoing sexual health care, including routine screening and follow-up."
      }
    ],
    "evidence_snippets": [
      "Randomized trials have shown that doxy-PEP can substantially reduce syphilis and chlamydia infections and may reduce gonorrhea in some populations of men who have sex with men and transgender women.",
      "CDC clinical guidelines now recommend that clinicians discuss doxy-PEP with certain high-risk patients and consider prescribing it using shared decision-making.",
      "Guideline-based doxy-PEP uses targeted dosing after exposures, not continuous antibiotics, and includes regular STI screening and follow-up."
    ],
    "pubmed_search_terms": [
      "doxycycline postexposure prophylaxis bacterial sexually transmitted infection MSM transgender women",
      "CDC clinical guidelines doxy PEP 2024 syphilis chlamydia gonorrhea",
      "doxy PEP randomized trial STI prevention"
    ]
  },
  "flexitouch-plus-denial": {
    "slug": "flexitouch-plus-denial",
    "title": "Appealing Flexitouch Plus & Advanced Pneumatic Compression Device Denials",
    "default_procedure": "Flexitouch Plus or Similar Advanced Pneumatic Compression Device",
    "default_condition": "Lymphedema",
    "tagline": "For many people with lymphedema, advanced compression devices are medically necessary — not luxury massage gear.",
    "hero_h1": "Appeal Your Flexitouch Plus or Lymphedema Pump Denial",
    "hero_subhead": "When basic compression isn’t enough, advanced pneumatic compression can protect function, skin, and quality of life.",
    "intro": "Devices like Flexitouch Plus are advanced pneumatic compression systems used at home to treat lymphedema, including limb and head-and-neck lymphedema. Insurers often deny them by saying \"use standard compression only,\" demanding long conservative-therapy trials, or calling them experimental. In reality, many coverage policies do allow these devices when conservative measures haven’t worked and there is documented, persistent lymphedema.",
    "common_denial_reasons": [
      "\"Conservative therapy not exhausted\" (e.g., not enough weeks of bandaging, garments, elevation, exercise)",
      "No documentation of persistent swelling, skin changes, or functional limits",
      "Device labeled as experimental or not medically necessary",
      "Request for trunk/head-and-neck treatment when policy is written for limb-only devices",
      "Lack of clear physician plan of care or follow-up notes"
    ],
    "how_we_help": "We help you lay out your full lymphedema history: how long you’ve had swelling, infections, skin breakdown, or pain; what conservative measures you’ve actually tried and for how long; and how much function you’re losing. We also help your clinician reference coverage criteria and clinical studies showing that advanced pneumatic compression can reduce swelling and symptoms, especially when standard care hasn’t been enough.",
    "cta": "Start your Flexitouch Plus or lymphedema pump appeal.",
    "faq": [
      {
        "question": "What counts as \"conservative therapy\" for lymphedema devices?",
        "answer": "Most policies expect a documented period (often 4 weeks or more) of consistent use of compression garments or bandaging, exercise, and elevation, sometimes with complete decongestive therapy. Your appeal should list dates, therapies used, and why they were not enough by themselves."
      },
      {
        "question": "How do I show that I really need an advanced device instead of a basic pump or just garments?",
        "answer": "Your appeal can include limb or neck measurements over time, photos (if you’re comfortable), therapist notes, episodes of cellulitis, difficulty with daily activities, and any failure of simpler devices. If your lymphedema involves the trunk or head and neck, it’s especially important to show why a device designed for those areas is needed."
      },
      {
        "question": "Is Flexitouch Plus actually studied, or is it experimental?",
        "answer": "Clinical studies have evaluated advanced pneumatic compression devices, including Flexitouch systems, in people with limb and head-and-neck lymphedema. Trials have reported improvements in swelling, symptoms, and function compared with self-care alone in selected patients. Your appeal can cite that there is published evidence and that the device is FDA-cleared for lymphedema, even if your plan’s policy summary sounds cautious."
      },
      {
        "question": "What documentation should my doctor or therapist provide?",
        "answer": "Helpful items include a formal lymphedema diagnosis, stage, limb/trunk/neck measurements, photos, a signed plan of care, notes from at least one recent in-person visit, and documentation of conservative measures already tried. If you’ve had hospitalizations or recurrent infections related to lymphedema, include those too."
      }
    ],
    "evidence_snippets": [
      "Coverage policies for home pneumatic compression devices often require a documented trial of conservative therapy and persistent lymphedema before covering advanced devices.",
      "Prospective and randomized studies of advanced pneumatic compression devices, including Flexitouch systems, have reported reductions in limb or head-and-neck swelling, symptom burden, and sometimes healthcare utilization.",
      "Advanced pneumatic compression devices are FDA-cleared for lymphedema treatment and are typically considered when standard garments and basic pumps are insufficient."
    ],
    "pubmed_search_terms": [
      "advanced pneumatic compression device lymphedema Flexitouch randomized trial",
      "home pneumatic compression lymphedema coverage criteria conservative therapy",
      "head and neck lymphedema Flexitouch Plus clinical outcomes"
    ],
    "advocacy_resources": [
      {
        "name": "Lymphatic Education & Research Network",
        "url": "https://lymphaticnetwork.org/",
        "description": "International nonprofit fighting lymphatic diseases through education, research and advocacy."
      },
      {
        "name": "National Lymphedema Network",
        "url": "https://lymphnet.org/",
        "description": "Empowering people with lymphedema through education, advocacy, and care."
      }
    ]
  },
  "continuity-of-care-formulary-change-denial": {
    "slug": "continuity-of-care-formulary-change-denial",
    "title": "Appealing Formulary Changes Using Continuity of Care",
    "default_procedure": "Medication Continuity of Care Exception",
    "tagline": "When your medication worked and the plan changes, you have rights.",
    "hero_h1": "Appeal Your Formulary Change Denial",
    "hero_subhead": "If your medication is removed from formulary or moved to a higher tier, you can request an exception to continue your treatment.",
    "intro": "Insurance plans frequently change their formularies (drug lists), sometimes removing medications that patients are already taking or moving them to higher cost-sharing tiers. Federal regulations and many state laws protect patients by requiring insurers to grant continuity of care exceptions when a formulary change would disrupt ongoing treatment. This page helps you understand your rights and appeal for continued coverage.",
    "common_denial_reasons": [
      "Drug removed from formulary — preferred alternative available",
      "Drug moved to non-preferred or specialty tier with higher cost-sharing",
      "Step therapy required before covering your current medication",
      "Insurer claims equivalent medication is available",
      "Mid-year formulary change with insufficient notice",
      "Prior authorization now required for previously covered drug"
    ],
    "how_we_help": "We help you document how long you've been taking the medication, your treatment history and response, why switching would be medically harmful, and cite the federal and state laws that protect you from disruptive formulary changes. We also help you request a medical exception based on continuity of care.",
    "cta": "Start your formulary change appeal.",
    "faq": [
      {
        "question": "What federal protections exist for formulary changes?",
        "answer": "Often insurers must provide a reasonable transition policy when they remove a drug from formulary. You have the right to request a medically necessary exception, and many state laws add additional protections against non-medical switching."
      },
      {
        "question": "Can my insurer force me to switch medications mid-year?",
        "answer": "Many states have 'non-medical switching' or 'continuity of care' laws that prevent insurers from forcing stable patients to switch medications mid-plan-year. Even without state law, federal regulations require a reasonable transition process. Your appeal can argue that switching now would disrupt your care."
      },
      {
        "question": "What should I include in my appeal?",
        "answer": "Document how long you've been on the medication, how well it's working, any previous failed treatments, and why switching would be harmful. A letter from your doctor explaining medical necessity is essential. Include specific details about your condition stability and any risks of changing medications."
      },
      {
        "question": "What if my insurer says a generic or alternative is available?",
        "answer": "Your appeal can explain why the alternative is not appropriate for you — for example, if you've tried it before and it didn't work, if you have allergies or intolerances, or if the medications are not truly therapeutically equivalent for your condition."
      },
      {
        "question": "How long can I get a continuity of care exception?",
        "answer": "Transition supplies are often limited (e.g., 30-90 days), but you can request a longer exception for the remainder of the plan year. Some states require coverage for the full plan year once granted. Check your state's laws and plan documents."
      }
    ],
    "evidence_snippets": [
      "Often health plans must have a transition policy when drugs are removed from formulary, and patients have the right to request a medically necessary exception.",
      "Many states have enacted non-medical switching laws that protect patients from being forced to change medications that are working well, especially for conditions like cancer, HIV, epilepsy, and mental health.",
      "Clinical research shows that medication switching can lead to adverse outcomes, treatment failures, and increased healthcare costs — supporting the medical necessity of continuity of care."
    ],
    "pubmed_search_terms": [
      "medication switching adverse outcomes treatment stability",
      "formulary exclusion patient impact continuity care",
      "non-medical switching legislation insurance coverage"
    ]
  },
  "humira-formulary-removal-denial": {
    "slug": "humira-formulary-removal-denial",
    "title": "Appealing Humira (Adalimumab) Formulary Removal",
    "default_procedure": "Humira (Adalimumab) Continuity of Care",
    "tagline": "Stable on Humira? You have the right to request continued coverage.",
    "hero_h1": "Fight Your Humira Formulary Removal",
    "hero_subhead": "Some major PBMs removed Humira, but you can appeal for continuity of care.",
    "intro": "CVS Caremark, Express Scripts, and other major pharmacy benefit managers have removed Humira from many formularies in favor of biosimilars. If you've been stable on Humira and your insurer wants you to switch, you have rights under federal continuity of care regulations and potentially state non-medical switching laws.",
    "common_denial_reasons": [
      "Humira removed from formulary — biosimilar required",
      "Plan requires switch to preferred biosimilar (Hyrimoz, Hadlima, etc.)",
      "Humira no longer covered at current tier",
      "Prior authorization required for continued Humira use",
      "Non-formulary exception denied"
    ],
    "how_we_help": "We help you document your treatment history with Humira, explain why biosimilar switching may be harmful in your case, and cite federal and state laws that protect stable patients from forced medication changes.",
    "cta": "Start your Humira continuity of care appeal.",
    "faq": [
      {
        "question": "Why are insurers removing Humira from formularies?",
        "answer": "Multiple adalimumab biosimilars have entered the market since 2023, and PBMs have negotiated deals to prefer certain biosimilars. CVS Caremark, Express Scripts, and OptumRx all excluded Humira from many formularies for 2025 in favor of lower-cost biosimilar options."
      },
      {
        "question": "Are biosimilars truly the same as Humira?",
        "answer": "Biosimilars are highly similar but not identical to the reference product. While FDA-approved biosimilars are considered safe and effective, some patients experience different responses when switching. Your appeal can document any concerns about switching."
      },
      {
        "question": "What if I've tried a biosimilar and it didn't work?",
        "answer": "Document your experience with the biosimilar — side effects, efficacy issues, or other problems. This strengthens your case for continued Humira coverage as medically necessary."
      },
      {
        "question": "Can I get Humira covered even if it's not on formulary?",
        "answer": "Yes. Depending on your plan and it's regulator you can request a non-formulary exception based on medical necessity. Your doctor should provide a letter explaining why Humira specifically is needed for your care."
      }
    ],
    "evidence_snippets": [
      "many health plans must provide a transition process when drugs are removed from formulary, and patients can request exceptions based on medical necessity.",
      "The FDA requires that biosimilars demonstrate no clinically meaningful differences from the reference product, but individual patient responses may vary.",
      "Studies on biosimilar switching show mixed results, and some patients may experience changes in efficacy or tolerability when switching from a reference biologic."
    ],
    "pubmed_search_terms": [
      "adalimumab biosimilar switching efficacy safety",
      "non-medical switching biologic therapy outcomes",
      "humira biosimilar interchangeability patient outcomes"
    ],
    "assistance_programs": [
      {
        "name": "HUMIRA Complete Savings Card",
        "url": "https://www.humira.com/humira-complete/cost-and-copay",
        "description": "Pay as little as $5 per month with commercial insurance. Not valid with government insurance."
      },
      {
        "name": "myAbbVie Assist",
        "url": "https://www.abbvie.com/patients/patient-assistance.html",
        "description": "Patient assistance for uninsured or underinsured patients who qualify based on income."
      }
    ],
    "advocacy_resources": [
      {
        "name": "Arthritis Foundation",
        "url": "https://www.arthritis.org/",
        "description": "Leading organization for arthritis advocacy and support."
      },
      {
        "name": "Crohn's & Colitis Foundation",
        "url": "https://www.crohnscolitisfoundation.org/",
        "description": "IBD patient advocacy and support organization."
      }
    ]
  },
  "stelara-formulary-removal-denial": {
    "slug": "stelara-formulary-removal-denial",
    "title": "Appealing Stelara (Ustekinumab) Formulary Removal",
    "default_procedure": "Stelara (Ustekinumab) Continuity of Care",
    "tagline": "Stable on Stelara? Fight for continued coverage as biosimilars enter the market.",
    "hero_h1": "Fight Your Stelara Formulary Removal",
    "hero_subhead": "Some major PBMs are removing Stelara in 2025-2026, but you can appeal for continuity of care.",
    "intro": "Health Alliance, Navitus, UnitedHealthcare, and other plans are removing Stelara from formularies in 2025-2026 as multiple ustekinumab biosimilars enter the market. If you've been stable on Stelara and your insurer wants you to switch to a biosimilar, you have rights under federal continuity of care regulations.",
    "common_denial_reasons": [
      "Stelara removed from formulary — biosimilar required",
      "Plan requires switch to Steqeyma, Yesintek, or other biosimilar",
      "Stelara no longer covered at current tier",
      "Prior authorization now required for Stelara",
      "Non-formulary exception denied"
    ],
    "how_we_help": "We help you document your treatment history with Stelara, explain why biosimilar switching may be harmful in your case, and cite federal and state laws that protect stable patients from forced medication changes.",
    "cta": "Start your Stelara continuity of care appeal.",
    "faq": [
      {
        "question": "Why are insurers removing Stelara from formularies?",
        "answer": "Multiple ustekinumab biosimilars entered the market in 2024-2025, and PBMs are negotiating deals to prefer lower-cost biosimilar options. By early 2026, most major PBMs will have removed Stelara from national formularies."
      },
      {
        "question": "When is Stelara being removed from my plan?",
        "answer": "Timelines vary: Health Alliance removed Stelara April 2025, Navitus/OptumRx in July 2025, UnitedHealthcare in September 2025, and Blue KC/Express Scripts in January 2026. Check with your specific plan for details."
      },
      {
        "question": "What biosimilars are being preferred instead?",
        "answer": "Common preferred biosimilars include Steqeyma, Yesintek, and private-label versions from Lumicera (OptumRx) and Quallent (Express Scripts). Plans may differ in which specific biosimilar they prefer."
      },
      {
        "question": "Can I get Stelara covered even after it's removed from formulary?",
        "answer": "Yes. You can request a non-formulary exception. However, some plans may require you to pay the difference in cost between Stelara and the preferred biosimilar."
      }
    ],
    "evidence_snippets": [
      "Ustekinumab (Stelara) has demonstrated long-term efficacy and safety in psoriasis, psoriatic arthritis, and inflammatory bowel disease.",
      "Non-medical switching of stable patients from biologic originators to biosimilars may carry risks of altered efficacy or immunogenicity."
    ],
    "pubmed_search_terms": [
      "ustekinumab biosimilar switching efficacy safety",
      "non-medical switching biologic therapy inflammatory bowel disease",
      "stelara biosimilar interchangeability patient outcomes"
    ],
    "assistance_programs": [
      {
        "name": "Janssen CarePath Savings Program",
        "url": "https://www.jnjwithme.com/patient/stelara/cost-support/",
        "description": "Eligible patients with commercial insurance may pay as little as $5 per dose. Not for government insurance."
      },
      {
        "name": "Johnson & Johnson Patient Assistance Foundation",
        "url": "https://www.jnjpaf.org/",
        "description": "Patient assistance for uninsured or underinsured patients who meet income requirements."
      }
    ],
    "advocacy_resources": [
      {
        "name": "Crohn's & Colitis Foundation",
        "url": "https://www.crohnscolitisfoundation.org/",
        "description": "Leading nonprofit for IBD research and patient support."
      },
      {
        "name": "National Psoriasis Foundation",
        "url": "https://www.psoriasis.org/",
        "description": "Patient advocacy for psoriasis and psoriatic arthritis."
      }
    ]
  },
  "entyvio-formulary-removal-denial": {
    "slug": "entyvio-formulary-removal-denial",
    "title": "Appealing Entyvio (Vedolizumab) Formulary Removal",
    "default_procedure": "Entyvio (Vedolizumab) Continuity of Care",
    "default_condition": "Inflammatory Bowel Disease",
    "tagline": "Stable on Entyvio for IBD? Fight for continued coverage.",
    "hero_h1": "Fight Your Entyvio Formulary Removal",
    "hero_subhead": "Express Scripts is excluding Entyvio IV in 2026 — but you can appeal especially for continuity of care.",
    "intro": "Express Scripts is excluding Entyvio IV from the National Preferred Formulary effective 2026. If you have Crohn's disease or ulcerative colitis and are stable on Entyvio, you may have rights under continuity of care regulations.",
    "common_denial_reasons": [
      "Entyvio IV excluded from formulary effective July 2026",
      "Plan requires switch to alternative biologic",
      "Prior authorization now required",
      "Non-formulary exception denied"
    ],
    "how_we_help": "We help you document your IBD treatment history with Entyvio, explain why switching biologics may trigger disease flares, and cite federal and state laws that protect stable patients from forced medication changes.",
    "cta": "Start your Entyvio continuity of care appeal.",
    "faq": [
      {
        "question": "Why is this particularly concerning for IBD patients?",
        "answer": "Switching biologics in IBD can trigger disease flares, and patients may develop antibodies that make returning to their original medication difficult. Your appeal should emphasize the risks of switching when stable."
      },
      {
        "question": "What alternatives might my plan prefer?",
        "answer": "Plans may push for other biologics or JAK inhibitors. Your appeal can explain why Entyvio's gut-selective mechanism is specifically appropriate for your case, especially if you've tried other medications."
      },
      {
        "question": "Can I get Entyvio covered even after exclusion?",
        "answer": "Yes. You can request a non-formulary exception based on medical necessity. Your gastroenterologist should provide a letter explaining why Entyvio specifically is needed."
      }
    ],
    "evidence_snippets": [
      "Vedolizumab (Entyvio) has a gut-selective mechanism of action, which may offer advantages for patients who have failed or are intolerant to systemic immunosuppressants.",
      "Switching biologics in IBD carries risk of disease flare, loss of response, and development of anti-drug antibodies."
    ],
    "pubmed_search_terms": [
      "vedolizumab inflammatory bowel disease switching biologics outcomes",
      "IBD biologic switching disease flare anti-drug antibodies",
      "vedolizumab gut selective mechanism ulcerative colitis Crohn"
    ],
    "assistance_programs": [
      {
        "name": "EntyvioConnect",
        "url": "https://www.entyvio.com/copay-support",
        "description": "Eligible patients with commercial insurance may pay as little as $5 per infusion. Not for government insurance."
      },
      {
        "name": "Takeda Patient Assistance Program",
        "url": "https://www.takeda.com/en-us/what-we-do/patient-services/",
        "description": "Patient assistance for uninsured or underinsured patients who qualify."
      }
    ],
    "advocacy_resources": [
      {
        "name": "Crohn's & Colitis Foundation",
        "url": "https://www.crohnscolitisfoundation.org/",
        "description": "Leading nonprofit organization focused on IBD research and patient support."
      }
    ]
  },
  "skyrizi-formulary-removal-denial": {
    "slug": "skyrizi-formulary-removal-denial",
    "title": "Appealing Skyrizi (Risankizumab) Formulary Removal",
    "default_procedure": "Skyrizi (Risankizumab) Continuity of Care",
    "default_condition": "Psoriasis",
    "tagline": "Stable on Skyrizi for psoriasis or IBD? Fight for continued coverage.",
    "hero_h1": "Fight Your Skyrizi Formulary Removal",
    "hero_subhead": "Some plans are excluding Skyrizi in 2026 — but you can appeal for continuity of care.",
    "intro": "Some PBMs are excluding Skyrizi from formularies in 2026. If you have psoriasis, psoriatic arthritis, or Crohn's disease and are stable on Skyrizi, you have rights under federal continuity of care regulations.",
    "common_denial_reasons": [
      "Skyrizi excluded from formulary",
      "Plan requires switch to alternative biologic (Cosentyx, biosimilar, etc.)",
      "Step therapy required before Skyrizi",
      "Prior authorization now required",
      "Non-formulary exception denied"
    ],
    "how_we_help": "We help you document your treatment history with Skyrizi, explain why switching biologics may trigger disease flares, and cite federal and state laws that protect stable patients from forced medication changes.",
    "cta": "Start your Skyrizi continuity of care appeal.",
    "faq": [
      {
        "question": "Can I get Skyrizi covered even after exclusion?",
        "answer": "Yes. You can request a non-formulary exception based on medical necessity. Your dermatologist or rheumatologist should provide a letter explaining why Skyrizi is specifically needed."
      }
    ],
    "evidence_snippets": [
      "Risankizumab (Skyrizi) selectively targets IL-23, showing high rates of skin clearance in plaque psoriasis and efficacy in psoriatic arthritis and Crohn's disease.",
      "Switching biologics in psoriasis and psoriatic arthritis can result in disease flare and incomplete response to subsequent agents."
    ],
    "pubmed_search_terms": [
      "risankizumab plaque psoriasis IL-23 clinical trial",
      "biologic switching psoriasis loss of response",
      "risankizumab psoriatic arthritis Crohn disease efficacy"
    ],
    "assistance_programs": [
      {
        "name": "Skyrizi Complete Savings Card",
        "url": "https://www.skyrizi.com/skyrizi-complete/save-on-skyrizi-costs",
        "description": "Eligible patients with commercial insurance may pay as little as $5 per dose. Not for government insurance."
      },
      {
        "name": "myAbbVie Assist",
        "url": "https://www.abbvie.com/patients/patient-assistance.html",
        "description": "Patient assistance for uninsured or underinsured patients who qualify based on income."
      }
    ],
    "advocacy_resources": [
      {
        "name": "National Psoriasis Foundation",
        "url": "https://www.psoriasis.org/",
        "description": "Patient-centric nonprofit driving research and improving lives of those with psoriatic disease."
      }
    ]
  },
  "tremfya-formulary-removal-denial": {
    "slug": "tremfya-formulary-removal-denial",
    "title": "Appealing Tremfya (Guselkumab) Formulary Removal",
    "default_procedure": "Tremfya (Guselkumab) Continuity of Care",
    "default_condition": "Psoriasis",
    "tagline": "Stable on Tremfya for psoriasis? Fight for continued coverage.",
    "hero_h1": "Fight Your Tremfya Formulary Removal",
    "hero_subhead": "Express Scripts is excluding Tremfya in 2026 — but you can appeal for continuity of care.",
    "intro": "Express Scripts is excluding Tremfya from the National Preferred Formulary in 2026. If you have psoriasis or psoriatic arthritis and are stable on Tremfya, you have rights under federal continuity of care regulations.",
    "common_denial_reasons": [
      "Tremfya excluded from formulary",
      "Plan requires switch to alternative biologic",
      "Step therapy required before Tremfya",
      "Prior authorization now required",
      "Non-formulary exception denied"
    ],
    "how_we_help": "We help you document your treatment history with Tremfya, explain why switching biologics may trigger disease flares, and cite federal and state laws that protect stable patients from forced medication changes.",
    "cta": "Start your Tremfya continuity of care appeal.",
    "faq": [],
    "evidence_snippets": [
      "Guselkumab (Tremfya) selectively targets IL-23, showing high rates of skin clearance in plaque psoriasis and efficacy in psoriatic arthritis.",
      "Switching biologics in psoriasis can result in disease flare and may not achieve the same level of clearance as the original medication."
    ],
    "pubmed_search_terms": [
      "guselkumab plaque psoriasis IL-23 clinical trial",
      "biologic switching psoriasis loss of response outcomes",
      "guselkumab psoriatic arthritis efficacy safety"
    ],
    "assistance_programs": [
      {
        "name": "Janssen CarePath Savings Program",
        "url": "https://www.janssencarepath.com/tremfya",
        "description": "Eligible patients with commercial insurance may pay as little as $5 per dose. Not for government insurance."
      },
      {
        "name": "Johnson & Johnson Patient Assistance Foundation",
        "url": "https://www.jnjpaf.org/",
        "description": "Patient assistance for uninsured or underinsured patients who meet income requirements."
      }
    ],
    "advocacy_resources": [
      {
        "name": "National Psoriasis Foundation",
        "url": "https://www.psoriasis.org/",
        "description": "Patient-centric nonprofit driving research and improving lives of those with psoriatic disease."
      }
    ]
  },
  "skilled-nursing-denial": {
    "slug": "skilled-nursing-denial",
    "title": "Appealing Skilled Nursing Facility Denials",
    "default_procedure": "Skilled Nursing Facility (SNF) Care",
    "tagline": "UHC Medicare Advantage SNF denials increased 9x from 2019 to 2022: fight back.",
    "hero_h1": "Appeal Your Skilled Nursing Facility Denial",
    "hero_subhead": "Post-hospital care is essential for recovery. Don't be discharged too early.",
    "intro": "Skilled nursing facility denials have exploded, especially in Medicare Advantage plans. Between 2019 and 2022, SNF denials increased 9-fold, often driven by AI algorithms rather than clinical judgment. The good news: studies suggest the majority of appealed SNF denials are overturned, but few patients appeal. You have rights — use them.",
    "common_denial_reasons": [
      "Patient no longer meets skilled care criteria",
      "Custodial care only — not skilled nursing",
      "Discharge to home is appropriate",
      "Maximum benefit reached",
      "Prior authorization expired"
    ],
    "how_we_help": "We help you document why skilled nursing care remains medically necessary, including specific skilled services needed (wound care, IV medications, PT/OT, complex medication management) and risks of premature discharge.",
    "cta": "Start your SNF appeal before you're discharged.",
    "faq": [
      {
        "question": "Can I stay in the SNF while I appeal?",
        "answer": "Often, under Medicare, you can request a 'fast appeal' and remain in the facility while your case is reviewed. Ask for a written denial notice and file immediately."
      },
      {
        "question": "What if the insurer says I can continue care at home?",
        "answer": "Your appeal should document why home care isn't safe or feasible: caregiver limitations, home environment issues, or medical complexity requiring 24/7 skilled oversight."
      }
    ],
    "evidence_snippets": [
      "Premature discharge from skilled nursing facilities is associated with higher hospital readmission rates.",
      "Medicare guidelines require coverage when skilled nursing or rehabilitation services are needed on a daily basis.",
      "Continued SNF care is medically necessary when the patient requires skilled services that cannot safely be provided in a less intensive setting.",
      "Refusal of Recovery: How Medicare Advantage Insurers Have Denied Patients Access to Post-Acute Care"
    ],
    "pubmed_search_terms": [
      "skilled nursing facility discharge outcomes readmission",
      "Medicare SNF coverage criteria medical necessity",
      "post-acute care denial Medicare Advantage"
    ],
    "alternatives": [
      "Home health care with visiting nurses may be an option if you have adequate support at home.",
      "Some long-term acute care hospitals (LTACHs) provide a higher level of care if SNF isn't sufficient.",
      "Ask about swing bed programs at community hospitals which combine acute and SNF-level care."
    ],
    "advocacy_resources": [
      {
        "name": "Center for Medicare Advocacy",
        "url": "https://www.medicareadvocacy.org/",
        "description": "Nonprofit providing legal resources for Medicare coverage issues including SNF care."
      }
    ]
  },
  "home-health-denial": {
    "slug": "home-health-denial",
    "title": "Appealing Home Health Care Denials",
    "default_procedure": "Home Health Care / Home Nursing Services",
    "tagline": "Medicare's 'homebound' requirement trips up many patients — learn how to appeal.",
    "hero_h1": "Appeal Your Home Health Care Denial",
    "hero_subhead": "You shouldn't have to choose between leaving home and losing coverage.",
    "intro": "Home health care denials often hinge on the 'homebound' requirement and whether you need 'skilled' nursing care. Medicare Advantage plans are increasingly using narrow interpretations to deny home health services, even when your doctor has ordered them. Understanding what qualifies as homebound and skilled care is key to winning your appeal.",
    "common_denial_reasons": [
      "Patient not homebound",
      "Skilled care not required",
      "Services are maintenance only",
      "Caregiver can provide this care",
      "Frequency of visits not justified"
    ],
    "how_we_help": "We help you document your homebound status (leaving home requires considerable effort, assistance, or poses medical risk) and why skilled nursing or therapy services are medically necessary.",
    "cta": "Start your home health appeal.",
    "faq": [],
    "evidence_snippets": [
      "Home health services reduce hospital readmissions and improve outcomes for patients recovering from illness, injury, or surgery.",
      "The homebound requirement is met when leaving home requires considerable effort or assistance, not complete inability to leave.",
      "Skilled nursing services are medically necessary when the complexity of the patient's condition requires professional assessment and intervention."
    ],
    "pubmed_search_terms": [
      "home health care outcomes hospital readmission prevention",
      "Medicare home health homebound criteria definition",
      "skilled nursing home health medical necessity"
    ],
    "alternatives": [
      "Adult day programs may provide supervision and therapy while preserving home health eligibility.",
      "Telehealth visits may supplement in-person home health for some services.",
      "Community-based waiver programs may provide additional home care services in some states."
    ],
    "advocacy_resources": [
      {
        "name": "National Association for Home Care & Hospice",
        "url": "https://www.nahc.org/",
        "description": "Trade association advocating for home care access and coverage."
      }
    ]
  },
  "joint-replacement-denial": {
    "slug": "joint-replacement-denial",
    "title": "Appealing Knee and Hip Replacement Denials",
    "default_procedure": "Total Knee or Hip Replacement",
    "tagline": "Joint replacement is one of the most successful surgeries — insurers shouldn't block it.",
    "hero_h1": "Appeal Your Joint Replacement Denial",
    "hero_subhead": "When conservative treatment fails, surgery is the answer.",
    "intro": "Knee and hip replacements are among the most successful surgeries performed, with high satisfaction rates and dramatic quality-of-life improvements. Yet insurers frequently deny them, claiming you haven't tried enough conservative treatments or the surgery isn't 'medically necessary.' If you're living with severe joint pain that limits your daily activities, you deserve surgery.",
    "common_denial_reasons": [
      "Insufficient conservative treatment trial",
      "BMI too high for surgery",
      "Not medically necessary",
      "Imaging doesn't show severe enough damage",
      "Must try injections or physical therapy first"
    ],
    "how_we_help": "We help you document your pain level, functional limitations, failed conservative treatments (PT, injections, medications), and imaging results that support surgical intervention.",
    "cta": "Start your joint replacement appeal.",
    "faq": [
      {
        "question": "How much conservative treatment is 'enough'?",
        "answer": "Most guidelines suggest 3-6 months of conservative treatment including PT, anti-inflammatory medications, and possibly injections. Your appeal should list everything you've tried, how long you tried it, and why it didn't work."
      },
      {
        "question": "What if my BMI is above their cutoff?",
        "answer": "BMI cutoffs vary and are controversial. Your appeal can cite studies showing successful outcomes at higher BMIs, your surgeon's assessment of surgical risk, and why delaying surgery may worsen outcomes."
      },
      {
        "question": "Do I need X-rays showing 'bone-on-bone'?",
        "answer": "Not necessarily. Imaging is one factor, but clinical symptoms matter too. Your appeal should describe your pain, functional limitations, and your surgeon's assessment, not just imaging findings."
      }
    ],
    "evidence_snippets": [
      "Total joint replacement is a cost-effective intervention that significantly improves quality of life and functional status.",
      "Delaying medically necessary joint replacement can lead to muscle atrophy, deconditioning, and poorer surgical outcomes.",
      "Patient-reported pain and functional limitation are important indicators for joint replacement, independent of radiographic severity."
    ],
    "pubmed_search_terms": [
      "total knee replacement outcomes quality of life",
      "joint replacement surgical criteria medical necessity",
      "delay hip replacement outcomes deconditioning"
    ],
    "alternatives": [
      "Partial knee replacement may be an option for some patients with localized arthritis.",
      "Joint preservation procedures like osteotomy may delay the need for replacement in younger patients.",
      "Ask about outpatient joint replacement programs which may have different coverage criteria."
    ],
    "advocacy_resources": [
      {
        "name": "Arthritis Foundation",
        "url": "https://www.arthritis.org/",
        "description": "Leading organization for arthritis support, advocacy, and research."
      }
    ]
  },
  "out-of-network-emergency-denial": {
    "slug": "out-of-network-emergency-denial",
    "title": "Appealing Out-of-Network Emergency Room Denials",
    "default_procedure": "Emergency Room Services",
    "tagline": "Federal law protects you from surprise ER bills — insurers must comply.",
    "hero_h1": "Appeal Your Out-of-Network ER Denial",
    "hero_subhead": "The No Surprises Act protects you. Make your insurer follow the law.",
    "intro": "Since 2022, the No Surprises Act helps protect patients from surprise bills when they receive emergency care at out-of-network facilities. Yet insurers continue to improperly deny or underpay these claims. You normally cannot be balance-billed more than your in-network cost-sharing, and your insurer must pay the emergency facility appropriately. If your claim was denied or you received a surprise bill, you have strong appeal rights.",
    "common_denial_reasons": [
      "Out-of-network provider",
      "Emergency not verified",
      "Post-stabilization care not covered",
      "Claim filed incorrectly",
      "Balance billing by provider"
    ],
    "how_we_help": "We help you document the emergency nature of your visit, cite the No Surprises Act protections, and explain why your insurer must cover the claim at in-network cost-sharing levels.",
    "cta": "Start your emergency care appeal.",
    "faq": [
      {
        "question": "What is the No Surprises Act?",
        "answer": "Federal law since January 2022 that protects patients from surprise bills when receiving emergency care, even at out-of-network facilities. Your insurer must cover the claim and you only owe in-network cost-sharing."
      },
      {
        "question": "Can I be balance-billed for emergency care?",
        "answer": "Normally no. Under the No Surprises Act, out-of-network emergency providers cannot balance bill you for more than your in-network deductible and coinsurance. Report violations to your state insurance department. Unfortunately there are exceptions (including ground ambulances)."
      },
      {
        "question": "What about care after I was stabilized?",
        "answer": "Some post-stabilization care at out-of-network facilities can be protected until you can safely be transferred. Your appeal should document that you were not stable enough to transfer."
      }
    ],
    "evidence_snippets": [
      "The No Surprises Act requires insurers to cover emergency services at out-of-network facilities without requiring prior authorization.",
      "Patients cannot be charged more than in-network cost-sharing for emergency services regardless of network status.",
      "Emergency medical conditions are defined as those requiring immediate medical attention to prevent serious health consequences."
    ],
    "pubmed_search_terms": [
      "surprise medical billing emergency department policy",
      "out of network emergency care patient protections",
      "No Surprises Act emergency services implementation"
    ],
    "alternatives": [
      "File a complaint with your state insurance department if you receive a surprise balance bill.",
      "Request the Independent Dispute Resolution process if your insurer and provider can't agree on payment.",
      "Contact the CMS No Surprises Help Desk at 1-800-985-3059 for assistance."
    ]
  },
  "medicare-work-requirements-denial": {
    "slug": "medicare-work-requirements-denial",
    "title": "Understanding Medicare Work Requirements",
    "default_procedure": "Medicare Work Requirements",
    "tagline": "Navigating the new Medicare work requirements and understanding your obligations.",
    "hero_h1": "Understanding Medicare Work Requirements",
    "hero_subhead": "Get clarity on the new work requirements and how they affect your Medicare coverage.",
    "intro": "Medicare has introduced new work requirements that affect certain beneficiaries. Understanding these requirements is crucial to maintaining your coverage. We can help you navigate what you need to know, what documentation you need, and how to comply with these new rules.",
    "common_denial_reasons": [
      "Insufficient documentation of work hours",
      "Missing verification of job search activities",
      "Lack of proof of exemption status",
      "Incomplete work requirement reporting",
      "Failure to meet monthly work hour minimums"
    ],
    "how_we_help": "We help you understand the Medicare work requirements, what documentation you need to maintain coverage, how to report your work activities, and what exemptions might apply to your situation.",
    "cta": "Get help understanding Medicare work requirements",
    "faq": [
      {
        "question": "What are the new Medicare work requirements?",
        "answer": "Medicare work requirements mandate that certain beneficiaries engage in work activities, job training, or community service for a specified number of hours per month to maintain their coverage. The specific requirements vary by state and individual circumstances."
      },
      {
        "question": "Who is subject to Medicare work requirements?",
        "answer": "Work requirements typically apply to able-bodied adults without dependents between certain ages. Many exemptions exist for individuals with disabilities, caregivers, students, and others. Check with your state Medicaid office for specific criteria."
      },
      {
        "question": "How do I report my work hours for Medicare?",
        "answer": "Most states have online portals or phone systems for reporting work hours. You typically need to report monthly and provide documentation such as pay stubs, employer verification, or volunteer service confirmation. Keep copies of all documentation you submit."
      },
      {
        "question": "What happens if I cannot meet the work requirements?",
        "answer": "If you cannot meet the requirements, you should immediately apply for an exemption. Valid exemptions include disability, caregiving responsibilities, pregnancy, student status, and other circumstances. Document your exemption status carefully to maintain coverage."
      },
      {
        "question": "Can I appeal if my coverage is terminated for not meeting work requirements?",
        "answer": "Yes, you have the right to appeal if your coverage is terminated. You typically have 60 days to file an appeal. Your appeal should include documentation of your work activities, proof of exemption status, or evidence of good cause for not meeting requirements."
      }
    ],
    "evidence_snippets": [
      "Medicare work requirements must include reasonable exemptions and good cause exceptions as mandated by federal regulations.",
      "Beneficiaries have the right to appeal coverage terminations related to work requirements through the standard Medicare appeals process.",
      "Proper documentation of work activities, exemptions, and compliance efforts is essential for maintaining coverage under work requirement policies."
    ],
    "pubmed_search_terms": [
      "Medicare Medicaid work requirements health outcomes",
      "work requirement policies health insurance coverage",
      "Medicare eligibility work mandate compliance"
    ],
    "medicare": true,
    "blog_post_url": "/blog/medicaid-work-requirements/"
  },
  "colonoscopy-denial": {
    "slug": "colonoscopy-denial",
    "title": "Appealing Colonoscopy Denials",
    "default_procedure": "Colonoscopy",
    "tagline": "Colonoscopy denials can delay life-saving cancer screening—here's how to fight back.",
    "hero_h1": "Appeal Your Colonoscopy Denial",
    "hero_subhead": "Don't let \"not medically necessary\" prevent critical screening.",
    "intro": "Colonoscopies are frequently denied when insurers claim you're too young, it's too soon for a repeat screening, or symptoms don't justify the procedure. But colorectal cancer screening saves lives, and if your doctor ordered it, there's a strong medical rationale you can use to overturn the denial.",
    "common_denial_reasons": [
      "Patient too young for screening",
      "Not enough time since last colonoscopy",
      "Insufficient documentation of symptoms",
      "Alternative screening test recommended first",
      "Family history not adequately documented",
      "Out-of-network provider"
    ],
    "how_we_help": "We help you document your risk factors, symptoms, and physician recommendations in a way that demonstrates medical necessity. Upload your denial letter and we'll generate a compelling appeal that cites clinical guidelines and your specific circumstances.",
    "cta": "Start your colonoscopy appeal — it takes about 3 minutes.",
    "faq": [
      {
        "question": "Can I appeal if I'm younger than 45 and my colonoscopy was denied?",
        "answer": "Yes. While routine screening typically starts at 45, many factors justify earlier screening including family history of colorectal cancer, personal history of polyps or inflammatory bowel disease, unexplained symptoms, or genetic conditions. Your appeal should clearly document these risk factors."
      },
      {
        "question": "What if my insurer says it's too soon for another colonoscopy?",
        "answer": "Standard intervals between colonoscopies depend on prior findings. If you had polyps, adenomas, or other concerning findings, shorter intervals may be medically appropriate. Your appeal should reference your prior colonoscopy results and current clinical guidelines for surveillance."
      },
      {
        "question": "My doctor recommended colonoscopy for symptoms—why was it denied?",
        "answer": "Insurers sometimes claim symptoms can be evaluated with less invasive tests first. Your appeal should detail your symptoms (bleeding, pain, changes in bowel habits, unexplained weight loss), their duration and severity, and why direct visualization with colonoscopy is the appropriate diagnostic approach."
      },
      {
        "question": "Do I need my doctor to write a letter for my colonoscopy appeal?",
        "answer": "It's very helpful. A letter from your gastroenterologist or ordering physician explaining why the colonoscopy is medically necessary—citing your specific risk factors, symptoms, or prior findings—significantly strengthens your appeal."
      },
      {
        "question": "What if they want me to do a stool test instead?",
        "answer": "While stool-based tests like FIT or Cologuard can be appropriate for average-risk screening, they're not suitable for everyone. If you have symptoms, a family history, prior polyps, or other risk factors, colonoscopy may be the recommended test. Your appeal should explain why a stool test is insufficient for your situation."
      }
    ],
    "evidence_snippets": [
      "Colorectal cancer is the third most common cancer and the second leading cause of cancer death in the United States. Early detection through colonoscopy significantly reduces mortality.",
      "Clinical guidelines support earlier or more frequent colonoscopy for individuals with increased risk factors including family history, personal history of polyps or colorectal cancer, inflammatory bowel disease, and certain genetic syndromes.",
      "Colonoscopy is the gold standard for colorectal cancer screening, allowing both detection and removal of precancerous polyps during the same procedure.",
      "Delayed colorectal cancer screening can result in later-stage diagnoses, worse outcomes, and higher treatment costs.",
      "The requested colonoscopy is consistent with evidence-based guidelines and the standard of care for this clinical presentation."
    ],
    "pubmed_search_terms": [
      "colonoscopy screening guidelines age family history",
      "colorectal cancer screening appropriateness criteria",
      "colonoscopy surveillance intervals polyps adenomas",
      "early-onset colorectal cancer risk factors",
      "colonoscopy diagnostic evaluation symptoms bleeding"
    ],
    "advocacy_resources": [
      {
        "name": "Colorectal Cancer Alliance",
        "url": "https://www.ccalliance.org/",
        "description": "National nonprofit providing support, raising awareness, and advocating for colorectal cancer screening."
      },
      {
        "name": "Fight Colorectal Cancer",
        "url": "https://fightcolorectalcancer.org/",
        "description": "Advocacy organization fighting for access to colorectal cancer screening and treatment."
      }
    ]
  },
  "myqorzo-denial": {
    "slug": "myqorzo-denial",
    "title": "Appealing Myqorzo (Aficamten) Denials",
    "default_procedure": "Myqorzo (aficamten)",
    "default_condition": "Obstructive Hypertrophic Cardiomyopathy",
    "tagline": "Help appealing denials for this cardiac myosin inhibitor for symptomatic obstructive HCM.",
    "hero_h1": "Appeal Your Myqorzo Denial",
    "hero_subhead": "Don't let your insurer deny access to this first-in-class treatment for obstructive hypertrophic cardiomyopathy.",
    "intro": "Myqorzo (aficamten) is a cardiac myosin inhibitor FDA-approved for adults with symptomatic obstructive hypertrophic cardiomyopathy (oHCM) to improve functional capacity and symptoms. Insurance denials often cite lack of prior authorization, preference for older treatments, or questions about medical necessity. If your cardiologist prescribed Myqorzo, you have strong grounds for appeal.",
    "manufacturer": "Cytokinetics",
    "common_denial_reasons": [
      "Not medically necessary",
      "Prior authorization required",
      "Preferred alternative available (mavacamten/Camzyos)",
      "Insufficient documentation of oHCM diagnosis",
      "Step therapy requirement not met",
      "Specialty tier drug not covered"
    ],
    "how_we_help": "We help you document your oHCM diagnosis, symptom severity, prior treatments, and why Myqorzo is the appropriate choice for your condition. Our AI-powered tool generates a compelling appeal letter citing clinical evidence.",
    "cta": "Start your Myqorzo appeal — it takes about 3 minutes.",
    "faq": [
      {
        "question": "Why was my Myqorzo prescription denied?",
        "answer": "Common reasons include lack of prior authorization, insurer preference for other treatments, insufficient documentation of your oHCM diagnosis, or the drug being on a high-cost specialty tier. Your denial letter should specify the reason."
      },
      {
        "question": "What documentation do I need for my Myqorzo appeal?",
        "answer": "Helpful documentation includes your echocardiogram results showing LVOT obstruction, documentation of your symptoms (shortness of breath, chest pain, exercise intolerance), records of prior treatments tried, and a letter from your cardiologist explaining why Myqorzo is medically necessary."
      },
      {
        "question": "Is Myqorzo covered by Medicare?",
        "answer": "Myqorzo is typically covered under Medicare Part D as a specialty pharmacy drug. However, prior authorization is usually required, and you may need to demonstrate that you meet specific clinical criteria for coverage."
      }
    ],
    "evidence_snippets": [
      "Aficamten is a selective cardiac myosin inhibitor that reduces excessive contractility in obstructive HCM, improving symptoms and exercise capacity.",
      "Clinical trials demonstrated significant improvement in peak oxygen uptake and reduction in LVOT gradient with aficamten treatment.",
      "Obstructive HCM significantly impacts quality of life and can lead to heart failure, arrhythmias, and sudden cardiac death if inadequately treated.",
      "Current guidelines support the use of cardiac myosin inhibitors for patients with symptomatic oHCM who have inadequate response to or cannot tolerate beta-blockers or calcium channel blockers."
    ],
    "pubmed_search_terms": [
      "aficamten obstructive hypertrophic cardiomyopathy clinical trials",
      "cardiac myosin inhibitor HCM treatment outcomes",
      "obstructive HCM medical therapy guidelines"
    ],
    "assistance_programs": [
      {
        "name": "MYQORZO & You Patient Support",
        "url": "https://www.cytokinetics.com/patients",
        "description": "Cytokinetics patient support program offering insurance navigation, financial assistance for eligible patients, and disease education. Call 833-MYQORZO (833-697-6796)."
      }
    ],
    "advocacy_resources": [
      {
        "name": "National Organization for Rare Disorders (NORD)",
        "url": "https://rarediseases.org/",
        "description": "Leading patient advocacy organization for rare disease community."
      },
      {
        "name": "Global Genes",
        "url": "https://globalgenes.org/",
        "description": "Leading rare disease patient advocacy organization connecting and empowering patients."
      }
    ]
  },
  "exdensur-denial": {
    "slug": "exdensur-denial",
    "title": "Appealing Exdensur (Depemokimab) Denials",
    "default_procedure": "Exdensur (depemokimab)",
    "default_condition": "Severe Eosinophilic Asthma",
    "tagline": "Help appealing denials for this twice-yearly biologic for severe eosinophilic asthma.",
    "hero_h1": "Appeal Your Exdensur Denial",
    "hero_subhead": "Get access to this ultra-long-acting IL-5 biologic for severe asthma.",
    "intro": "Exdensur (depemokimab) is the first and only ultra-long-acting biologic with twice-yearly dosing approved for patients with severe asthma with an eosinophilic phenotype. Insurance denials often require documentation of eosinophil levels, prior biologic use, or step therapy requirements. If you have severe eosinophilic asthma, you deserve access to this innovative treatment.",
    "manufacturer": "GlaxoSmithKline (GSK)",
    "common_denial_reasons": [
      "Eosinophil levels not documented",
      "Must try other biologics first",
      "Step therapy requirement not met",
      "Prior authorization not obtained",
      "Not medically necessary",
      "Documentation of severe asthma inadequate"
    ],
    "how_we_help": "We help you compile your eosinophil counts, asthma control scores, exacerbation history, and prior treatment records to demonstrate medical necessity for Exdensur.",
    "cta": "Start your Exdensur appeal — it takes about 3 minutes.",
    "faq": [
      {
        "question": "What eosinophil level do I need for Exdensur coverage?",
        "answer": "Most insurers require documentation of blood eosinophils at 150 cells/mcL or higher at initiation or 300 cells/mcL or higher in the past 12 months. Your appeal should include lab results showing your eosinophil levels."
      },
      {
        "question": "Do I need to try other biologics before Exdensur?",
        "answer": "Some insurers require step therapy through other IL-5 pathway biologics first. However, you may appeal this requirement if you have specific reasons why Exdensur's twice-yearly dosing is medically necessary for you."
      },
      {
        "question": "How is Exdensur administered?",
        "answer": "Exdensur is given as a subcutaneous injection every 6 months (twice yearly), making it the longest-acting asthma biologic available. This may be covered under your medical benefit rather than pharmacy benefit."
      }
    ],
    "evidence_snippets": [
      "Depemokimab is an ultra-long-acting anti-IL-5 monoclonal antibody that provides sustained eosinophil suppression with twice-yearly dosing.",
      "Clinical trials demonstrated significant reduction in annual asthma exacerbation rates in patients with severe eosinophilic asthma.",
      "Severe eosinophilic asthma significantly impacts quality of life and can lead to frequent exacerbations, hospitalizations, and oral corticosteroid dependence.",
      "IL-5 pathway biologics are recommended by guidelines for patients with severe eosinophilic asthma uncontrolled on high-dose inhaled corticosteroids."
    ],
    "pubmed_search_terms": [
      "depemokimab severe eosinophilic asthma",
      "IL-5 biologics asthma exacerbation reduction",
      "ultra-long-acting asthma biologics"
    ],
    "assistance_programs": [
      {
        "name": "GSK Patient Assistance Programs",
        "url": "https://gskforyou.com/",
        "description": "GSK offers copay assistance (eligible patients may pay $0, up to $26,000/year) and patient assistance for uninsured patients. Call 1-866-728-4368."
      }
    ],
    "advocacy_resources": [
      {
        "name": "Asthma and Allergy Foundation of America",
        "url": "https://aafa.org/",
        "description": "Leading patient advocacy organization for asthma and allergies, certified by National Health Council."
      },
      {
        "name": "Allergy & Asthma Network",
        "url": "https://allergyasthmanetwork.org/",
        "description": "Nonprofit patient outreach, education, advocacy and research organization."
      }
    ]
  },
  "cardamyst-denial": {
    "slug": "cardamyst-denial",
    "title": "Appealing Cardamyst (Etripamil) Denials",
    "default_procedure": "Cardamyst (etripamil) nasal spray",
    "default_condition": "Paroxysmal Supraventricular Tachycardia",
    "tagline": "Help appealing denials for this first self-administered nasal spray for PSVT episodes.",
    "hero_h1": "Appeal Your Cardamyst Denial",
    "hero_subhead": "Get access to the first at-home treatment for acute PSVT episodes.",
    "intro": "Cardamyst (etripamil) is the first and only self-administered nasal spray approved for converting acute paroxysmal supraventricular tachycardia (PSVT) episodes to normal heart rhythm. This means you can treat episodes at home instead of going to the emergency room. Insurance denials often cite preference for ER treatment or questions about PSVT diagnosis.",
    "manufacturer": "Milestone Pharmaceuticals",
    "common_denial_reasons": [
      "Prior authorization required",
      "PSVT diagnosis not adequately documented",
      "Preference for emergency department treatment",
      "Not medically necessary",
      "New drug with limited coverage policies",
      "Step therapy through vagal maneuvers first"
    ],
    "how_we_help": "We help you document your PSVT diagnosis, frequency of episodes, impact on quality of life, and prior emergency room visits to demonstrate why at-home treatment is medically necessary and cost-effective.",
    "cta": "Start your Cardamyst appeal — it takes about 3 minutes.",
    "faq": [
      {
        "question": "Why would I want Cardamyst instead of going to the ER?",
        "answer": "Cardamyst allows you to treat PSVT episodes at home, avoiding the time, cost, and stress of emergency room visits. For many patients, this significantly improves quality of life and reduces healthcare costs."
      },
      {
        "question": "What documentation helps my Cardamyst appeal?",
        "answer": "Include your electrophysiology study or EKG documentation of PSVT, records of prior ER visits for PSVT, documentation of episode frequency, and a letter from your cardiologist or electrophysiologist."
      },
      {
        "question": "How does Cardamyst work?",
        "answer": "Cardamyst is a calcium channel blocker delivered as a nasal spray that works to convert PSVT episodes back to normal sinus rhythm. It's designed to be self-administered during an episode."
      }
    ],
    "evidence_snippets": [
      "Etripamil nasal spray provides rapid conversion of PSVT episodes, with most conversions occurring within 30 minutes of administration.",
      "Self-administered PSVT treatment significantly reduces emergency department utilization and associated healthcare costs.",
      "PSVT affects over 2 million Americans and causes significant anxiety, loss of work productivity, and impaired quality of life.",
      "At-home treatment options for PSVT align with patient-centered care principles and reduce burden on emergency services."
    ],
    "pubmed_search_terms": [
      "etripamil paroxysmal supraventricular tachycardia",
      "PSVT self-treatment nasal spray",
      "PSVT emergency department utilization costs"
    ],
    "assistance_programs": [],
    "advocacy_resources": [
      {
        "name": "StopAfib.org",
        "url": "https://www.stopafib.org/",
        "description": "Patient advocacy organization founded by and for afib patients."
      }
    ]
  },
  "lerochol-denial": {
    "slug": "lerochol-denial",
    "title": "Appealing Lerochol (Lerodalcibep) Denials",
    "default_procedure": "Lerochol (lerodalcibep)",
    "default_condition": "Hypercholesterolemia",
    "tagline": "Help appealing denials for this monthly PCSK9 inhibitor for high LDL cholesterol.",
    "hero_h1": "Appeal Your Lerochol Denial",
    "hero_subhead": "Get access to this once-monthly injectable for lowering LDL cholesterol.",
    "intro": "Lerochol (lerodalcibep) is a PCSK9 inhibitor approved as an adjunct to diet and exercise for adults with hypercholesterolemia, including heterozygous familial hypercholesterolemia (HeFH). Unlike other PCSK9 inhibitors, it's dosed once monthly. Insurance often denies PCSK9 inhibitors due to high cost, but these medications are essential for patients who cannot reach LDL goals with statins alone.",
    "manufacturer": "LIB Therapeutics",
    "common_denial_reasons": [
      "Must try maximum-tolerated statin first",
      "LDL goal not defined or documented",
      "Prior authorization required",
      "Preferred PCSK9 inhibitor required",
      "Documentation of statin intolerance inadequate",
      "High-cost specialty medication"
    ],
    "how_we_help": "We help you document your LDL levels, statin history (including intolerance if applicable), cardiovascular risk factors, and why achieving LDL goals is critical for your health.",
    "cta": "Start your Lerochol appeal — it takes about 3 minutes.",
    "faq": [
      {
        "question": "What LDL level do I need for PCSK9 inhibitor coverage?",
        "answer": "Coverage criteria vary by insurer, but typically require LDL of 70-100 mg/dL or higher despite maximum-tolerated statin therapy, especially for patients with established cardiovascular disease or familial hypercholesterolemia."
      },
      {
        "question": "What if I can't tolerate statins?",
        "answer": "Document your statin intolerance (muscle pain, elevated liver enzymes, etc.) and which statins you've tried. PCSK9 inhibitors are particularly important for statin-intolerant patients who still need aggressive LDL lowering."
      },
      {
        "question": "How is Lerochol different from other PCSK9 inhibitors?",
        "answer": "Lerochol is dosed once monthly, compared to every 2 weeks for most other PCSK9 inhibitors. This may improve adherence and convenience for some patients."
      }
    ],
    "evidence_snippets": [
      "PCSK9 inhibitors significantly reduce LDL cholesterol by 50-60% and decrease cardiovascular events in high-risk patients.",
      "Patients with familial hypercholesterolemia often cannot reach LDL goals with statins alone and benefit from PCSK9 inhibitor therapy.",
      "Lower LDL cholesterol levels are associated with reduced risk of heart attack, stroke, and cardiovascular death.",
      "Once-monthly dosing may improve medication adherence compared to more frequent injection schedules."
    ],
    "pubmed_search_terms": [
      "lerodalcibep PCSK9 inhibitor LDL reduction",
      "PCSK9 inhibitors cardiovascular outcomes",
      "familial hypercholesterolemia treatment PCSK9"
    ],
    "assistance_programs": [
      {
        "name": "LIB Therapeutics Patient Support",
        "url": "https://www.lerochol.com/",
        "description": "Patient assistance program information will be available at launch (Spring 2026). LIB Therapeutics is committed to ensuring broad access to LEROCHOL."
      }
    ]
  },
  "voyxact-denial": {
    "slug": "voyxact-denial",
    "title": "Appealing Voyxact (Sibeprenlimab) Denials",
    "default_procedure": "Voyxact (sibeprenlimab)",
    "default_condition": "IgA Nephropathy",
    "tagline": "Help appealing denials for this first biologic treatment for IgA nephropathy.",
    "hero_h1": "Appeal Your Voyxact Denial",
    "hero_subhead": "Get access to this breakthrough APRIL-blocking treatment for IgA nephropathy.",
    "intro": "Voyxact (sibeprenlimab) is the first biologic drug approved for reducing proteinuria in adults with primary IgA nephropathy (IgAN) at risk for disease progression. IgA nephropathy is a serious kidney disease that can lead to kidney failure. If your nephrologist prescribed Voyxact, you have strong grounds for appeal.",
    "manufacturer": "Otsuka Pharmaceutical",
    "common_denial_reasons": [
      "Prior authorization required",
      "Biopsy-proven IgAN not documented",
      "Proteinuria level not high enough",
      "Must try ACE inhibitors/ARBs first",
      "Specialty tier drug not covered",
      "Accelerated approval status concerns"
    ],
    "how_we_help": "We help you document your biopsy results, proteinuria levels, eGFR, prior treatments, and risk of disease progression to demonstrate medical necessity for Voyxact.",
    "cta": "Start your Voyxact appeal — it takes about 3 minutes.",
    "faq": [
      {
        "question": "What documentation do I need for Voyxact coverage?",
        "answer": "Key documentation includes kidney biopsy confirming IgA nephropathy, recent proteinuria levels (typically 1 g/day or higher), eGFR results, and records showing you've been on ACE inhibitors or ARBs for an adequate period."
      },
      {
        "question": "How is Voyxact administered?",
        "answer": "Voyxact is given as a subcutaneous injection once every 4 weeks and can be self-administered at home after training."
      },
      {
        "question": "What does 'at risk for disease progression' mean?",
        "answer": "This typically means having significant proteinuria (1 g/day or more) despite treatment with renin-angiotensin system blockers, which indicates higher risk of progressing to kidney failure."
      }
    ],
    "evidence_snippets": [
      "Sibeprenlimab blocks APRIL, reducing the production of pathogenic IgA antibodies that cause kidney damage in IgA nephropathy.",
      "Clinical trials demonstrated significant reduction in proteinuria and stabilization of kidney function with sibeprenlimab treatment.",
      "IgA nephropathy is the most common primary glomerulonephritis worldwide and leads to kidney failure in 20-40% of patients over 20 years.",
      "Reducing proteinuria is associated with slower disease progression and reduced risk of kidney failure in IgA nephropathy."
    ],
    "pubmed_search_terms": [
      "sibeprenlimab IgA nephropathy proteinuria",
      "APRIL inhibition IgA nephropathy treatment",
      "IgA nephropathy disease progression risk factors"
    ],
    "assistance_programs": [
      {
        "name": "Otsuka Patient Services (VOYXACT)",
        "url": "https://www.voyxact.com/",
        "description": "Eligible patients may pay as little as $0 through the VOYXACT Copay Program. Bridge program available for coverage delays. Call 833-VOYXACT (869-9228)."
      }
    ],
    "advocacy_resources": [
      {
        "name": "IgA Nephropathy Foundation of America",
        "url": "https://www.iganephropathy.org/",
        "description": "Foundation dedicated to IgA nephropathy awareness, research, and patient support."
      },
      {
        "name": "National Kidney Foundation",
        "url": "https://www.kidney.org/",
        "description": "Leading kidney health organization with advocacy and patient resources."
      }
    ]
  },
  "hyrnuo-denial": {
    "slug": "hyrnuo-denial",
    "title": "Appealing Hyrnuo (Sevabertinib) Denials",
    "default_procedure": "Hyrnuo (sevabertinib)",
    "default_condition": "HER2-Mutant Non-Small Cell Lung Cancer",
    "tagline": "Help appealing denials for this HER2-targeted therapy for NSCLC with HER2 mutations.",
    "hero_h1": "Appeal Your Hyrnuo Denial",
    "hero_subhead": "Get access to this targeted therapy for HER2-mutant lung cancer.",
    "intro": "Hyrnuo (sevabertinib) is a HER2-targeted tyrosine kinase inhibitor approved for adults with metastatic non-squamous non-small cell lung cancer (NSCLC) with HER2-activating mutations who have received prior systemic therapy. Insurance denials often require proof of HER2 mutation testing and prior treatment history.",
    "manufacturer": "Bayer HealthCare",
    "common_denial_reasons": [
      "HER2 mutation not documented by approved test",
      "Prior authorization required",
      "Prior systemic therapy not documented",
      "Must try other targeted therapies first",
      "Specialty tier drug not covered",
      "Accelerated approval concerns"
    ],
    "how_we_help": "We help you compile your HER2 mutation testing results, prior treatment history, and oncologist recommendations to demonstrate medical necessity for Hyrnuo.",
    "cta": "Start your Hyrnuo appeal — it takes about 3 minutes.",
    "faq": [
      {
        "question": "What HER2 test do I need for Hyrnuo coverage?",
        "answer": "You need documentation of HER2-activating mutations detected by an FDA-approved or validated next-generation sequencing (NGS) test. Common mutations include exon 20 insertions."
      },
      {
        "question": "Do I need to have failed other treatments first?",
        "answer": "Yes, Hyrnuo is approved for patients who have received prior systemic therapy. This typically means at least one prior line of treatment for metastatic disease."
      },
      {
        "question": "How is Hyrnuo taken?",
        "answer": "Hyrnuo is an oral medication taken daily. This makes it convenient compared to IV therapies, though you'll still need regular monitoring."
      }
    ],
    "evidence_snippets": [
      "Sevabertinib is a selective HER2 tyrosine kinase inhibitor designed to target HER2-activating mutations in NSCLC.",
      "HER2 mutations occur in approximately 2-4% of NSCLC patients and represent an actionable target for precision medicine.",
      "Clinical trials demonstrated meaningful response rates and durable disease control with sevabertinib in pretreated HER2-mutant NSCLC.",
      "Targeted therapy based on tumor genomic profiling represents the standard of care for advanced NSCLC with actionable mutations."
    ],
    "pubmed_search_terms": [
      "sevabertinib HER2 NSCLC",
      "HER2 mutations non-small cell lung cancer treatment",
      "HER2 targeted therapy lung cancer outcomes"
    ],
    "assistance_programs": [
      {
        "name": "Bayer HYRNUO $0 Co-Pay Program",
        "url": "https://www.hyrnuo-us.com/",
        "description": "Commercially insured patients may pay as little as $0 per month. Free trial program available. Bayer Patient Assistance Foundation offers free medication for eligible uninsured patients. Call 1-866-228-7723."
      }
    ],
    "advocacy_resources": [
      {
        "name": "American Cancer Society",
        "url": "https://www.cancer.org/",
        "description": "Nationwide voluntary health organization providing cancer support, information, and advocacy."
      },
      {
        "name": "CancerCare",
        "url": "https://www.cancercare.org/",
        "description": "Free professional support services including counseling, support groups, and financial assistance."
      },
      {
        "name": "Cancer Support Community",
        "url": "https://www.cancersupportcommunity.org/",
        "description": "Largest professionally led nonprofit network of cancer support worldwide."
      }
    ]
  },
  "redemplo-denial": {
    "slug": "redemplo-denial",
    "title": "Appealing Redemplo (Plozasiran) Denials",
    "default_procedure": "Redemplo (plozasiran)",
    "default_condition": "Familial Chylomicronemia Syndrome",
    "tagline": "Help appealing denials for this siRNA therapy for rare severe triglyceride disorders.",
    "hero_h1": "Appeal Your Redemplo Denial",
    "hero_subhead": "Get access to this breakthrough treatment for familial chylomicronemia syndrome.",
    "intro": "Redemplo (plozasiran) is an siRNA therapy approved as an adjunct to diet for reducing triglycerides in adults with familial chylomicronemia syndrome (FCS), an ultra-rare genetic disorder. Patients with FCS have extremely high triglycerides that can cause life-threatening pancreatitis. Insurance denials are common for rare disease medications, but these treatments are medically essential.",
    "manufacturer": "Arrowhead Pharmaceuticals",
    "common_denial_reasons": [
      "FCS diagnosis not genetically confirmed",
      "Prior authorization required",
      "Triglyceride levels not documented",
      "Ultra-high cost orphan drug",
      "Must try diet therapy first",
      "Rare disease with limited coverage policies"
    ],
    "how_we_help": "We help you document your FCS diagnosis, genetic testing results, triglyceride levels, history of pancreatitis, and the failure of dietary management alone to control your condition.",
    "cta": "Start your Redemplo appeal — it takes about 3 minutes.",
    "faq": [
      {
        "question": "What is familial chylomicronemia syndrome?",
        "answer": "FCS is a rare genetic disorder where the body cannot properly break down triglycerides, leading to extremely high levels (often over 1,000 mg/dL) and recurrent episodes of severe pancreatitis."
      },
      {
        "question": "What documentation do I need for Redemplo coverage?",
        "answer": "Key documentation includes genetic testing confirming FCS (mutations in LPL, APOC2, APOA5, LMF1, or GPIHBP1), fasting triglyceride levels, history of pancreatitis episodes, and documentation of adherence to strict dietary fat restriction."
      },
      {
        "question": "How is Redemplo administered?",
        "answer": "Redemplo is given as a subcutaneous injection once every 3 months (quarterly) and can be self-administered at home."
      }
    ],
    "evidence_snippets": [
      "Plozasiran is an siRNA that targets apolipoprotein C-III (ApoC-III), reducing triglyceride production and lowering the risk of pancreatitis in FCS.",
      "Familial chylomicronemia syndrome is an ultra-rare genetic disorder affecting approximately 1 in 500,000 to 1 million people.",
      "Patients with FCS are at high risk of recurrent acute pancreatitis, which can be life-threatening.",
      "No other approved therapies specifically target FCS, making plozasiran an essential treatment option for these patients."
    ],
    "pubmed_search_terms": [
      "plozasiran familial chylomicronemia syndrome",
      "FCS treatment triglyceride reduction",
      "apoC-III inhibition severe hypertriglyceridemia"
    ],
    "assistance_programs": [
      {
        "name": "Rely On REDEMPLO Patient Support",
        "url": "https://arrowheadpharma.com/",
        "description": "Arrowhead's patient support program offers financial assistance options for eligible patients at each stage of treatment journey."
      }
    ],
    "advocacy_resources": [
      {
        "name": "National Organization for Rare Disorders (NORD)",
        "url": "https://rarediseases.org/",
        "description": "Leading patient advocacy organization for rare disease community."
      },
      {
        "name": "Global Genes",
        "url": "https://globalgenes.org/",
        "description": "Leading rare disease patient advocacy organization connecting and empowering patients."
      }
    ]
  },
  "komzifti-denial": {
    "slug": "komzifti-denial",
    "title": "Appealing Komzifti (Ziftomenib) Denials",
    "default_procedure": "Komzifti (ziftomenib)",
    "default_condition": "NPM1-Mutated Acute Myeloid Leukemia",
    "tagline": "Help appealing denials for this first menin inhibitor for relapsed/refractory AML.",
    "hero_h1": "Appeal Your Komzifti Denial",
    "hero_subhead": "Get access to this targeted therapy for NPM1-mutated acute myeloid leukemia.",
    "intro": "Komzifti (ziftomenib) is the first and only menin inhibitor approved for adults with relapsed or refractory acute myeloid leukemia (AML) with NPM1 mutation who have no satisfactory alternative treatment options. This oral medication targets a key driver of NPM1-mutated AML. Insurance denials often require proof of NPM1 mutation testing and prior treatment failure.",
    "manufacturer": "Kura Oncology / Kyowa Kirin",
    "common_denial_reasons": [
      "NPM1 mutation not documented by approved test",
      "Prior authorization required",
      "Prior therapies not adequately documented",
      "No satisfactory alternatives not established",
      "Specialty tier drug not covered",
      "Off-label use concerns"
    ],
    "how_we_help": "We help you compile your NPM1 mutation testing results, prior treatment history, and oncologist recommendations to demonstrate that you have no satisfactory alternative treatment options.",
    "cta": "Start your Komzifti appeal — it takes about 3 minutes.",
    "faq": [
      {
        "question": "What test do I need for Komzifti coverage?",
        "answer": "You need documentation of a susceptible NPM1 mutation detected by an FDA-approved companion diagnostic or validated molecular testing. Your oncologist should have ordered this testing as part of your AML workup."
      },
      {
        "question": "What does 'no satisfactory alternative treatment options' mean?",
        "answer": "This means you've tried other available AML treatments or they are not appropriate for you due to your specific situation, comorbidities, or disease characteristics. Your oncologist should document why Komzifti is the best option."
      },
      {
        "question": "How is Komzifti taken?",
        "answer": "Komzifti is an oral medication taken once daily, making it more convenient than many other AML treatments that require IV administration."
      }
    ],
    "evidence_snippets": [
      "Ziftomenib is a menin inhibitor that blocks the interaction between menin and MLL proteins, disrupting leukemia cell growth in NPM1-mutated AML.",
      "NPM1 mutations occur in approximately 30% of AML patients and represent a distinct molecular subtype.",
      "Clinical trials demonstrated meaningful response rates in heavily pretreated patients with relapsed/refractory NPM1-mutated AML.",
      "Oral targeted therapy offers improved quality of life compared to intensive chemotherapy regimens."
    ],
    "pubmed_search_terms": [
      "ziftomenib NPM1 mutated AML",
      "menin inhibitor acute myeloid leukemia",
      "NPM1 mutation targeted therapy AML"
    ],
    "assistance_programs": [],
    "advocacy_resources": [
      {
        "name": "Leukemia & Lymphoma Society",
        "url": "https://www.lls.org/",
        "description": "World's largest voluntary health agency dedicated to blood cancer research and patient support."
      },
      {
        "name": "International Myeloma Foundation",
        "url": "https://www.myeloma.org/",
        "description": "Largest organization focusing specifically on multiple myeloma research and patient education."
      }
    ]
  },
  "lynkuet-denial": {
    "slug": "lynkuet-denial",
    "title": "Appealing Lynkuet (Elinzanetant) Denials",
    "default_procedure": "Lynkuet (elinzanetant)",
    "default_condition": "Menopause Vasomotor Symptoms",
    "tagline": "Help appealing denials for this non-hormonal treatment for menopause hot flashes.",
    "hero_h1": "Appeal Your Lynkuet Denial",
    "hero_subhead": "Get access to this first dual-target non-hormonal treatment for menopause hot flashes.",
    "intro": "Lynkuet (elinzanetant) is the first and only dual neurokinin receptor antagonist approved for moderate to severe hot flashes due to menopause. As a non-hormonal option, it's particularly important for women who cannot or prefer not to take hormone therapy. Insurance denials often impose step therapy through hormone therapy first.",
    "manufacturer": "Bayer AG",
    "common_denial_reasons": [
      "Must try hormone therapy first",
      "Prior authorization required",
      "Not medically necessary",
      "Hot flash severity not documented",
      "Preferred alternative required",
      "New drug with limited coverage policies"
    ],
    "how_we_help": "We help you document your hot flash severity, reasons for avoiding hormone therapy (breast cancer history, cardiovascular risk, personal preference), and impact on quality of life.",
    "cta": "Start your Lynkuet appeal — it takes about 3 minutes.",
    "faq": [
      {
        "question": "Why might I need a non-hormonal option like Lynkuet?",
        "answer": "Many women cannot take hormone therapy due to breast cancer history, blood clot risk, cardiovascular disease, or other medical conditions. Others prefer to avoid hormones. Your appeal should document your specific reasons."
      },
      {
        "question": "How do I document hot flash severity?",
        "answer": "Track the number and severity of hot flashes per day, night sweats, sleep disruption, and impact on work and daily activities. Your healthcare provider can also document this in clinical notes."
      },
      {
        "question": "How is Lynkuet different from other menopause treatments?",
        "answer": "Lynkuet is the first treatment that blocks both NK1 and NK3 receptors, addressing the underlying neurokinin imbalance that causes hot flashes without using hormones."
      }
    ],
    "evidence_snippets": [
      "Elinzanetant is a dual NK1/NK3 receptor antagonist that reduces hot flashes by targeting the neurokinin pathway in the brain's thermoregulatory center.",
      "Clinical trials demonstrated significant reduction in hot flash frequency and severity compared to placebo.",
      "Non-hormonal options are essential for women with contraindications to hormone therapy, including breast cancer survivors.",
      "Menopause symptoms significantly impact quality of life, sleep, and work productivity for millions of women."
    ],
    "pubmed_search_terms": [
      "elinzanetant vasomotor symptoms menopause",
      "neurokinin antagonist hot flashes",
      "non-hormonal menopause treatment efficacy"
    ],
    "assistance_programs": [
      {
        "name": "Lynkuet Access Savings & Support (LASS)",
        "url": "https://www.lynkuet.com/",
        "description": "Commercially insured women may pay as little as $25 per month through the LASS program with Blink Rx. Bayer Patient Assistance Foundation available for eligible uninsured patients. Call 1-866-228-7723."
      }
    ],
    "advocacy_resources": [
      {
        "name": "North American Menopause Society",
        "url": "https://www.menopause.org/",
        "description": "Leading nonprofit organization for menopause health information and advocacy."
      },
      {
        "name": "The Menopause Society",
        "url": "https://www.menopause.org/",
        "description": "Professional organization promoting menopause health through education and advocacy."
      }
    ]
  },
  "jascayd-denial": {
    "slug": "jascayd-denial",
    "title": "Appealing Jascayd (Nerandomilast) Denials",
    "default_procedure": "Jascayd (nerandomilast)",
    "default_condition": "Idiopathic Pulmonary Fibrosis",
    "tagline": "Help appealing denials for this oral PDE4 inhibitor for lung fibrosis.",
    "hero_h1": "Appeal Your Jascayd Denial",
    "hero_subhead": "Get access to this new treatment option for idiopathic pulmonary fibrosis.",
    "intro": "Jascayd (nerandomilast) is a PDE4 inhibitor approved for the treatment of idiopathic pulmonary fibrosis (IPF) in adults. IPF is a serious, progressive lung disease with limited treatment options. If your pulmonologist prescribed Jascayd, you have strong grounds for appeal.",
    "manufacturer": "Boehringer Ingelheim",
    "common_denial_reasons": [
      "Prior authorization required",
      "IPF diagnosis not adequately documented",
      "Must try nintedanib or pirfenidone first",
      "Step therapy requirement not met",
      "High-cost specialty medication",
      "Pulmonary function tests not provided"
    ],
    "how_we_help": "We help you document your IPF diagnosis (including high-resolution CT findings), pulmonary function tests, prior treatments, and why Jascayd is the appropriate choice for your condition.",
    "cta": "Start your Jascayd appeal — it takes about 3 minutes.",
    "faq": [
      {
        "question": "What documentation supports my Jascayd appeal?",
        "answer": "Include your high-resolution CT scan showing UIP pattern, pulmonary function tests (FVC, DLCO), biopsy results if available, and documentation of any prior antifibrotic therapy and why you need an alternative."
      },
      {
        "question": "Can I take Jascayd with other IPF treatments?",
        "answer": "Discuss combination therapy options with your pulmonologist. Your appeal should document why your current treatment regimen is insufficient and how Jascayd fits into your care plan."
      },
      {
        "question": "How does Jascayd work differently from other IPF treatments?",
        "answer": "Jascayd is a PDE4 inhibitor with a different mechanism than nintedanib or pirfenidone, potentially offering benefits for patients who cannot tolerate or do not respond to existing therapies."
      }
    ],
    "evidence_snippets": [
      "Nerandomilast is a phosphodiesterase 4 (PDE4) inhibitor that reduces inflammation and fibrotic processes in the lungs.",
      "Clinical trials demonstrated slowing of lung function decline in patients with idiopathic pulmonary fibrosis.",
      "IPF is a progressive, fatal disease with median survival of 3-5 years from diagnosis without treatment.",
      "Additional treatment options are needed for patients who cannot tolerate or do not respond to existing antifibrotic therapies."
    ],
    "pubmed_search_terms": [
      "nerandomilast idiopathic pulmonary fibrosis",
      "PDE4 inhibitor lung fibrosis treatment",
      "IPF antifibrotic therapy outcomes"
    ],
    "assistance_programs": [
      {
        "name": "CareConnect4Me (Boehringer Ingelheim)",
        "url": "https://www.jascayd.com/",
        "description": "Patient support program offering copay assistance, insurance navigation, and help with access. Boehringer Cares Patient Assistance Program available for eligible uninsured patients. Call 1-800-542-6257."
      }
    ],
    "advocacy_resources": [
      {
        "name": "Pulmonary Fibrosis Foundation",
        "url": "https://www.pulmonaryfibrosis.org/",
        "description": "Largest nonprofit dedicated to pulmonary fibrosis research and patient support. Help Center: 844.TalkPFF."
      }
    ]
  },
  "rhapsido-denial": {
    "slug": "rhapsido-denial",
    "title": "Appealing Rhapsido (Remibrutinib) Denials",
    "default_procedure": "Rhapsido (remibrutinib)",
    "default_condition": "Chronic Spontaneous Urticaria",
    "tagline": "Help appealing denials for this BTK inhibitor for chronic hives.",
    "hero_h1": "Appeal Your Rhapsido Denial",
    "hero_subhead": "Get access to this first oral BTK inhibitor for chronic spontaneous urticaria.",
    "intro": "Rhapsido (remibrutinib) is the first and only BTK inhibitor approved for chronic spontaneous urticaria (CSU) in adults who have not responded adequately to antihistamines. CSU causes persistent, unpredictable hives that significantly impact quality of life. If antihistamines haven't controlled your hives, you deserve access to this targeted therapy.",
    "manufacturer": "Novartis AG",
    "common_denial_reasons": [
      "Prior authorization required",
      "Must try multiple antihistamines first",
      "Must try omalizumab (Xolair) first",
      "Step therapy requirement not met",
      "Inadequate documentation of antihistamine failure",
      "Specialty tier drug not covered"
    ],
    "how_we_help": "We help you document your history of antihistamine use, hive severity and frequency, impact on quality of life, and prior treatment failures to demonstrate medical necessity for Rhapsido.",
    "cta": "Start your Rhapsido appeal — it takes about 3 minutes.",
    "faq": [
      {
        "question": "What treatments do I need to try before Rhapsido?",
        "answer": "Most insurers require you to have tried and failed H1 antihistamines (like cetirizine, loratadine, or fexofenadine) at standard and often higher doses. Some may also require trial of omalizumab (Xolair). Document all treatments tried and why they failed."
      },
      {
        "question": "How do I document CSU severity?",
        "answer": "Track your hives using a diary noting daily hive count, itching severity, sleep disruption, and impact on work/activities. The Urticaria Activity Score (UAS7) is commonly used to document disease severity."
      },
      {
        "question": "How is Rhapsido taken?",
        "answer": "Rhapsido is an oral tablet taken daily, offering convenience compared to injectable treatments like omalizumab."
      }
    ],
    "evidence_snippets": [
      "Remibrutinib is a highly selective BTK inhibitor that blocks mast cell activation, reducing hive formation and itching.",
      "Clinical trials demonstrated significant improvement in urticaria symptoms and quality of life in patients with inadequate response to antihistamines.",
      "Chronic spontaneous urticaria affects quality of life comparable to severe heart disease or asthma.",
      "Oral targeted therapy offers improved convenience and tolerability compared to injectable biologics for some patients."
    ],
    "pubmed_search_terms": [
      "remibrutinib chronic spontaneous urticaria",
      "BTK inhibitor urticaria treatment",
      "CSU refractory antihistamine therapy"
    ],
    "assistance_programs": [
      {
        "name": "Novartis Patient Support (Rhapsido)",
        "url": "https://support.rhapsido.com/",
        "description": "Eligible commercially insured patients may pay as little as $0 through Co-Pay Plus. Bridge Program provides free medication for up to 12 months while awaiting insurance approval. Call Novartis Patient Support."
      }
    ],
    "advocacy_resources": [
      {
        "name": "Asthma and Allergy Foundation of America",
        "url": "https://aafa.org/",
        "description": "Leading patient advocacy for allergic conditions including chronic urticaria."
      },
      {
        "name": "We CU",
        "url": "https://www.wecu.org/",
        "description": "Nonprofit dedicated to empowering those affected by chronic urticaria."
      }
    ]
  },
  "palsonify-denial": {
    "slug": "palsonify-denial",
    "title": "Appealing Palsonify (Paltusotine) Denials",
    "default_procedure": "Palsonify (paltusotine)",
    "default_condition": "Acromegaly",
    "tagline": "Help appealing denials for this first oral treatment for acromegaly.",
    "hero_h1": "Appeal Your Palsonify Denial",
    "hero_subhead": "Get access to the first once-daily oral treatment for acromegaly.",
    "intro": "Palsonify (paltusotine) is the first and only once-daily oral medication approved for acromegaly in adults who have had inadequate response to surgery or for whom surgery is not an option. This represents a major advance over injectable somatostatin analogs. Insurance denials often require documentation of surgery failure or ineligibility.",
    "manufacturer": "Crinetics Pharmaceuticals",
    "common_denial_reasons": [
      "Prior authorization required",
      "Must try injectable somatostatin analogs first",
      "Surgical history not documented",
      "IGF-1 levels not provided",
      "Specialty tier drug not covered",
      "New drug with limited coverage policies"
    ],
    "how_we_help": "We help you document your acromegaly diagnosis, surgical history, IGF-1 levels, prior treatment with injectables, and why oral therapy is medically necessary for you.",
    "cta": "Start your Palsonify appeal — it takes about 3 minutes.",
    "faq": [
      {
        "question": "Do I need to have had surgery for acromegaly?",
        "answer": "You need to have either had inadequate response to pituitary surgery or have a reason why surgery is not an option for you (tumor location, surgical risk, patient preference with documented discussion). Your endocrinologist should document this."
      },
      {
        "question": "What if I'm currently on injectable therapy?",
        "answer": "Document why you want to switch to oral therapy, including injection-site reactions, needle phobia, inconvenience of monthly injections, or need for more flexible dosing. Some insurers may require documented inadequate response to injectables."
      },
      {
        "question": "What IGF-1 documentation do I need?",
        "answer": "Include your IGF-1 levels before and during treatment, showing they are above normal range (indicating active acromegaly) or documenting your response to current therapy."
      }
    ],
    "evidence_snippets": [
      "Paltusotine is an oral somatostatin receptor agonist that suppresses growth hormone secretion in acromegaly.",
      "Clinical trials demonstrated effective control of IGF-1 levels with once-daily oral dosing.",
      "Oral therapy eliminates the burden of monthly injections, improving quality of life and treatment adherence.",
      "Acromegaly causes serious complications including cardiovascular disease, diabetes, and joint problems if not adequately controlled."
    ],
    "pubmed_search_terms": [
      "paltusotine acromegaly oral treatment",
      "oral somatostatin agonist acromegaly",
      "acromegaly medical therapy IGF-1 control"
    ],
    "assistance_programs": [
      {
        "name": "CrinetiCARE Patient Support",
        "url": "https://crineticare.com/",
        "description": "Eligible commercially insured patients may pay as little as $0. Bridge program available while awaiting coverage. Patient assistance for uninsured/underinsured patients. Visit CrinetiCARE.com or Palsonify.com."
      }
    ],
    "advocacy_resources": [
      {
        "name": "National Organization for Rare Disorders (NORD)",
        "url": "https://rarediseases.org/",
        "description": "Leading patient advocacy organization for rare disease community."
      },
      {
        "name": "Global Genes",
        "url": "https://globalgenes.org/",
        "description": "Leading rare disease patient advocacy organization connecting and empowering patients."
      }
    ]
  },
  "journavx-denial": {
    "slug": "journavx-denial",
    "title": "Appealing Journavx (Suzetrigine) Denials",
    "default_procedure": "Journavx (suzetrigine)",
    "default_condition": "Acute Pain",
    "tagline": "Help appealing denials for this first non-opioid pain medication targeting sodium channels.",
    "hero_h1": "Appeal Your Journavx Denial",
    "hero_subhead": "Get access to this breakthrough non-opioid treatment for acute pain.",
    "intro": "Journavx (suzetrigine) is the first non-opioid medication targeting the NaV1.8 sodium channel approved for moderate to severe acute pain in adults. This represents a major advance in pain management without the addiction risks of opioids. Insurance may impose restrictions, but this medication offers important benefits for appropriate patients.",
    "manufacturer": "Vertex Pharmaceuticals",
    "common_denial_reasons": [
      "Prior authorization required",
      "Must try NSAIDs/acetaminophen first",
      "Not medically necessary",
      "Quantity limits exceeded",
      "Acute pain indication not documented",
      "New drug with limited coverage policies"
    ],
    "how_we_help": "We help you document your pain condition, prior treatments tried, reasons for avoiding opioids, and why Journavx is the appropriate choice for your acute pain management.",
    "cta": "Start your Journavx appeal — it takes about 3 minutes.",
    "faq": [
      {
        "question": "Why would I choose Journavx over other pain medications?",
        "answer": "Journavx provides effective pain relief without the addiction, dependence, or cognitive effects associated with opioids. It's appropriate for patients who need more than OTC pain relievers but want to avoid opioid risks."
      },
      {
        "question": "Is Journavx for chronic or acute pain?",
        "answer": "Journavx is currently approved for acute pain (such as post-surgical pain). Your appeal should document the acute nature of your pain condition."
      },
      {
        "question": "What if I have a history of opioid problems?",
        "answer": "A history of opioid use disorder or concerns about opioid use is a strong argument for Journavx. Document any history of addiction, adverse reactions to opioids, or preferences to avoid opioid therapy."
      }
    ],
    "evidence_snippets": [
      "Suzetrigine selectively blocks NaV1.8 sodium channels, inhibiting pain signals without affecting the brain's reward pathways.",
      "Clinical trials demonstrated effective pain relief comparable to opioids without evidence of addictive potential.",
      "Non-opioid pain options are critically needed given the ongoing opioid crisis and risks of opioid dependence.",
      "NaV1.8 inhibition represents a novel mechanism for pain control that does not produce euphoria or dependence."
    ],
    "pubmed_search_terms": [
      "suzetrigine acute pain NaV1.8",
      "non-opioid analgesic sodium channel",
      "acute pain management alternatives opioids"
    ],
    "assistance_programs": [
      {
        "name": "JOURNAVX+you Patient Support",
        "url": "https://www.journavx.com/support",
        "description": "Commercially insured patients may pay as little as $30 per fill. Patient Assistance Program at JOURNAVXpap.com for uninsured patients. Call 1-833-589-7246."
      }
    ],
    "advocacy_resources": [
      {
        "name": "American Chronic Pain Association",
        "url": "https://www.theacpa.org/",
        "description": "Peer support and education for people living with chronic pain."
      },
      {
        "name": "U.S. Pain Foundation",
        "url": "https://uspainfoundation.org/",
        "description": "Nonprofit connecting people with pain to resources, support, and advocacy."
      }
    ]
  },
  "wayrilz-denial": {
    "slug": "wayrilz-denial",
    "title": "Appealing Wayrilz (Rilzabrutinib) Denials",
    "default_procedure": "Wayrilz (rilzabrutinib)",
    "default_condition": "Immune Thrombocytopenia",
    "tagline": "Help appealing denials for this first BTK inhibitor for chronic ITP.",
    "hero_h1": "Appeal Your Wayrilz Denial",
    "hero_subhead": "Get access to this first oral BTK inhibitor for immune thrombocytopenia.",
    "intro": "Wayrilz (rilzabrutinib) is the first BTK inhibitor approved for adults with persistent or chronic immune thrombocytopenia (ITP) who have had insufficient response to previous treatment. ITP causes dangerously low platelet counts and bleeding risk. If standard treatments haven't worked, you deserve access to this targeted therapy.",
    "manufacturer": "Sanofi",
    "common_denial_reasons": [
      "Prior authorization required",
      "Must try steroids first",
      "Must try other ITP therapies (IVIG, TPO-RA) first",
      "Step therapy requirement not met",
      "Platelet count documentation inadequate",
      "Specialty tier drug not covered"
    ],
    "how_we_help": "We help you document your platelet count history, prior ITP treatments and their results, bleeding episodes, and why Wayrilz is the appropriate next step in your care.",
    "cta": "Start your Wayrilz appeal — it takes about 3 minutes.",
    "faq": [
      {
        "question": "What treatments do I need to try before Wayrilz?",
        "answer": "Most insurers require you to have tried and failed or been intolerant to first-line therapies like steroids, IVIG, or TPO receptor agonists (romiplostim, eltrombopag). Document all prior treatments and why they failed."
      },
      {
        "question": "How do I document ITP severity?",
        "answer": "Include your platelet count history over time, any bleeding episodes (bruising, nosebleeds, gum bleeding, heavy periods), transfusion requirements, and impact on daily activities."
      },
      {
        "question": "How is Wayrilz different from other ITP treatments?",
        "answer": "Wayrilz is an oral BTK inhibitor that works by blocking the immune system's destruction of platelets. It offers a different mechanism than steroids or TPO-RAs and may work for patients who haven't responded to those treatments."
      }
    ],
    "evidence_snippets": [
      "Rilzabrutinib is a reversible BTK inhibitor that reduces platelet destruction by inhibiting Fc receptor signaling in macrophages.",
      "Clinical trials demonstrated significant platelet count improvements in patients with persistent or chronic ITP who had failed prior treatments.",
      "ITP can cause life-threatening bleeding, particularly when platelet counts fall below 20,000/mcL.",
      "Oral targeted therapy offers convenience and tolerability advantages compared to infusion-based treatments."
    ],
    "pubmed_search_terms": [
      "rilzabrutinib immune thrombocytopenia",
      "BTK inhibitor ITP treatment",
      "refractory ITP targeted therapy"
    ],
    "assistance_programs": [
      {
        "name": "Sanofi HemAssist (Wayrilz)",
        "url": "https://www.wayrilz.com/us/patient-support",
        "description": "Eligible patients may pay as little as $0 copay. QuickStart program provides first month free while awaiting coverage. Patient Assistance Program for uninsured. Call 1-833-723-5463."
      }
    ],
    "advocacy_resources": [
      {
        "name": "National Organization for Rare Disorders (NORD)",
        "url": "https://rarediseases.org/",
        "description": "Leading patient advocacy organization for rare disease community."
      },
      {
        "name": "Global Genes",
        "url": "https://globalgenes.org/",
        "description": "Leading rare disease patient advocacy organization connecting and empowering patients."
      }
    ]
  },
  "dawnzera-denial": {
    "slug": "dawnzera-denial",
    "title": "Appealing Dawnzera (Donidalorsen) Denials",
    "default_procedure": "Dawnzera (donidalorsen)",
    "default_condition": "Hereditary Angioedema",
    "tagline": "Help appealing denials for this first RNA-targeted prophylaxis for HAE attacks.",
    "hero_h1": "Appeal Your Dawnzera Denial",
    "hero_subhead": "Get access to this breakthrough RNA therapy for preventing hereditary angioedema attacks.",
    "intro": "Dawnzera (donidalorsen) is the first RNA-targeted therapy approved for preventing hereditary angioedema (HAE) attacks in adults and adolescents 12 years and older. HAE causes unpredictable, potentially life-threatening swelling episodes. Insurance often requires step therapy through older prophylactic treatments first.",
    "manufacturer": "Ionis Pharmaceuticals",
    "common_denial_reasons": [
      "Prior authorization required",
      "Must try C1-inhibitor products first",
      "Must try lanadelumab first",
      "Step therapy requirement not met",
      "HAE diagnosis not adequately documented",
      "Ultra-high cost orphan drug concerns"
    ],
    "how_we_help": "We help you document your HAE diagnosis, attack frequency and severity, prior prophylactic treatments, and why Dawnzera is the best option for preventing your attacks.",
    "cta": "Start your Dawnzera appeal — it takes about 3 minutes.",
    "faq": [
      {
        "question": "What documentation supports my Dawnzera appeal?",
        "answer": "Include your HAE diagnosis confirmation (C4, C1-inhibitor levels, genetic testing), attack diary showing frequency and severity, prior prophylactic treatments tried, and documentation of breakthrough attacks on current therapy."
      },
      {
        "question": "How is Dawnzera different from other HAE prophylaxis?",
        "answer": "Dawnzera is an antisense oligonucleotide that reduces prekallikrein production, targeting HAE at the RNA level. It's given as a monthly subcutaneous injection."
      },
      {
        "question": "What if I'm currently on another HAE prophylaxis?",
        "answer": "Document why you need to switch, including breakthrough attacks despite current therapy, injection site reactions, or other tolerability issues with your current treatment."
      }
    ],
    "evidence_snippets": [
      "Donidalorsen is an antisense oligonucleotide that reduces prekallikrein synthesis, preventing the kallikrein-kinin cascade that causes HAE attacks.",
      "Clinical trials demonstrated an 81% reduction in HAE attack rate compared to placebo.",
      "HAE attacks can be life-threatening when affecting the airway and severely impact quality of life.",
      "Monthly dosing with donidalorsen offers convenience compared to more frequent injection schedules."
    ],
    "pubmed_search_terms": [
      "donidalorsen hereditary angioedema",
      "antisense oligonucleotide HAE prophylaxis",
      "prekallikrein inhibition HAE prevention"
    ],
    "assistance_programs": [
      {
        "name": "Ionis Every Step (Dawnzera)",
        "url": "https://dawnzera.com/get-started",
        "description": "Comprehensive support including insurance navigation, financial assistance, and injection training. Free trial program available for all patients including Medicare/Medicaid. Call 1-844-444-4305."
      }
    ],
    "advocacy_resources": [
      {
        "name": "US Hereditary Angioedema Association",
        "url": "https://www.haea.org/",
        "description": "Nonprofit advocacy organization for people with HAE and their caregivers."
      },
      {
        "name": "HAE International",
        "url": "https://haei.org/",
        "description": "Global network of HAE organizations dedicated to improving lives of people with HAE."
      }
    ]
  },
  "brinsupri-denial": {
    "slug": "brinsupri-denial",
    "title": "Appealing Brinsupri (Brensocatib) Denials",
    "default_procedure": "Brinsupri (brensocatib)",
    "default_condition": "Non-Cystic Fibrosis Bronchiectasis",
    "tagline": "Help appealing denials for this first approved treatment for bronchiectasis.",
    "hero_h1": "Appeal Your Brinsupri Denial",
    "hero_subhead": "Get access to the first and only treatment specifically approved for bronchiectasis.",
    "intro": "Brinsupri (brensocatib) is the first and only medication specifically approved for non-cystic fibrosis bronchiectasis in adults and adolescents 12 years and older. Bronchiectasis causes recurring lung infections and progressive lung damage. If you have this condition, you finally have a targeted treatment option.",
    "manufacturer": "Insmed Incorporated",
    "common_denial_reasons": [
      "Prior authorization required",
      "Bronchiectasis diagnosis not documented by CT",
      "Exacerbation history not provided",
      "Must try antibiotics/airway clearance first",
      "New drug with limited coverage policies",
      "High-cost specialty medication"
    ],
    "how_we_help": "We help you document your bronchiectasis diagnosis, CT scan findings, exacerbation history, prior treatments, and the impact on your quality of life to demonstrate medical necessity.",
    "cta": "Start your Brinsupri appeal — it takes about 3 minutes.",
    "faq": [
      {
        "question": "What documentation do I need for Brinsupri coverage?",
        "answer": "Include your high-resolution CT scan showing bronchiectasis, history of pulmonary exacerbations (typically 2 or more in the past year), sputum culture results, and documentation of current management with airway clearance and antibiotics."
      },
      {
        "question": "How does Brinsupri work?",
        "answer": "Brinsupri inhibits dipeptidyl peptidase 1 (DPP1), which reduces neutrophil-mediated inflammation and damage in the airways. This helps reduce exacerbations and slow disease progression."
      },
      {
        "question": "Is Brinsupri for cystic fibrosis?",
        "answer": "No, Brinsupri is specifically approved for non-cystic fibrosis bronchiectasis. You must have bronchiectasis from other causes (infections, immune deficiency, etc.) to be eligible."
      }
    ],
    "evidence_snippets": [
      "Brensocatib inhibits DPP1, reducing neutrophil serine protease activity and inflammation in bronchiectatic airways.",
      "Clinical trials demonstrated a 21% reduction in annual exacerbation rate with brensocatib treatment.",
      "Non-cystic fibrosis bronchiectasis has had no approved disease-modifying treatments until now.",
      "Reducing exacerbations preserves lung function and improves quality of life in bronchiectasis patients."
    ],
    "pubmed_search_terms": [
      "brensocatib bronchiectasis DPP1 inhibitor",
      "non-cystic fibrosis bronchiectasis treatment",
      "bronchiectasis exacerbation prevention"
    ],
    "assistance_programs": [
      {
        "name": "inLighten Patient Support (Insmed)",
        "url": "https://www.insmed.com/",
        "description": "Copay assistance for commercially insured patients. Patient support program offers insurance navigation and access assistance. Contact Insmed for details."
      }
    ],
    "advocacy_resources": [
      {
        "name": "Pulmonary Fibrosis Foundation",
        "url": "https://www.pulmonaryfibrosis.org/",
        "description": "Largest nonprofit dedicated to pulmonary fibrosis research and patient support. Help Center: 844.TalkPFF."
      }
    ]
  },
  "ekterly-denial": {
    "slug": "ekterly-denial",
    "title": "Appealing Ekterly (Sebetralstat) Denials",
    "default_procedure": "Ekterly (sebetralstat)",
    "default_condition": "Hereditary Angioedema",
    "tagline": "Help appealing denials for this first oral on-demand treatment for HAE attacks.",
    "hero_h1": "Appeal Your Ekterly Denial",
    "hero_subhead": "Get access to the first and only oral on-demand therapy for acute HAE attacks.",
    "intro": "Ekterly (sebetralstat) is the first and only oral on-demand treatment for acute hereditary angioedema (HAE) attacks in adults and adolescents 12 years and older. Unlike injectable treatments, you can take it as a pill when an attack starts. Insurance may prefer older injectable options, but oral therapy offers important convenience and faster treatment initiation.",
    "manufacturer": "KalVista Pharmaceuticals",
    "common_denial_reasons": [
      "Prior authorization required",
      "Must try injectable on-demand treatments first",
      "HAE diagnosis not adequately documented",
      "Attack frequency not documented",
      "New drug with limited coverage policies",
      "Orphan drug pricing concerns"
    ],
    "how_we_help": "We help you document your HAE diagnosis, attack patterns, experience with injectable treatments, and why oral on-demand therapy is the appropriate choice for you.",
    "cta": "Start your Ekterly appeal — it takes about 3 minutes.",
    "faq": [
      {
        "question": "Why would oral on-demand therapy be better for me?",
        "answer": "Oral therapy allows faster treatment initiation since you don't need to prepare an injection. It's also easier to carry and use in any setting, and some patients have needle phobia or difficulty with self-injection."
      },
      {
        "question": "What if I'm already using injectable on-demand treatment?",
        "answer": "Document any issues with your current injectable, such as injection site reactions, difficulty self-injecting during attacks (shaking hands, swelling), needle phobia, or delays in treatment due to injection preparation."
      },
      {
        "question": "How quickly does Ekterly work?",
        "answer": "Ekterly is designed for rapid absorption when taken orally at the start of an HAE attack. Clinical trials showed meaningful symptom relief within hours of dosing."
      }
    ],
    "evidence_snippets": [
      "Sebetralstat is an oral plasma kallikrein inhibitor that blocks the enzyme responsible for HAE attack symptoms.",
      "Clinical trials demonstrated significant reduction in attack severity and duration compared to placebo.",
      "Oral on-demand therapy eliminates barriers to treatment that exist with injectable options.",
      "Earlier treatment of HAE attacks leads to faster resolution and less severe symptoms."
    ],
    "pubmed_search_terms": [
      "sebetralstat hereditary angioedema oral",
      "oral kallikrein inhibitor HAE attacks",
      "on-demand HAE treatment comparison"
    ],
    "assistance_programs": [
      {
        "name": "KalVista Cares (Ekterly)",
        "url": "https://www.ekterly.com/patient-support-program/",
        "description": "Eligible commercially insured patients may pay as little as $0 (up to $40,000 annual maximum). QuickStart program for coverage delays. Patient assistance available. Call 1-844-432-3322."
      }
    ],
    "advocacy_resources": [
      {
        "name": "US Hereditary Angioedema Association",
        "url": "https://www.haea.org/",
        "description": "Nonprofit advocacy organization for people with HAE and their caregivers."
      },
      {
        "name": "HAE International",
        "url": "https://haei.org/",
        "description": "Global network of HAE organizations dedicated to improving lives of people with HAE."
      }
    ]
  },
  "qfitlia-denial": {
    "slug": "qfitlia-denial",
    "title": "Appealing Qfitlia (Fitusiran) Denials",
    "default_procedure": "Qfitlia (fitusiran)",
    "default_condition": "Hemophilia A or B",
    "tagline": "Help appealing denials for this RNA therapy for hemophilia prophylaxis.",
    "hero_h1": "Appeal Your Qfitlia Denial",
    "hero_subhead": "Get access to this first antithrombin-lowering therapy for hemophilia.",
    "intro": "Qfitlia (fitusiran) is the first therapy that lowers antithrombin to prevent bleeding in patients with hemophilia A or B, with or without factor inhibitors. With just 6 injections per year using a convenient pen device, it offers a new approach to hemophilia prophylaxis. Insurance may require step therapy through factor products or emicizumab first.",
    "manufacturer": "Sanofi Genzyme / Alnylam",
    "common_denial_reasons": [
      "Prior authorization required",
      "Must try factor replacement therapy first",
      "Must try emicizumab first (for hemophilia A)",
      "Step therapy requirement not met",
      "Inhibitor status not documented",
      "Ultra-high cost orphan drug"
    ],
    "how_we_help": "We help you document your hemophilia diagnosis, bleeding history, current treatment regimen, and why Qfitlia offers benefits for your specific situation.",
    "cta": "Start your Qfitlia appeal — it takes about 3 minutes.",
    "faq": [
      {
        "question": "How is Qfitlia different from other hemophilia treatments?",
        "answer": "Qfitlia works by lowering antithrombin (a natural anticoagulant), which rebalances hemostasis rather than replacing missing clotting factors. It's given just once every 2 months (6 times per year)."
      },
      {
        "question": "Can Qfitlia be used with inhibitors?",
        "answer": "Yes, Qfitlia is approved for hemophilia A or B with or without factor inhibitors. This is particularly important for patients with inhibitors who have limited treatment options."
      },
      {
        "question": "What documentation supports my appeal?",
        "answer": "Include your hemophilia type and severity, inhibitor status if applicable, bleeding history, current treatment regimen and burden, and any issues with current therapy (venous access, adherence challenges, breakthrough bleeds)."
      }
    ],
    "evidence_snippets": [
      "Fitusiran is an siRNA that reduces antithrombin production, rebalancing hemostasis in hemophilia patients.",
      "Clinical trials demonstrated significant reduction in annualized bleeding rate with fitusiran prophylaxis.",
      "Every-two-month dosing significantly reduces treatment burden compared to more frequent factor infusions.",
      "Fitusiran works regardless of inhibitor status, providing an option for patients with this challenging complication."
    ],
    "pubmed_search_terms": [
      "fitusiran hemophilia antithrombin",
      "siRNA hemophilia prophylaxis",
      "hemophilia inhibitors treatment options"
    ],
    "assistance_programs": [
      {
        "name": "Sanofi HemAssist (Qfitlia)",
        "url": "https://www.sanofihemassist.com/",
        "description": "Eligible patients may pay as little as $0 copay (up to $20,000/year). QuickStart provides up to 6 months free while awaiting coverage. Call 1-833-723-5463."
      }
    ],
    "advocacy_resources": [
      {
        "name": "National Bleeding Disorders Foundation",
        "url": "https://www.bleeding.org/",
        "description": "Patient advocacy organization for hemophilia and bleeding disorders since 1948."
      },
      {
        "name": "Hemophilia Federation of America",
        "url": "https://www.hemophiliafed.org/",
        "description": "National nonprofit serving the bleeding disorders community."
      }
    ]
  },
  "blujepa-denial": {
    "slug": "blujepa-denial",
    "title": "Appealing Blujepa (Gepotidacin) Denials",
    "default_procedure": "Blujepa (gepotidacin)",
    "default_condition": "Uncomplicated Urinary Tract Infection",
    "tagline": "Help appealing denials for this first-in-class antibiotic for UTIs.",
    "hero_h1": "Appeal Your Blujepa Denial",
    "hero_subhead": "Get access to this new oral antibiotic for uncomplicated UTIs.",
    "intro": "Blujepa (gepotidacin) is the first new class of oral antibiotic approved for uncomplicated urinary tract infections in nearly 30 years. It works against bacteria that have become resistant to older antibiotics. If you have recurrent UTIs or antibiotic allergies, this new option may be important for your care.",
    "manufacturer": "GlaxoSmithKline (GSK)",
    "common_denial_reasons": [
      "Prior authorization required",
      "Must try first-line antibiotics first",
      "Not medically necessary",
      "Culture and sensitivity not provided",
      "Resistance pattern not documented",
      "New drug with limited coverage policies"
    ],
    "how_we_help": "We help you document your UTI history, antibiotic allergies or intolerances, culture results showing resistance, and why Blujepa is the appropriate antibiotic choice.",
    "cta": "Start your Blujepa appeal — it takes about 3 minutes.",
    "faq": [
      {
        "question": "When would Blujepa be used instead of other antibiotics?",
        "answer": "Blujepa may be appropriate when you have allergies to first-line antibiotics (like sulfa drugs or fluoroquinolones), your infection is caused by resistant bacteria, or you have recurrent UTIs that haven't responded to standard treatments."
      },
      {
        "question": "What documentation helps my appeal?",
        "answer": "Include urine culture results showing the bacteria causing your UTI, sensitivity testing showing resistance to other antibiotics, documentation of antibiotic allergies, and history of prior UTIs and treatments."
      },
      {
        "question": "How is Blujepa taken?",
        "answer": "Blujepa is taken as two tablets twice daily for 5 days. Taking it after a meal may help reduce stomach upset."
      }
    ],
    "evidence_snippets": [
      "Gepotidacin is a first-in-class triazaacenaphthylene antibiotic with a novel mechanism of action against common UTI pathogens.",
      "Clinical trials demonstrated effectiveness against E. coli and other common UTI-causing bacteria.",
      "New antibiotic classes are critically needed given increasing antibiotic resistance.",
      "Gepotidacin retains activity against bacteria resistant to fluoroquinolones and other commonly used antibiotics."
    ],
    "pubmed_search_terms": [
      "gepotidacin urinary tract infection",
      "novel antibiotic uncomplicated UTI",
      "antibiotic resistance UTI treatment"
    ],
    "assistance_programs": [
      {
        "name": "GSK Patient Assistance",
        "url": "https://gskforyou.com/",
        "description": "GSK offers copay assistance and patient assistance programs. Visit gskforyou.com or call 1-866-GSK-FOR-U (1-866-475-3678) for details on Blujepa coverage."
      }
    ]
  },
  "datroway-denial": {
    "slug": "datroway-denial",
    "title": "Appealing Datroway (Datopotamab Deruxtecan) Denials",
    "default_procedure": "Datroway (datopotamab deruxtecan)",
    "default_condition": "HR-Positive, HER2-Negative Breast Cancer",
    "tagline": "Help appealing denials for this TROP2-directed antibody-drug conjugate for breast cancer.",
    "hero_h1": "Appeal Your Datroway Denial",
    "hero_subhead": "Get access to this targeted therapy for HR-positive, HER2-negative breast cancer.",
    "intro": "Datroway (datopotamab deruxtecan) is a TROP2-directed antibody-drug conjugate approved for adults with unresectable or metastatic hormone receptor-positive, HER2-negative breast cancer who have received prior endocrine therapy and chemotherapy. Insurance denials often require documentation of prior treatments and HR/HER2 status.",
    "manufacturer": "Daiichi Sankyo / AstraZeneca",
    "common_denial_reasons": [
      "Prior authorization required",
      "HR/HER2 status not documented",
      "Prior endocrine therapy not documented",
      "Prior chemotherapy not documented",
      "Must try other treatments first",
      "High-cost specialty medication"
    ],
    "how_we_help": "We help you compile your tumor receptor status, prior treatment history, and oncologist recommendations to demonstrate medical necessity for Datroway.",
    "cta": "Start your Datroway appeal — it takes about 3 minutes.",
    "faq": [
      {
        "question": "What prior treatments do I need for Datroway coverage?",
        "answer": "You must have received prior endocrine-based therapy (like aromatase inhibitors, fulvestrant, or CDK4/6 inhibitors) and at least one prior chemotherapy regimen for metastatic disease."
      },
      {
        "question": "What documentation shows my HR/HER2 status?",
        "answer": "Include your pathology report showing estrogen receptor positive (ER+) and/or progesterone receptor positive (PR+) status and HER2-negative status by IHC and/or FISH testing."
      },
      {
        "question": "How is Datroway administered?",
        "answer": "Datroway is given as an IV infusion every 3 weeks at an infusion center or hospital. Your oncology team will monitor you for side effects."
      }
    ],
    "evidence_snippets": [
      "Datopotamab deruxtecan is a TROP2-directed antibody-drug conjugate that delivers chemotherapy directly to cancer cells expressing TROP2.",
      "Clinical trials demonstrated significant improvement in progression-free survival compared to chemotherapy in pretreated HR+/HER2- breast cancer.",
      "TROP2 is highly expressed in HR+/HER2- breast cancer, making it an effective target for antibody-drug conjugate therapy.",
      "Targeted delivery of chemotherapy may provide efficacy advantages while potentially reducing systemic side effects."
    ],
    "pubmed_search_terms": [
      "datopotamab deruxtecan breast cancer",
      "TROP2 ADC HR positive breast cancer",
      "metastatic breast cancer targeted therapy"
    ],
    "assistance_programs": [
      {
        "name": "Datroway4u Patient Support",
        "url": "https://www.datroway.com/",
        "description": "Patient support program offering reimbursement assistance and financial support. Visit Datroway4u.com or call 1-855-DAT-RO4U (1-855-328-7648)."
      }
    ],
    "advocacy_resources": [
      {
        "name": "National Breast Cancer Coalition",
        "url": "https://www.stopbreastcancer.org/",
        "description": "Grassroots advocacy organization dedicated to ending breast cancer through research and policy."
      },
      {
        "name": "Susan G. Komen",
        "url": "https://www.komen.org/",
        "description": "Leading breast cancer organization funding research and providing patient support."
      }
    ]
  },
  "keytruda-qlex-denial": {
    "slug": "keytruda-qlex-denial",
    "title": "Appealing Keytruda Qlex (Subcutaneous Pembrolizumab) Denials",
    "default_procedure": "Keytruda Qlex (pembrolizumab subcutaneous)",
    "default_condition": "Solid Tumors",
    "tagline": "Help appealing denials for this subcutaneous formulation of pembrolizumab immunotherapy.",
    "hero_h1": "Appeal Your Keytruda Qlex Denial",
    "hero_subhead": "Get access to this convenient subcutaneous formulation of Keytruda.",
    "intro": "Keytruda Qlex is the first subcutaneous formulation of pembrolizumab, the leading checkpoint inhibitor immunotherapy. It offers the same efficacy as IV Keytruda with a 1-2 minute injection instead of a 30-minute infusion. Insurance may initially prefer the IV formulation, but subcutaneous delivery offers important benefits for many patients.",
    "manufacturer": "Merck & Co.",
    "common_denial_reasons": [
      "Prior authorization required",
      "IV formulation required/preferred",
      "Must try IV Keytruda first",
      "Indication not approved for SC formulation",
      "New formulation not yet on formulary",
      "Cost difference concerns"
    ],
    "how_we_help": "We help you document why subcutaneous administration is beneficial for you, including reduced infusion time, venous access issues, or patient preference, while demonstrating equivalent efficacy.",
    "cta": "Start your Keytruda Qlex appeal — it takes about 3 minutes.",
    "faq": [
      {
        "question": "Is Keytruda Qlex as effective as IV Keytruda?",
        "answer": "Yes, clinical trials demonstrated equivalent efficacy between subcutaneous and IV formulations. The active ingredient (pembrolizumab) and mechanism of action are the same."
      },
      {
        "question": "Why would I want subcutaneous instead of IV?",
        "answer": "Subcutaneous injection takes only 1-2 minutes versus 30 minutes for IV. It's also easier for patients with poor venous access, reduces time in the infusion center, and may be more convenient overall."
      },
      {
        "question": "Is Keytruda Qlex approved for all the same cancers?",
        "answer": "Keytruda Qlex is approved for adult solid tumor indications where IV Keytruda is indicated. Check with your oncologist to confirm your specific cancer type is covered."
      }
    ],
    "evidence_snippets": [
      "Subcutaneous pembrolizumab demonstrated equivalent pharmacokinetics and efficacy to IV pembrolizumab in clinical trials.",
      "Subcutaneous administration reduces infusion time from 30 minutes to 1-2 minutes.",
      "Patient preference and convenience are recognized as important factors in cancer treatment adherence.",
      "Subcutaneous formulations reduce burden on infusion centers and healthcare resources."
    ],
    "pubmed_search_terms": [
      "pembrolizumab subcutaneous vs IV",
      "checkpoint inhibitor subcutaneous formulation",
      "immunotherapy administration convenience"
    ],
    "assistance_programs": [
      {
        "name": "Merck Access Program (Keytruda)",
        "url": "https://www.merckaccessprogram-keytruda.com/",
        "description": "Co-pay assistance for eligible commercially insured patients. Patient assistance for uninsured/underinsured. Call 855-257-3932."
      }
    ],
    "advocacy_resources": [
      {
        "name": "American Cancer Society",
        "url": "https://www.cancer.org/",
        "description": "Nationwide voluntary health organization providing cancer support, information, and advocacy."
      },
      {
        "name": "CancerCare",
        "url": "https://www.cancercare.org/",
        "description": "Free professional support services including counseling, support groups, and financial assistance."
      },
      {
        "name": "Cancer Support Community",
        "url": "https://www.cancersupportcommunity.org/",
        "description": "Largest professionally led nonprofit network of cancer support worldwide."
      }
    ]
  },
  "inluriyo-denial": {
    "slug": "inluriyo-denial",
    "title": "Appealing Inluriyo (Imlunestrant) Denials",
    "default_procedure": "Inluriyo (imlunestrant)",
    "default_condition": "ER-Positive, HER2-Negative Breast Cancer",
    "tagline": "Help appealing denials for this oral SERD for ESR1-mutated breast cancer.",
    "hero_h1": "Appeal Your Inluriyo Denial",
    "hero_subhead": "Get access to this targeted oral therapy for ESR1-mutated advanced breast cancer.",
    "intro": "Inluriyo (imlunestrant) is an oral selective estrogen receptor degrader (SERD) approved for adults with ER-positive, HER2-negative, ESR1-mutated advanced breast cancer who have progressed on prior endocrine therapy. ESR1 mutations cause resistance to standard hormone therapies, making targeted treatment essential.",
    "manufacturer": "Eli Lilly & Co.",
    "common_denial_reasons": [
      "ESR1 mutation not documented",
      "Prior authorization required",
      "Prior endocrine therapy not documented",
      "Must try fulvestrant first",
      "Specialty tier drug not covered",
      "New drug with limited coverage policies"
    ],
    "how_we_help": "We help you compile your ESR1 mutation testing results, prior endocrine therapy history, and oncologist recommendations to demonstrate medical necessity.",
    "cta": "Start your Inluriyo appeal — it takes about 3 minutes.",
    "faq": [
      {
        "question": "What test do I need for Inluriyo coverage?",
        "answer": "You need documentation of an ESR1 mutation detected by an FDA-approved companion diagnostic or validated molecular testing, typically from a blood or tumor sample."
      },
      {
        "question": "What prior treatments are required?",
        "answer": "You must have received and progressed on at least one prior endocrine-based therapy (aromatase inhibitor, fulvestrant, or CDK4/6 inhibitor combination) for advanced/metastatic disease."
      },
      {
        "question": "How is Inluriyo different from fulvestrant?",
        "answer": "Inluriyo is an oral medication taken daily, while fulvestrant requires monthly injections. Inluriyo was specifically designed to work against ESR1 mutations that cause fulvestrant resistance."
      }
    ],
    "evidence_snippets": [
      "Imlunestrant is an oral SERD that degrades the estrogen receptor, including mutant ESR1 forms that cause endocrine resistance.",
      "ESR1 mutations occur in 30-40% of metastatic ER+ breast cancers after prior endocrine therapy.",
      "Clinical trials demonstrated meaningful response rates in heavily pretreated ESR1-mutated breast cancer.",
      "Oral administration offers convenience compared to injectable fulvestrant."
    ],
    "pubmed_search_terms": [
      "imlunestrant ESR1 mutation breast cancer",
      "oral SERD ER positive breast cancer",
      "ESR1 mutated breast cancer treatment"
    ],
    "assistance_programs": [
      {
        "name": "Lilly Oncology Support Center",
        "url": "https://oncologysupport.lilly.com/",
        "description": "Copay assistance for commercially insured patients. Lilly Cares patient assistance for eligible uninsured patients. Call 1-866-472-8663."
      }
    ],
    "advocacy_resources": [
      {
        "name": "National Breast Cancer Coalition",
        "url": "https://www.stopbreastcancer.org/",
        "description": "Grassroots advocacy organization dedicated to ending breast cancer through research and policy."
      },
      {
        "name": "Susan G. Komen",
        "url": "https://www.komen.org/",
        "description": "Leading breast cancer organization funding research and providing patient support."
      }
    ]
  },
  "forzinity-denial": {
    "slug": "forzinity-denial",
    "title": "Appealing Forzinity (Elamipretide) Denials",
    "default_procedure": "Forzinity (elamipretide)",
    "default_condition": "Barth Syndrome",
    "tagline": "Help appealing denials for this mitochondrial therapy for Barth syndrome.",
    "hero_h1": "Appeal Your Forzinity Denial",
    "hero_subhead": "Get access to this breakthrough treatment for Barth syndrome cardiomyopathy.",
    "intro": "Forzinity (elamipretide) is a mitochondrial-targeted peptide approved for improving muscle strength in patients with Barth syndrome weighing at least 30 kg. Barth syndrome is an ultra-rare genetic disorder causing cardiomyopathy and muscle weakness. Insurance denials are common for rare disease medications, but this is an essential treatment.",
    "manufacturer": "Stealth BioTherapeutics",
    "common_denial_reasons": [
      "Prior authorization required",
      "Barth syndrome diagnosis not genetically confirmed",
      "Weight requirement not documented",
      "Ultra-high cost orphan drug",
      "Rare disease with limited coverage policies",
      "New drug with limited experience"
    ],
    "how_we_help": "We help you document your Barth syndrome diagnosis, genetic testing results, cardiac function, muscle weakness, and how this condition impacts your daily life.",
    "cta": "Start your Forzinity appeal — it takes about 3 minutes.",
    "faq": [
      {
        "question": "What is Barth syndrome?",
        "answer": "Barth syndrome is a rare X-linked genetic disorder caused by TAZ gene mutations. It affects the heart (cardiomyopathy), skeletal muscles, immune system, and growth, primarily in males."
      },
      {
        "question": "What documentation do I need?",
        "answer": "Include genetic testing confirming TAZ mutation, documentation of current weight (must be at least 30 kg), cardiac function tests showing cardiomyopathy, and muscle strength assessments."
      },
      {
        "question": "How is Forzinity administered?",
        "answer": "Forzinity is given as a daily subcutaneous injection that can be self-administered at home after training."
      }
    ],
    "evidence_snippets": [
      "Elamipretide targets the inner mitochondrial membrane, improving mitochondrial function in Barth syndrome.",
      "Clinical trials demonstrated improvement in muscle strength and functional capacity.",
      "Barth syndrome affects approximately 1 in 300,000-400,000 births, making it an ultra-rare disease.",
      "No other approved therapies specifically target the underlying mitochondrial dysfunction in Barth syndrome."
    ],
    "pubmed_search_terms": [
      "elamipretide Barth syndrome",
      "mitochondrial therapy cardiomyopathy",
      "TAZ mutation treatment"
    ],
    "assistance_programs": [
      {
        "name": "Stealth BioTherapeutics Patient Support",
        "url": "https://www.stealthbt.com/",
        "description": "Patient support program for Forzinity offering access assistance and financial support for eligible patients."
      }
    ],
    "advocacy_resources": [
      {
        "name": "National Organization for Rare Disorders (NORD)",
        "url": "https://rarediseases.org/",
        "description": "Leading patient advocacy organization for rare disease community."
      },
      {
        "name": "Global Genes",
        "url": "https://globalgenes.org/",
        "description": "Leading rare disease patient advocacy organization connecting and empowering patients."
      }
    ]
  },
  "nuzolvence-denial": {
    "slug": "nuzolvence-denial",
    "title": "Appealing Nuzolvence (Zoliflodacin) Denials",
    "default_procedure": "Nuzolvence (zoliflodacin)",
    "default_condition": "Uncomplicated Gonorrhea",
    "tagline": "Help appealing denials for this first-in-class oral antibiotic for gonorrhea.",
    "hero_h1": "Appeal Your Nuzolvence Denial",
    "hero_subhead": "Get access to this new oral treatment for uncomplicated gonorrhea.",
    "intro": "Nuzolvence (zoliflodacin) is the first spiropyrimidinetrione antibiotic approved for uncomplicated urogenital gonorrhea. With increasing antibiotic resistance in gonorrhea, new treatment options are critically needed. This single-dose oral treatment offers an important alternative when other antibiotics may not be effective.",
    "manufacturer": "Innoviva Specialty Therapeutics",
    "common_denial_reasons": [
      "Prior authorization required",
      "Must try ceftriaxone first",
      "Culture and sensitivity not provided",
      "Not medically necessary",
      "New drug with limited coverage policies",
      "Single-dose treatment cost concerns"
    ],
    "how_we_help": "We help you document your gonorrhea diagnosis, any antibiotic allergies, prior treatment failures, and why Nuzolvence is the appropriate choice for your infection.",
    "cta": "Start your Nuzolvence appeal — it takes about 3 minutes.",
    "faq": [
      {
        "question": "When is Nuzolvence used instead of ceftriaxone?",
        "answer": "Nuzolvence may be appropriate if you have allergies to cephalosporins or other first-line antibiotics, if there's concern about antibiotic resistance, or if you prefer oral over injectable treatment."
      },
      {
        "question": "How is Nuzolvence taken?",
        "answer": "Nuzolvence is taken as a single oral dose, making it convenient for treating uncomplicated gonorrhea without needing an injection."
      },
      {
        "question": "Does Nuzolvence treat other STIs?",
        "answer": "Nuzolvence is specifically approved for uncomplicated urogenital gonorrhea. You may still need testing and treatment for other STIs like chlamydia."
      }
    ],
    "evidence_snippets": [
      "Zoliflodacin is a first-in-class spiropyrimidinetrione antibiotic with a novel mechanism of action.",
      "Clinical trials demonstrated non-inferiority to ceftriaxone plus azithromycin for uncomplicated gonorrhea.",
      "Antibiotic-resistant gonorrhea is a growing public health threat requiring new treatment options.",
      "Single-dose oral treatment improves adherence compared to multi-dose regimens."
    ],
    "pubmed_search_terms": [
      "zoliflodacin gonorrhea treatment",
      "novel antibiotic Neisseria gonorrhoeae",
      "antibiotic resistant gonorrhea treatment"
    ],
    "assistance_programs": []
  },
  "imaavy-denial": {
    "slug": "imaavy-denial",
    "title": "Appealing Imaavy (Nipocalimab) Denials",
    "default_procedure": "Imaavy (nipocalimab)",
    "default_condition": "Generalized Myasthenia Gravis",
    "tagline": "Help appealing denials for this FcRn antibody for autoimmune myasthenia gravis.",
    "hero_h1": "Appeal Your Imaavy Denial",
    "hero_subhead": "Get access to this IgG-lowering therapy for generalized myasthenia gravis.",
    "intro": "Imaavy (nipocalimab) is an FcRn-blocking antibody approved for adults with generalized myasthenia gravis (gMG) who are anti-acetylcholine receptor (AChR) antibody positive. By lowering pathogenic IgG antibodies, it addresses the underlying cause of muscle weakness. Insurance often requires step therapy through other treatments first.",
    "manufacturer": "Janssen Biotech",
    "common_denial_reasons": [
      "Prior authorization required",
      "AChR antibody status not documented",
      "Must try steroids/immunosuppressants first",
      "Must try other MG therapies first",
      "MGFA class not documented",
      "High-cost biologic medication"
    ],
    "how_we_help": "We help you document your AChR antibody status, MGFA classification, prior treatment history, and current disease severity to demonstrate medical necessity.",
    "cta": "Start your Imaavy appeal — it takes about 3 minutes.",
    "faq": [
      {
        "question": "What antibody test do I need for Imaavy?",
        "answer": "You need documentation of positive anti-acetylcholine receptor (AChR) antibodies. Imaavy is specifically approved for AChR-positive gMG."
      },
      {
        "question": "What prior treatments are typically required?",
        "answer": "Most insurers require trial of conventional therapies like steroids, pyridostigmine, azathioprine, or mycophenolate before approving newer biologics. Document all prior treatments and their results."
      },
      {
        "question": "How is Imaavy administered?",
        "answer": "Imaavy is given as a weekly subcutaneous injection that can be self-administered at home after training."
      }
    ],
    "evidence_snippets": [
      "Nipocalimab blocks the neonatal Fc receptor (FcRn), reducing pathogenic IgG antibodies that attack the neuromuscular junction.",
      "Clinical trials demonstrated improvement in MG-ADL scores and reduced need for rescue therapy.",
      "Generalized myasthenia gravis causes significant disability including weakness, fatigue, and respiratory compromise.",
      "FcRn inhibition offers a novel mechanism for treating antibody-mediated autoimmune diseases."
    ],
    "pubmed_search_terms": [
      "nipocalimab myasthenia gravis",
      "FcRn inhibitor autoimmune disease",
      "generalized myasthenia gravis treatment"
    ],
    "assistance_programs": [
      {
        "name": "Janssen CarePath",
        "url": "https://www.janssencarepath.com/",
        "description": "Copay assistance for eligible commercially insured patients. Patient assistance for uninsured. Call Janssen CarePath for details."
      }
    ],
    "advocacy_resources": [
      {
        "name": "Myasthenia Gravis Foundation of America",
        "url": "https://myasthenia.org/",
        "description": "Largest patient advocacy organization solely focused on myasthenia gravis."
      }
    ]
  },
  "vanrafia-denial": {
    "slug": "vanrafia-denial",
    "title": "Appealing Vanrafia (Atrasentan) Denials",
    "default_procedure": "Vanrafia (atrasentan)",
    "default_condition": "IgA Nephropathy",
    "tagline": "Help appealing denials for this endothelin receptor antagonist for IgA nephropathy.",
    "hero_h1": "Appeal Your Vanrafia Denial",
    "hero_subhead": "Get access to this treatment for reducing proteinuria in IgA nephropathy.",
    "intro": "Vanrafia (atrasentan) is an endothelin receptor antagonist approved for reducing proteinuria in adults with primary IgA nephropathy at risk for disease progression. Reducing proteinuria is critical for slowing kidney disease. Insurance often requires documentation of biopsy-proven diagnosis and prior treatment with ACE inhibitors or ARBs.",
    "manufacturer": "Travere Therapeutics",
    "common_denial_reasons": [
      "Prior authorization required",
      "Biopsy-proven IgAN not documented",
      "Proteinuria level not high enough",
      "Must be on maximum ACEi/ARB therapy",
      "Specialty tier drug not covered",
      "New drug with limited coverage policies"
    ],
    "how_we_help": "We help you document your kidney biopsy results, proteinuria levels, eGFR, current ACE inhibitor/ARB therapy, and risk factors for disease progression.",
    "cta": "Start your Vanrafia appeal — it takes about 3 minutes.",
    "faq": [
      {
        "question": "What documentation do I need?",
        "answer": "Include kidney biopsy confirming IgA nephropathy, urine protein levels showing significant proteinuria (typically 1 g/day or higher), eGFR results, and documentation that you're on maximally tolerated ACE inhibitor or ARB therapy."
      },
      {
        "question": "Can I take Vanrafia with other IgAN treatments?",
        "answer": "Yes, Vanrafia is typically used in addition to supportive care with ACE inhibitors or ARBs. Discuss with your nephrologist how it fits with your overall treatment plan."
      },
      {
        "question": "How does Vanrafia work?",
        "answer": "Vanrafia blocks the endothelin A receptor, reducing inflammation and scarring in the kidneys and decreasing protein leakage into the urine."
      }
    ],
    "evidence_snippets": [
      "Atrasentan is a selective endothelin A receptor antagonist that reduces proteinuria in IgA nephropathy.",
      "Clinical trials demonstrated significant reduction in proteinuria compared to placebo.",
      "Reducing proteinuria is associated with slower progression to kidney failure in IgA nephropathy.",
      "Endothelin pathway blockade provides a complementary mechanism to renin-angiotensin system inhibition."
    ],
    "pubmed_search_terms": [
      "atrasentan IgA nephropathy",
      "endothelin receptor antagonist proteinuria",
      "IgA nephropathy disease progression treatment"
    ],
    "assistance_programs": [
      {
        "name": "Travere Therapeutics Patient Support",
        "url": "https://www.travere.com/",
        "description": "Patient support program offering access and affordability assistance for eligible patients."
      }
    ],
    "advocacy_resources": [
      {
        "name": "IgA Nephropathy Foundation of America",
        "url": "https://www.iganephropathy.org/",
        "description": "Foundation dedicated to IgA nephropathy awareness, research, and patient support."
      },
      {
        "name": "National Kidney Foundation",
        "url": "https://www.kidney.org/",
        "description": "Leading kidney health organization with advocacy and patient resources."
      }
    ]
  },
  "enflonsia-denial": {
    "slug": "enflonsia-denial",
    "title": "Appealing Enflonsia (Clesrovimab) Denials",
    "default_procedure": "Enflonsia (clesrovimab)",
    "default_condition": "RSV Prevention in Infants",
    "tagline": "Help appealing denials for this long-acting RSV antibody for infants.",
    "hero_h1": "Appeal Your Enflonsia Denial",
    "hero_subhead": "Get access to this RSV prevention treatment for your infant.",
    "intro": "Enflonsia (clesrovimab) is a long-acting monoclonal antibody for preventing RSV lower respiratory tract disease in neonates and infants. RSV is a leading cause of infant hospitalization. While similar to other RSV preventives, insurance may have specific criteria or prefer alternatives.",
    "manufacturer": "Merck & Co.",
    "common_denial_reasons": [
      "Prior authorization required",
      "Not meeting high-risk criteria",
      "Preferred RSV preventive required",
      "Age/timing criteria not met",
      "Dosing/administration concerns",
      "New drug with limited coverage policies"
    ],
    "how_we_help": "We help you document your infant's RSV risk factors, age eligibility, and why RSV prevention is medically necessary for protecting your baby.",
    "cta": "Start your Enflonsia appeal — it takes about 3 minutes.",
    "faq": [
      {
        "question": "Which infants are eligible for RSV prevention?",
        "answer": "RSV preventives are recommended for all infants under 8 months entering their first RSV season, and for certain high-risk infants up to 19 months. Your pediatrician can determine eligibility."
      },
      {
        "question": "How is Enflonsia given?",
        "answer": "Enflonsia is given as a single intramuscular injection, typically before or during RSV season (fall through spring in most areas)."
      },
      {
        "question": "Is Enflonsia covered as a vaccine or prescription?",
        "answer": "RSV preventives are typically covered under medical benefits (like vaccines) rather than pharmacy benefits. Check with your insurance about specific coverage."
      }
    ],
    "evidence_snippets": [
      "Clesrovimab is a long-acting monoclonal antibody that neutralizes RSV, preventing severe lower respiratory tract infection.",
      "RSV is the leading cause of infant hospitalization in the United States.",
      "Clinical trials demonstrated significant reduction in medically attended RSV infections.",
      "Single-dose administration provides protection throughout the RSV season."
    ],
    "pubmed_search_terms": [
      "clesrovimab RSV prevention infants",
      "RSV monoclonal antibody prophylaxis",
      "infant RSV hospitalization prevention"
    ],
    "assistance_programs": [
      {
        "name": "Merck Patient Assistance",
        "url": "https://www.merck.com/company-overview/responsibility/access-to-health/patient-assistance-programs/",
        "description": "Merck offers patient assistance programs for eligible patients. Contact Merck for Enflonsia-specific assistance information."
      }
    ],
    "advocacy_resources": [
      {
        "name": "American Lung Association",
        "url": "https://www.lung.org/",
        "description": "Leading organization fighting lung disease including RSV through research and advocacy."
      }
    ]
  },
  "abbott-volt-pfa-denial": {
    "slug": "abbott-volt-pfa-denial",
    "title": "Appealing Abbott Volt PFA System Denials",
    "default_procedure": "Abbott Volt PFA System (pulsed field ablation)",
    "default_condition": "Atrial Fibrillation",
    "tagline": "Help appealing denials for this pulsed field ablation catheter for AFib treatment.",
    "hero_h1": "Appeal Your Abbott Volt PFA Denial",
    "hero_subhead": "Get access to this next-generation ablation technology for atrial fibrillation.",
    "intro": "The Abbott Volt PFA System uses pulsed field ablation (PFA) technology for catheter-based treatment of atrial fibrillation. PFA selectively targets cardiac tissue while sparing nearby structures, potentially offering safety advantages over traditional thermal ablation. Insurance may require documentation of AFib diagnosis and failed medical therapy.",
    "manufacturer": "Abbott",
    "common_denial_reasons": [
      "Prior authorization required",
      "AFib diagnosis not documented",
      "Must try antiarrhythmic drugs first",
      "Facility/provider not approved",
      "Traditional ablation preferred",
      "New technology coverage limitations"
    ],
    "how_we_help": "We help you document your atrial fibrillation diagnosis, symptoms, failed medical management, and why catheter ablation with PFA technology is appropriate for you.",
    "cta": "Start your Abbott Volt PFA appeal — it takes about 3 minutes.",
    "faq": [
      {
        "question": "What is pulsed field ablation?",
        "answer": "PFA uses electrical pulses to create lesions in heart tissue, isolating the pulmonary veins that trigger AFib. Unlike thermal ablation (radiofrequency or cryo), PFA selectively affects cardiac cells while sparing nerves, esophagus, and other nearby structures."
      },
      {
        "question": "Do I need to try medications first?",
        "answer": "Most insurers require documentation that you've tried and failed or are intolerant to at least one antiarrhythmic medication before approving ablation. Document all medications tried and why they failed."
      },
      {
        "question": "How is the procedure performed?",
        "answer": "The Abbott Volt system is used during a cardiac catheterization procedure in an electrophysiology lab. Catheters are inserted through blood vessels to reach the heart and deliver PFA energy."
      }
    ],
    "evidence_snippets": [
      "Pulsed field ablation offers tissue selectivity, potentially reducing complications affecting the esophagus, phrenic nerve, and pulmonary veins.",
      "Clinical trials demonstrated high rates of pulmonary vein isolation with PFA technology.",
      "Catheter ablation is a guideline-recommended treatment for symptomatic atrial fibrillation refractory to or intolerant of antiarrhythmic drugs.",
      "PFA may offer faster procedure times compared to traditional point-by-point ablation."
    ],
    "pubmed_search_terms": [
      "pulsed field ablation atrial fibrillation",
      "PFA catheter ablation AFib outcomes",
      "tissue selectivity pulsed field ablation"
    ],
    "assistance_programs": [],
    "advocacy_resources": [
      {
        "name": "StopAfib.org",
        "url": "https://www.stopafib.org/",
        "description": "Patient advocacy organization founded by and for afib patients."
      }
    ]
  },
  "edwards-sapien-m3-denial": {
    "slug": "edwards-sapien-m3-denial",
    "title": "Appealing Edwards SAPIEN M3 (Mitral Valve) Denials",
    "default_procedure": "Edwards SAPIEN M3 TMVR System",
    "default_condition": "Mitral Regurgitation",
    "tagline": "Help appealing denials for this transcatheter mitral valve replacement for inoperable patients.",
    "hero_h1": "Appeal Your Edwards SAPIEN M3 Denial",
    "hero_subhead": "Get access to this first transfemoral mitral valve replacement.",
    "intro": "The Edwards SAPIEN M3 is the first transcatheter mitral valve replacement (TMVR) system approved for patients with symptomatic moderate-to-severe mitral regurgitation who cannot undergo traditional surgery. This represents a breakthrough for patients with no other options. Insurance may require documentation of surgical ineligibility.",
    "manufacturer": "Edwards Lifesciences",
    "common_denial_reasons": [
      "Prior authorization required",
      "Surgical candidacy not adequately ruled out",
      "Imaging requirements not met",
      "Must try MitraClip or other repair first",
      "Facility/center not approved",
      "New technology coverage limitations"
    ],
    "how_we_help": "We help you document your mitral regurgitation severity, symptoms, heart team evaluation, reasons for surgical ineligibility, and why TMVR is your best option.",
    "cta": "Start your Edwards SAPIEN M3 appeal — it takes about 3 minutes.",
    "faq": [
      {
        "question": "Who is eligible for SAPIEN M3?",
        "answer": "SAPIEN M3 is for patients with symptomatic moderate-to-severe mitral regurgitation who are at prohibitive risk for surgical mitral valve replacement or repair, as determined by a heart team."
      },
      {
        "question": "What documentation proves surgical ineligibility?",
        "answer": "Include your surgical risk assessment (STS score), heart team evaluation notes, comorbidities that increase surgical risk, and any prior cardiac surgeries that complicate reoperation."
      },
      {
        "question": "How is the procedure performed?",
        "answer": "SAPIEN M3 is implanted through the femoral vein using a transseptal approach, avoiding the need for open-heart surgery or chest incision."
      }
    ],
    "evidence_snippets": [
      "SAPIEN M3 is the first transcatheter mitral valve replacement approved for transfemoral delivery.",
      "Clinical trials demonstrated significant reduction in mitral regurgitation and improvement in symptoms.",
      "Transcatheter options provide treatment for patients who previously had no surgical options.",
      "Heart team evaluation is essential for determining appropriate patient selection."
    ],
    "pubmed_search_terms": [
      "transcatheter mitral valve replacement outcomes",
      "TMVR SAPIEN mitral regurgitation",
      "inoperable mitral regurgitation treatment"
    ],
    "assistance_programs": [],
    "advocacy_resources": [
      {
        "name": "American Heart Association",
        "url": "https://www.heart.org/",
        "description": "Leading nonprofit fighting heart disease through education, advocacy, and research."
      },
      {
        "name": "Mended Hearts",
        "url": "https://mendedhearts.org/",
        "description": "Peer support network for heart patients and their families."
      }
    ]
  },
  "setpoint-vns-denial": {
    "slug": "setpoint-vns-denial",
    "title": "Appealing SetPoint Vagus Nerve Stimulation Denials",
    "default_procedure": "SetPoint System (vagus nerve stimulation)",
    "default_condition": "Rheumatoid Arthritis",
    "tagline": "Help appealing denials for this bioelectronic therapy for treatment-resistant RA.",
    "hero_h1": "Appeal Your SetPoint VNS Denial",
    "hero_subhead": "Get access to this first-in-class bioelectronic medicine for rheumatoid arthritis.",
    "intro": "The SetPoint System is the first implantable vagus nerve stimulation device approved for treating moderate-to-severe rheumatoid arthritis in patients who have not responded to biologic DMARDs. This bioelectronic approach offers a drug-free alternative for patients who have exhausted medication options.",
    "manufacturer": "SetPoint Medical",
    "common_denial_reasons": [
      "Prior authorization required",
      "Must try multiple biologics first",
      "Experimental/investigational designation",
      "Implant surgery not covered",
      "New technology coverage limitations",
      "Facility/surgeon not approved"
    ],
    "how_we_help": "We help you document your RA history, all prior DMARDs and biologics tried, disease activity scores, and why bioelectronic therapy is appropriate after failing multiple medications.",
    "cta": "Start your SetPoint VNS appeal — it takes about 3 minutes.",
    "faq": [
      {
        "question": "What is vagus nerve stimulation for RA?",
        "answer": "The SetPoint device delivers electrical pulses to the vagus nerve, which reduces inflammation through the cholinergic anti-inflammatory pathway. This is a fundamentally different approach from medications."
      },
      {
        "question": "What prior treatments are required?",
        "answer": "SetPoint is approved for patients who have not responded adequately to biologic or targeted synthetic DMARDs. You'll need to document failure or intolerance to multiple biologic therapies."
      },
      {
        "question": "How is the device implanted?",
        "answer": "The SetPoint device is implanted in a minimally invasive outpatient surgical procedure. A small pulse generator is placed in the chest and connected to the vagus nerve."
      }
    ],
    "evidence_snippets": [
      "Vagus nerve stimulation activates the inflammatory reflex, reducing systemic inflammation in rheumatoid arthritis.",
      "Clinical trials demonstrated significant improvement in ACR response rates in biologic-refractory RA patients.",
      "Bioelectronic medicine offers a drug-free approach for patients who have exhausted medication options.",
      "The SetPoint system represents the first FDA-approved bioelectronic therapy for an autoimmune disease."
    ],
    "pubmed_search_terms": [
      "vagus nerve stimulation rheumatoid arthritis",
      "bioelectronic medicine autoimmune disease",
      "cholinergic anti-inflammatory pathway RA"
    ],
    "assistance_programs": [
      {
        "name": "SetPoint Medical Patient Support",
        "url": "https://www.setpointmedical.com/",
        "description": "SetPoint is working with payers to establish coverage. Contact SetPoint Medical for information on access and financial assistance options."
      }
    ],
    "advocacy_resources": [
      {
        "name": "Arthritis Foundation",
        "url": "https://www.arthritis.org/",
        "description": "Nationwide advocacy, support, and research organization for all forms of arthritis."
      }
    ]
  },
  "flow-tdcs-depression-denial": {
    "slug": "flow-tdcs-depression-denial",
    "title": "Appealing Flow tDCS Device Denials",
    "default_procedure": "Flow Neuroscience FL-100 (tDCS device)",
    "default_condition": "Major Depressive Disorder",
    "tagline": "Help appealing denials for this at-home brain stimulation device for depression.",
    "hero_h1": "Appeal Your Flow tDCS Device Denial",
    "hero_subhead": "Get access to this first FDA-approved at-home brain stimulation for depression.",
    "intro": "The Flow Neuroscience FL-100 is the first FDA-approved at-home transcranial direct current stimulation (tDCS) device for treating major depressive disorder. It offers a drug-free, non-invasive treatment option that can be used at home. Insurance coverage is still developing for this new category of treatment.",
    "manufacturer": "Flow Neuroscience",
    "common_denial_reasons": [
      "Prior authorization required",
      "Must try antidepressants first",
      "Experimental/investigational designation",
      "DME coverage limitations",
      "New device not yet on formulary",
      "Provider prescription requirements"
    ],
    "how_we_help": "We help you document your depression history, prior antidepressant trials, reasons for seeking non-medication treatment, and how the Flow device fits your treatment plan.",
    "cta": "Start your Flow tDCS appeal — it takes about 3 minutes.",
    "faq": [
      {
        "question": "What is tDCS?",
        "answer": "Transcranial direct current stimulation (tDCS) delivers a weak electrical current to the brain through electrodes on the scalp. This modulates brain activity and has been shown to improve depression symptoms."
      },
      {
        "question": "Do I need to try medications first?",
        "answer": "Flow is approved for moderate-to-severe depression that is not treatment-resistant. Insurers may require trial of antidepressants, but Flow can also be used as an adjunct to medication."
      },
      {
        "question": "How often do I use the device?",
        "answer": "The typical treatment protocol involves daily 30-minute sessions during the initial treatment phase, with maintenance sessions as needed. The device connects to a smartphone app for guidance."
      }
    ],
    "evidence_snippets": [
      "tDCS has been shown to improve depression symptoms by modulating activity in the prefrontal cortex.",
      "Clinical trials demonstrated significant improvement in depression scores compared to sham stimulation.",
      "At-home tDCS offers a convenient, drug-free treatment option that can be combined with other therapies.",
      "Non-invasive brain stimulation may benefit patients who prefer to avoid or cannot tolerate antidepressants."
    ],
    "pubmed_search_terms": [
      "tDCS major depressive disorder efficacy",
      "transcranial direct current stimulation depression",
      "at-home brain stimulation depression treatment"
    ],
    "assistance_programs": [
      {
        "name": "Flow Neuroscience Direct Purchase",
        "url": "https://www.flowneuroscience.com/",
        "description": "Flow is available for direct purchase while insurance coverage develops. Contact Flow Neuroscience for current pricing and any available payment plans."
      }
    ],
    "advocacy_resources": [
      {
        "name": "NAMI - National Alliance on Mental Illness",
        "url": "https://www.nami.org/",
        "description": "Nation's largest grassroots mental health organization. HelpLine: 1-800-950-NAMI."
      },
      {
        "name": "Depression and Bipolar Support Alliance",
        "url": "https://www.dbsalliance.org/",
        "description": "Peer-based support and education for people with depression and bipolar disorder."
      }
    ]
  },
  "teal-wand-hpv-denial": {
    "slug": "teal-wand-hpv-denial",
    "title": "Appealing Teal Wand HPV Self-Collection Denials",
    "default_procedure": "Teal Wand (at-home HPV test kit)",
    "default_condition": "Cervical Cancer Screening",
    "tagline": "Help appealing denials for this at-home cervical cancer screening device.",
    "hero_h1": "Appeal Your Teal Wand Denial",
    "hero_subhead": "Get access to this first at-home HPV self-collection test for cervical screening.",
    "intro": "The Teal Wand is the first FDA-approved at-home self-collection device for HPV testing as part of cervical cancer screening. It allows women to collect their own sample at home, addressing barriers to screening like discomfort with pelvic exams or difficulty accessing healthcare. Insurance coverage is still developing.",
    "manufacturer": "Teal Health",
    "common_denial_reasons": [
      "Must have in-office screening",
      "Device not covered as DME",
      "Lab test covered but kit not covered",
      "New device not yet on formulary",
      "Provider order requirements",
      "Telehealth service limitations"
    ],
    "how_we_help": "We help you document why at-home screening is necessary for you, including access barriers, anxiety about pelvic exams, or history of non-compliance with traditional screening.",
    "cta": "Start your Teal Wand appeal — it takes about 3 minutes.",
    "faq": [
      {
        "question": "How does the Teal Wand work?",
        "answer": "The Teal Wand is a vaginal self-collection device. You collect your own sample at home and send it to a lab for HPV testing. Results are reviewed by a healthcare provider via telehealth."
      },
      {
        "question": "Is at-home HPV testing as accurate as in-office?",
        "answer": "Self-collected samples have been shown to be equivalent to clinician-collected samples for HPV detection. The FDA has approved the Teal Wand for this purpose."
      },
      {
        "question": "Do I still need a Pap smear?",
        "answer": "HPV testing is the primary cervical cancer screening for women 25-65. If your HPV test is positive, you may need follow-up with a Pap test or colposcopy as recommended by your provider."
      }
    ],
    "evidence_snippets": [
      "Self-collected HPV samples show equivalent sensitivity to clinician-collected samples for detecting high-risk HPV.",
      "Barriers to cervical cancer screening include discomfort, embarrassment, time constraints, and access issues.",
      "Self-collection options may increase screening rates in underscreened populations.",
      "HPV screening is a critical preventive service for reducing cervical cancer incidence and mortality."
    ],
    "pubmed_search_terms": [
      "HPV self-collection cervical screening",
      "at-home HPV test accuracy",
      "cervical cancer screening barriers self-collection"
    ],
    "assistance_programs": [
      {
        "name": "Teal Health Direct Access",
        "url": "https://www.tealhealth.com/",
        "description": "Teal Health offers the Teal Wand through their telehealth service. Contact Teal Health for current pricing and insurance coverage information."
      }
    ],
    "advocacy_resources": [
      {
        "name": "National Cervical Cancer Coalition",
        "url": "https://www.nccc-online.org/",
        "description": "Grassroots nonprofit advocating for cervical cancer prevention and awareness."
      },
      {
        "name": "Foundation for Women's Cancer",
        "url": "https://www.foundationforwomenscancer.org/",
        "description": "Supporting women with gynecologic cancers through research and education."
      }
    ]
  },
  "physical-therapy-denial": {
    "slug": "physical-therapy-denial",
    "title": "Appealing Physical Therapy Denials",
    "default_procedure": "Physical Therapy",
    "tagline": "Help appealing denials for physical therapy coverage.",
    "hero_h1": "Appeal Your Physical Therapy Denial",
    "hero_subhead": "Don't let your insurer limit your access to medically necessary rehabilitation.",
    "intro": "Physical therapy is essential for recovering from injuries, surgeries, and chronic conditions. Insurance companies often deny or limit physical therapy visits based on arbitrary session limits, claiming that continued therapy is not medically necessary even when your provider prescribes it. These denials can prevent full recovery and lead to long-term disability.",
    "common_denial_reasons": [
      "Exceeded plan visit limits",
      "Not medically necessary after initial visits",
      "Maintenance therapy not covered",
      "Plateau in progress claimed",
      "Must try home exercises first",
      "Out-of-network provider",
      "Prior authorization not obtained"
    ],
    "how_we_help": "We help you document your functional limitations, treatment goals, objective progress measures, and why continued physical therapy is necessary to prevent decline or achieve further meaningful improvement.",
    "cta": "Start your physical therapy appeal — it takes about 3 minutes.",
    "faq": [
      {
        "question": "My insurer says I've plateaued. Can I still appeal?",
        "answer": "Yes. You can argue that maintenance therapy is needed to prevent decline, or provide new objective measurements showing continued improvement. Your therapist's documentation of functional gains is key evidence."
      },
      {
        "question": "What if I've exceeded my plan's visit limits?",
        "answer": "Many plans have exceptions for medical necessity. Your appeal can document why additional visits are needed based on your specific condition, surgery, or injury severity."
      },
      {
        "question": "Can my physical therapist help with the appeal?",
        "answer": "Yes, and they should. A letter from your PT documenting your progress, functional deficits, and treatment goals is critical evidence for your appeal."
      }
    ],
    "evidence_snippets": [
      "Physical therapy reduces pain and improves function in patients with musculoskeletal conditions.",
      "Post-surgical physical therapy improves outcomes and reduces complications.",
      "Maintenance physical therapy can prevent functional decline in chronic conditions.",
      "Limiting physical therapy sessions often leads to worse long-term outcomes and higher costs."
    ],
    "pubmed_search_terms": [
      "physical therapy effectiveness musculoskeletal",
      "post-surgical rehabilitation outcomes",
      "physical therapy visit frequency outcomes"
    ],
    "advocacy_resources": [
      {
        "name": "American Physical Therapy Association",
        "url": "https://www.apta.org/",
        "description": "Professional organization advocating for physical therapy access and coverage."
      }
    ]
  },
  "bilateral-orchiectomy-denial": {
    "slug": "bilateral-orchiectomy-denial",
    "title": "Appealing Bilateral Orchiectomy Denials",
    "default_procedure": "Bilateral Orchiectomy",
    "default_condition": "Gender Dysphoria",
    "tagline": "Help appealing denials for medically necessary bilateral orchiectomy.",
    "hero_h1": "Appeal Your Orchiectomy Denial",
    "hero_subhead": "Don't let your insurer deny this medically necessary procedure for gender dysphoria treatment.",
    "intro": "Bilateral orchiectomy is a recognized treatment for gender dysphoria and may also be performed for prostate cancer treatment. For transgender women, orchiectomy eliminates the need for testosterone-blocking medications and provides permanent feminizing effects. Insurance denials often cite cosmetic or experimental exclusions, despite major medical organizations recognizing this as medically necessary care.",
    "common_denial_reasons": [
      "Considered cosmetic surgery",
      "Deemed experimental or investigational",
      "Prior authorization requirements not met",
      "Insufficient documentation of gender dysphoria",
      "Time on hormone therapy requirements",
      "Mental health evaluation requirements",
      "Out-of-network surgeon"
    ],
    "how_we_help": "We help you document your gender dysphoria diagnosis, treatment history, mental health evaluations, and how this procedure is medically necessary per WPATH Standards of Care.",
    "cta": "Start your orchiectomy appeal — it takes about 3 minutes.",
    "faq": [
      {
        "question": "Is orchiectomy considered medically necessary?",
        "answer": "Yes. Major medical organizations including WPATH, the Endocrine Society, and the AMA recognize surgical treatment of gender dysphoria as medically necessary, not cosmetic."
      },
      {
        "question": "What documentation do I need for an appeal?",
        "answer": "Key documents include your gender dysphoria diagnosis, letters from mental health providers, hormone therapy history, and a letter of medical necessity from your surgeon."
      },
      {
        "question": "What are the WPATH criteria for this surgery?",
        "answer": "WPATH Standards of Care recommend persistent, well-documented gender dysphoria, capacity to consent, and if significant medical or mental health concerns are present, they should be reasonably well-controlled."
      }
    ],
    "evidence_snippets": [
      "Surgical treatment significantly reduces gender dysphoria and improves quality of life.",
      "WPATH Standards of Care recognize genital surgery as medically necessary treatment.",
      "Orchiectomy eliminates the need for testosterone-blocking medications, reducing medication costs and side effects.",
      "Withholding gender-affirming care is associated with significant mental health harms."
    ],
    "pubmed_search_terms": [
      "orchiectomy gender dysphoria outcomes",
      "gender-affirming surgery quality of life",
      "transgender surgical treatment mental health"
    ],
    "advocacy_resources": [
      {
        "name": "National Center for Transgender Equality",
        "url": "https://transequality.org/",
        "description": "Nation's leading social justice advocacy organization for transgender people."
      },
      {
        "name": "Transgender Law Center",
        "url": "https://transgenderlawcenter.org/",
        "description": "Legal organization advocating for transgender rights and providing legal resources."
      },
      {
        "name": "WPATH",
        "url": "https://www.wpath.org/",
        "description": "World Professional Association for Transgender Health - promotes evidence-based care and standards."
      }
    ]
  },
  "clonoseq-mrd-testing-denial": {
    "slug": "clonoseq-mrd-testing-denial",
    "title": "Appealing clonoSEQ MRD Testing Denials",
    "default_procedure": "clonoSEQ MRD Testing",
    "default_condition": "Blood Cancer",
    "tagline": "Help appealing denials for minimal residual disease testing.",
    "hero_h1": "Appeal Your clonoSEQ MRD Testing Denial",
    "hero_subhead": "Don't let your insurer deny access to this important cancer monitoring test.",
    "intro": "clonoSEQ is an FDA-cleared test that detects minimal residual disease (MRD) in blood cancers like multiple myeloma, leukemia, and lymphoma. MRD testing helps oncologists determine if cancer cells remain after treatment and guides critical treatment decisions. Insurance companies sometimes deny coverage despite Medicare and major insurers recognizing its clinical value.",
    "manufacturer": "Adaptive Biotechnologies",
    "common_denial_reasons": [
      "Test not medically necessary",
      "Experimental or investigational",
      "Not covered under lab benefits",
      "Surveillance testing not covered",
      "Frequency limits exceeded",
      "Out-of-network laboratory",
      "Prior authorization not obtained"
    ],
    "how_we_help": "We help you document your cancer diagnosis, treatment history, and how MRD testing will guide your treatment decisions and monitoring.",
    "cta": "Start your clonoSEQ appeal — it takes about 3 minutes.",
    "faq": [
      {
        "question": "Is clonoSEQ covered by Medicare?",
        "answer": "Yes. Medicare provides national coverage for clonoSEQ in multiple myeloma, ALL, CLL, DLBCL, and mantle cell lymphoma. This coverage can support appeals to private insurers."
      },
      {
        "question": "Why is MRD testing important?",
        "answer": "MRD testing can detect cancer cells at much lower levels than standard tests. Achieving MRD negativity is associated with better outcomes, and MRD results help guide decisions about treatment duration and intensity."
      },
      {
        "question": "What if my insurer says MRD testing is experimental?",
        "answer": "clonoSEQ is FDA-cleared and Medicare-covered. Your appeal should cite these regulatory decisions and clinical guidelines recommending MRD assessment."
      }
    ],
    "evidence_snippets": [
      "MRD negativity is associated with improved survival in multiple myeloma and leukemias.",
      "clonoSEQ is the only FDA-cleared MRD test for blood cancers.",
      "MRD assessment guides treatment decisions including duration of therapy.",
      "Medicare provides national coverage for clonoSEQ in multiple blood cancers."
    ],
    "pubmed_search_terms": [
      "minimal residual disease multiple myeloma prognosis",
      "MRD testing leukemia outcomes",
      "clonoSEQ clinical utility"
    ],
    "assistance_programs": [
      {
        "name": "Adaptive Assist Patient Support",
        "url": "https://www.clonoseq.com/adaptive-assist/",
        "description": "90% of patients have no out-of-pocket costs. Adaptive Assist helps with insurance navigation and financial assistance for qualified patients. Call 1-855-236-9230."
      }
    ],
    "advocacy_resources": [
      {
        "name": "Leukemia & Lymphoma Society",
        "url": "https://www.lls.org/",
        "description": "World's largest voluntary health agency dedicated to blood cancer research and patient support."
      },
      {
        "name": "International Myeloma Foundation",
        "url": "https://www.myeloma.org/",
        "description": "Largest organization focusing specifically on multiple myeloma research and patient education."
      }
    ]
  },
  "botox-denial": {
    "slug": "botox-denial",
    "title": "Appealing Botox (OnabotulinumtoxinA) Denials",
    "default_procedure": "Botox (onabotulinumtoxinA)",
    "tagline": "Help appealing denials for medical Botox treatment.",
    "hero_h1": "Appeal Your Botox Denial",
    "hero_subhead": "Don't let your insurer deny medically necessary Botox treatment.",
    "intro": "Botox (onabotulinumtoxinA) is FDA-approved for many medical conditions including chronic migraine, overactive bladder, cervical dystonia, spasticity, and hyperhidrosis. Insurance companies often deny Botox claiming it's cosmetic, even when prescribed for legitimate medical conditions. These denials can leave patients suffering from debilitating symptoms that Botox effectively treats.",
    "manufacturer": "AbbVie/Allergan",
    "common_denial_reasons": [
      "Deemed cosmetic procedure",
      "Prior authorization not obtained",
      "Step therapy requirements not met",
      "Diagnosis code mismatch",
      "Dosage not covered",
      "Frequency limits exceeded",
      "Not covered for this indication"
    ],
    "how_we_help": "We help you document your medical diagnosis, failed prior treatments, and how Botox is being used for an FDA-approved or medically necessary indication, not cosmetic purposes.",
    "cta": "Start your Botox appeal — it takes about 3 minutes.",
    "faq": [
      {
        "question": "What medical conditions is Botox approved for?",
        "answer": "FDA-approved indications include chronic migraine, cervical dystonia, upper and lower limb spasticity, overactive bladder, severe hyperhidrosis, blepharospasm, and strabismus, among others."
      },
      {
        "question": "My insurer says Botox is cosmetic. How do I fight this?",
        "answer": "Your appeal must clearly document that Botox is being used for a medical condition, not cosmetic purposes. Include your diagnosis, treatment history, and your physician's statement of medical necessity."
      },
      {
        "question": "What if I haven't tried other treatments first?",
        "answer": "Some insurers require step therapy. Your appeal should document any prior treatments tried and why they failed, or argue that Botox should be first-line based on clinical guidelines for your condition."
      }
    ],
    "evidence_snippets": [
      "OnabotulinumtoxinA significantly reduces chronic migraine frequency and severity.",
      "Botox is FDA-approved for multiple neurological and urological conditions.",
      "For chronic migraine, Botox reduced headache days by approximately 50% in clinical trials.",
      "Botox improves quality of life in patients with spasticity, dystonia, and overactive bladder."
    ],
    "pubmed_search_terms": [
      "onabotulinumtoxinA chronic migraine efficacy",
      "botulinum toxin spasticity outcomes",
      "botox overactive bladder treatment"
    ],
    "assistance_programs": [
      {
        "name": "Allergan BOTOX Savings Program",
        "url": "https://www.botoxsavingsprogram.com/",
        "description": "Eligible commercially insured patients may pay as little as $0 per treatment. Savings limits apply."
      }
    ],
    "advocacy_resources": [
      {
        "name": "American Migraine Foundation",
        "url": "https://americanmigrainefoundation.org/",
        "description": "Resources for Botox coverage for chronic migraine."
      },
      {
        "name": "Dystonia Medical Research Foundation",
        "url": "https://dystonia-foundation.org/",
        "description": "Leading organization for dystonia research and patient support."
      }
    ]
  },
  "breast-reduction-denial": {
    "slug": "breast-reduction-denial",
    "title": "Appealing Breast Reduction Denials",
    "default_procedure": "Breast Reduction (Reduction Mammaplasty)",
    "tagline": "Help appealing denials for medically necessary breast reduction surgery.",
    "hero_h1": "Appeal Your Breast Reduction Denial",
    "hero_subhead": "Don't let your insurer dismiss your chronic pain as cosmetic.",
    "intro": "Breast reduction surgery is medically necessary for many patients suffering from chronic neck pain, back pain, shoulder grooving from bra straps, rashes, and nerve symptoms caused by macromastia (excessively large breasts). Insurance companies often deny these claims as cosmetic, despite the significant physical symptoms and functional limitations these patients experience.",
    "common_denial_reasons": [
      "Deemed cosmetic surgery",
      "Does not meet gram weight requirements",
      "BMI too high for surgery",
      "Insufficient documentation of symptoms",
      "Conservative treatment not tried",
      "Physical therapy not completed",
      "Prior authorization not obtained"
    ],
    "how_we_help": "We help you document your physical symptoms, functional limitations, failed conservative treatments, and the weight of tissue to be removed according to your insurer's criteria.",
    "cta": "Start your breast reduction appeal — it takes about 3 minutes.",
    "faq": [
      {
        "question": "What gram weight requirements do insurers typically have?",
        "answer": "Most insurers use the Schnur Sliding Scale or require removal of 300-500 grams per breast minimum. Requirements vary by body surface area. Your surgeon should calculate the anticipated tissue removal."
      },
      {
        "question": "What symptoms help prove medical necessity?",
        "answer": "Document chronic neck, back, and shoulder pain; shoulder grooving from bra straps; intertrigo (rashes under breasts); headaches; numbness or tingling in arms; and difficulty with physical activities."
      },
      {
        "question": "Does my BMI affect coverage?",
        "answer": "Some insurers require BMI under 30-35 for approval. If your BMI is higher, you may need to document that weight loss hasn't resolved symptoms or that losing weight is not medically feasible."
      }
    ],
    "evidence_snippets": [
      "Breast reduction surgery significantly reduces chronic pain in the neck, back, and shoulders.",
      "Patients report improved quality of life and ability to exercise after reduction mammaplasty.",
      "Conservative treatments including physical therapy, NSAIDs, and supportive bras often fail for macromastia.",
      "Breast reduction is a well-established treatment for symptomatic macromastia with high satisfaction rates."
    ],
    "pubmed_search_terms": [
      "breast reduction chronic pain outcomes",
      "reduction mammaplasty quality of life",
      "macromastia conservative treatment failure"
    ]
  },
  "cardiovascular-risk-panel-denial": {
    "slug": "cardiovascular-risk-panel-denial",
    "title": "Appealing Cardiovascular Risk Panel Denials",
    "default_procedure": "Advanced Cardiovascular Risk Panel",
    "default_condition": "Cardiovascular Disease Risk",
    "tagline": "Help appealing denials for advanced cardiac risk testing.",
    "hero_h1": "Appeal Your Cardiovascular Panel Denial",
    "hero_subhead": "Don't let your insurer deny tests that could predict heart disease.",
    "intro": "Advanced cardiovascular risk panels include tests like apolipoprotein measurements, Lp(a), high-sensitivity CRP, and advanced lipid panels that go beyond basic cholesterol testing. These tests help identify patients at higher risk for heart attack and stroke who may benefit from more aggressive treatment. Insurance companies sometimes deny these as experimental or unnecessary.",
    "common_denial_reasons": [
      "Standard lipid panel sufficient",
      "Test deemed experimental",
      "Not medically necessary",
      "No family history documented",
      "No prior cardiovascular event",
      "Lab not in network",
      "Duplicate testing"
    ],
    "how_we_help": "We help you document your cardiovascular risk factors, family history, and why advanced testing beyond standard lipid panels is necessary to guide your treatment.",
    "cta": "Start your cardiovascular panel appeal — it takes about 3 minutes.",
    "faq": [
      {
        "question": "What tests are included in advanced cardiovascular panels?",
        "answer": "Tests may include Lp(a), apolipoprotein B, high-sensitivity CRP, LDL particle number, homocysteine, and coronary artery calcium scoring, depending on the panel ordered."
      },
      {
        "question": "When are advanced panels appropriate?",
        "answer": "Advanced testing is appropriate for patients with family history of premature heart disease, borderline risk on standard tests, or patients whose standard lipid panels don't explain their risk level."
      },
      {
        "question": "Is Lp(a) testing covered by insurance?",
        "answer": "Coverage varies. Recent guidelines from major cardiology organizations recommend Lp(a) testing at least once, which can support appeals. High Lp(a) identifies patients who may benefit from more aggressive treatment."
      }
    ],
    "evidence_snippets": [
      "Lp(a) is an independent risk factor for cardiovascular disease not captured by standard lipid testing.",
      "Advanced lipid testing can reclassify patient risk and guide statin therapy decisions.",
      "Family history of premature cardiovascular disease warrants additional risk assessment.",
      "Apolipoprotein B may be a better predictor of cardiovascular risk than LDL cholesterol alone."
    ],
    "pubmed_search_terms": [
      "Lp(a) cardiovascular risk prediction",
      "advanced lipid panel clinical utility",
      "apolipoprotein B cardiovascular outcomes"
    ],
    "advocacy_resources": [
      {
        "name": "American Heart Association",
        "url": "https://www.heart.org/",
        "description": "Leading nonprofit fighting heart disease and stroke through education and advocacy."
      },
      {
        "name": "FH Foundation",
        "url": "https://thefhfoundation.org/",
        "description": "Advocacy organization for familial hypercholesterolemia awareness and testing."
      }
    ]
  },
  "breast-augmentation-trans-denial": {
    "slug": "breast-augmentation-trans-denial",
    "title": "Appealing Breast Augmentation Denials for Transgender Patients",
    "default_procedure": "Breast Augmentation",
    "default_condition": "Gender Dysphoria",
    "tagline": "Help appealing denials for gender-affirming breast augmentation.",
    "hero_h1": "Appeal Your Breast Augmentation Denial",
    "hero_subhead": "Don't let your insurer deny this medically necessary gender-affirming procedure.",
    "intro": "Breast augmentation for transgender women is a recognized treatment for gender dysphoria when hormone therapy has not produced sufficient breast development. Major medical organizations including WPATH recognize this as medically necessary care, not cosmetic surgery. Insurance denials often incorrectly classify this as cosmetic despite the gender dysphoria diagnosis.",
    "common_denial_reasons": [
      "Deemed cosmetic surgery",
      "Considered experimental",
      "Insufficient hormone therapy duration",
      "Breast development from hormones not documented",
      "Mental health evaluation not completed",
      "Prior authorization requirements",
      "Out-of-network surgeon"
    ],
    "how_we_help": "We help you document your gender dysphoria diagnosis, hormone therapy history, inadequate breast development on hormones, and how this surgery is medically necessary per WPATH guidelines.",
    "cta": "Start your breast augmentation appeal — it takes about 3 minutes.",
    "faq": [
      {
        "question": "When is breast augmentation considered medically necessary?",
        "answer": "WPATH recommends breast augmentation be considered after a minimum of 12 months of hormone therapy if breast growth is insufficient to alleviate gender dysphoria."
      },
      {
        "question": "What documentation do I need for an appeal?",
        "answer": "Key documents include your gender dysphoria diagnosis, hormone therapy records showing duration and breast development, mental health evaluation, and surgeon's letter of medical necessity."
      },
      {
        "question": "How do I prove breast development is insufficient?",
        "answer": "Your surgeon or endocrinologist can document breast measurements and compare them to expectations after hormone therapy. Photos may also be used to document current breast size."
      }
    ],
    "evidence_snippets": [
      "Hormone therapy typically produces Tanner stage 2-3 breast development, which may be insufficient for some patients.",
      "Breast augmentation significantly reduces chest dysphoria in transgender women.",
      "WPATH Standards of Care recognize breast augmentation as medically necessary when hormone therapy is inadequate.",
      "Gender-affirming surgeries improve mental health outcomes and quality of life."
    ],
    "pubmed_search_terms": [
      "breast augmentation transgender outcomes",
      "gender-affirming surgery quality of life",
      "hormone therapy breast development transgender"
    ],
    "advocacy_resources": [
      {
        "name": "National Center for Transgender Equality",
        "url": "https://transequality.org/",
        "description": "Nation's leading social justice advocacy organization for transgender people."
      },
      {
        "name": "Transgender Law Center",
        "url": "https://transgenderlawcenter.org/",
        "description": "Legal organization advocating for transgender rights and providing legal resources."
      },
      {
        "name": "WPATH",
        "url": "https://www.wpath.org/",
        "description": "World Professional Association for Transgender Health - promotes evidence-based care and standards."
      }
    ]
  },
  "breast-reconstruction-cancer-denial": {
    "slug": "breast-reconstruction-cancer-denial",
    "title": "Appealing Breast Reconstruction Denials After Cancer",
    "default_procedure": "Breast Reconstruction",
    "default_condition": "Breast Cancer",
    "tagline": "Help appealing denials for breast reconstruction after mastectomy.",
    "hero_h1": "Appeal Your Breast Reconstruction Denial",
    "hero_subhead": "Federal law protects your right to breast reconstruction after cancer surgery.",
    "intro": "Breast reconstruction after mastectomy is protected by the Women's Health and Cancer Rights Act (WHCRA), which requires group health plans that cover mastectomy to also cover reconstruction. Despite this federal protection, insurance companies still deny reconstruction procedures, second breast procedures for symmetry, and associated services. You have legal rights to this coverage.",
    "common_denial_reasons": [
      "Procedure deemed cosmetic",
      "Symmetry procedure not covered",
      "Type of reconstruction not approved",
      "Out-of-network surgeon",
      "Prior authorization requirements",
      "Revision surgery denied",
      "Nipple reconstruction denied"
    ],
    "how_we_help": "We help you cite the Women's Health and Cancer Rights Act and document that your reconstruction is a federally protected benefit that your insurer must cover.",
    "cta": "Start your breast reconstruction appeal — it takes about 3 minutes.",
    "faq": [
      {
        "question": "What does the Women's Health and Cancer Rights Act cover?",
        "answer": "WHCRA requires coverage of: reconstruction of the breast on which mastectomy was performed, surgery on the other breast for symmetry, prostheses, and treatment of physical complications at all stages of mastectomy including lymphedema."
      },
      {
        "question": "Can my insurer limit the type of reconstruction?",
        "answer": "WHCRA requires coverage of 'reconstruction of the breast' without specifying type. Your appeal can argue that the reconstruction method chosen by you and your surgeon should be covered."
      },
      {
        "question": "Is nipple reconstruction covered?",
        "answer": "Yes. Nipple reconstruction is considered part of breast reconstruction under WHCRA. If denied, your appeal should cite this federal requirement."
      }
    ],
    "evidence_snippets": [
      "The Women's Health and Cancer Rights Act requires insurance coverage of breast reconstruction after mastectomy.",
      "Breast reconstruction improves quality of life and psychological well-being after cancer surgery.",
      "WHCRA mandates coverage for symmetry procedures on the contralateral breast.",
      "Denying federally mandated breast reconstruction coverage violates federal law."
    ],
    "pubmed_search_terms": [
      "breast reconstruction quality of life",
      "mastectomy reconstruction outcomes",
      "WHCRA breast reconstruction coverage"
    ],
    "advocacy_resources": [
      {
        "name": "National Breast Cancer Coalition",
        "url": "https://www.stopbreastcancer.org/",
        "description": "Grassroots advocacy organization dedicated to ending breast cancer through research and policy."
      },
      {
        "name": "Susan G. Komen",
        "url": "https://www.komen.org/",
        "description": "Leading breast cancer organization funding research and providing patient support."
      }
    ]
  },
  "xphozah-denial": {
    "slug": "xphozah-denial",
    "title": "Appealing Xphozah (Tenapanor) Denials",
    "default_procedure": "Xphozah (tenapanor)",
    "default_condition": "Hyperphosphatemia in Chronic Kidney Disease",
    "tagline": "Help appealing denials for this phosphate absorption inhibitor.",
    "hero_h1": "Appeal Your Xphozah Denial",
    "hero_subhead": "Don't let your insurer deny access to this treatment for high phosphorus levels.",
    "intro": "Xphozah (tenapanor) is an FDA-approved medication for controlling serum phosphorus in adults with chronic kidney disease on dialysis. Unlike traditional phosphate binders, Xphozah works by blocking phosphate absorption in the gut. This offers an important option for patients who cannot adequately control phosphorus with binders alone or who experience side effects from binders.",
    "manufacturer": "Ardelyx",
    "common_denial_reasons": [
      "Must try phosphate binders first",
      "Not on formulary",
      "Prior authorization required",
      "Dose limits or quantity restrictions",
      "Medicare Part D coverage changes",
      "Cost-effectiveness criteria",
      "Inadequate documentation of binder failure"
    ],
    "how_we_help": "We help you document your phosphorus levels, why traditional phosphate binders have failed or are inadequate, and how Xphozah's unique mechanism of action addresses your needs.",
    "cta": "Start your Xphozah appeal — it takes about 3 minutes.",
    "faq": [
      {
        "question": "How is Xphozah different from phosphate binders?",
        "answer": "Unlike binders that bind phosphorus in food, Xphozah blocks phosphorus absorption in the intestinal lining. It can be used alone or with binders for additional phosphorus control."
      },
      {
        "question": "What if I've had side effects from binders?",
        "answer": "Document specific side effects like GI upset, pill burden, or drug interactions. Xphozah offers an alternative mechanism that may be better tolerated."
      },
      {
        "question": "Has Medicare coverage changed for Xphozah?",
        "answer": "Coverage policies have evolved. The ArdelyxAssist program can help navigate current coverage options and provide financial assistance for eligible patients."
      }
    ],
    "evidence_snippets": [
      "Tenapanor significantly reduces serum phosphorus levels in dialysis patients.",
      "Xphozah offers a novel mechanism distinct from phosphate binders for controlling hyperphosphatemia.",
      "Combination therapy with tenapanor and binders provides additional phosphorus reduction.",
      "Managing hyperphosphatemia reduces cardiovascular risk in chronic kidney disease patients."
    ],
    "pubmed_search_terms": [
      "tenapanor hyperphosphatemia dialysis",
      "phosphate control chronic kidney disease",
      "Xphozah phosphorus reduction efficacy"
    ],
    "assistance_programs": [
      {
        "name": "ArdelyxAssist Patient Support",
        "url": "https://xphozah.com/",
        "description": "ArdelyxAssist provides insurance navigation, copay assistance, and patient assistance for eligible patients. Call 877-527-3927."
      }
    ],
    "advocacy_resources": [
      {
        "name": "American Kidney Fund",
        "url": "https://www.kidneyfund.org/",
        "description": "Leading kidney nonprofit fighting kidney disease through patient services and advocacy."
      },
      {
        "name": "National Kidney Foundation",
        "url": "https://www.kidney.org/",
        "description": "75 years of impact in kidney health through advocacy, research, and education."
      }
    ]
  },
  "vasectomy-denial": {
    "slug": "vasectomy-denial",
    "title": "Appealing Vasectomy Denials",
    "default_procedure": "Vasectomy",
    "tagline": "Help appealing denials for permanent contraception coverage.",
    "hero_h1": "Appeal Your Vasectomy Denial",
    "hero_subhead": "Don't let your insurer deny this safe, effective contraception.",
    "intro": "Vasectomy is a safe, effective, and cost-effective form of permanent male contraception. While the ACA requires coverage of female contraception without cost-sharing, male contraception coverage varies by plan. Many insurers do cover vasectomy as a preventive service, and denials can often be successfully appealed.",
    "common_denial_reasons": [
      "Not covered under plan benefits",
      "Considered elective procedure",
      "Age or marital status requirements",
      "Prior authorization not obtained",
      "Out-of-network provider",
      "Plan exclusion for male sterilization",
      "Cooling-off period not completed"
    ],
    "how_we_help": "We help you document why vasectomy is a covered benefit under your plan and cite state laws or plan provisions that require contraception coverage.",
    "cta": "Start your vasectomy appeal — it takes about 3 minutes.",
    "faq": [
      {
        "question": "Does the ACA require vasectomy coverage?",
        "answer": "The ACA mandates coverage of FDA-approved contraceptive methods for women. Male contraception is not explicitly required, but many state laws and plan designs include vasectomy coverage."
      },
      {
        "question": "What if my plan specifically excludes vasectomy?",
        "answer": "Check your state laws, as some states mandate vasectomy coverage. Also review if your plan covers female sterilization, as arguments can be made for equal coverage."
      },
      {
        "question": "Do I need my spouse's consent for coverage?",
        "answer": "Spousal consent requirements are not legal in most states. If your insurer requires this, cite applicable state law prohibiting such requirements."
      }
    ],
    "evidence_snippets": [
      "Vasectomy is one of the safest and most effective forms of contraception.",
      "Vasectomy is more cost-effective than female sterilization and long-term contraception costs.",
      "Office-based vasectomy has low complication rates and quick recovery.",
      "Vasectomy prevents unintended pregnancy with over 99% effectiveness."
    ],
    "pubmed_search_terms": [
      "vasectomy safety efficacy",
      "male sterilization cost effectiveness",
      "vasectomy contraception outcomes"
    ],
    "advocacy_resources": [
      {
        "name": "Planned Parenthood",
        "url": "https://www.plannedparenthood.org/",
        "description": "Leading reproductive health organization advocating for contraception access."
      }
    ]
  },
  "sleeve-gastrectomy-denial": {
    "slug": "sleeve-gastrectomy-denial",
    "title": "Appealing Laparoscopic Sleeve Gastrectomy Denials",
    "default_procedure": "Laparoscopic Sleeve Gastrectomy",
    "default_condition": "Obesity",
    "tagline": "Help appealing denials for bariatric surgery coverage.",
    "hero_h1": "Appeal Your Sleeve Gastrectomy Denial",
    "hero_subhead": "Don't let your insurer deny access to life-changing weight loss surgery.",
    "intro": "Laparoscopic sleeve gastrectomy is a proven, effective bariatric surgery that removes approximately 80% of the stomach, promoting significant weight loss and resolution of obesity-related conditions. Insurance companies often deny this surgery with extensive requirements or claim it's not medically necessary, despite overwhelming evidence of its safety and effectiveness.",
    "common_denial_reasons": [
      "BMI does not meet threshold",
      "Insufficient documentation of obesity-related conditions",
      "Required diet program not completed",
      "Psychological evaluation not done",
      "Prior authorization not obtained",
      "Bariatric surgery excluded from plan",
      "Preferred procedure is different surgery"
    ],
    "how_we_help": "We help you document your BMI history, obesity-related comorbidities, failed weight loss attempts, and completion of pre-surgical requirements.",
    "cta": "Start your sleeve gastrectomy appeal — it takes about 3 minutes.",
    "faq": [
      {
        "question": "What BMI is typically required for coverage?",
        "answer": "Most insurers require BMI ≥40, or BMI ≥35 with obesity-related conditions like type 2 diabetes, sleep apnea, or hypertension. Some newer guidelines support surgery at lower BMIs with metabolic disease."
      },
      {
        "question": "What pre-surgical requirements are typical?",
        "answer": "Common requirements include 3-6 months of medically supervised diet, psychological evaluation, nutritional counseling, and documentation of failed weight loss attempts."
      },
      {
        "question": "What if my insurer prefers gastric bypass?",
        "answer": "Your surgeon's recommendation matters. Sleeve gastrectomy may be more appropriate for your specific situation. Document why your surgeon recommends this procedure for you."
      }
    ],
    "evidence_snippets": [
      "Sleeve gastrectomy produces significant, sustained weight loss with lower complication rates than some other bariatric procedures.",
      "Bariatric surgery leads to resolution or improvement of type 2 diabetes in the majority of patients.",
      "Weight loss surgery reduces mortality and improves quality of life in patients with severe obesity.",
      "Long-term studies show durable weight loss and metabolic improvements after sleeve gastrectomy."
    ],
    "pubmed_search_terms": [
      "sleeve gastrectomy outcomes weight loss",
      "bariatric surgery diabetes resolution",
      "laparoscopic sleeve gastrectomy safety efficacy"
    ],
    "advocacy_resources": [
      {
        "name": "Obesity Action Coalition",
        "url": "https://www.obesityaction.org/",
        "description": "National nonprofit empowering those affected by obesity through advocacy, education and support."
      }
    ]
  },
  "toenail-surgery-denial": {
    "slug": "toenail-surgery-denial",
    "title": "Appealing Toenail Surgery Denials",
    "default_procedure": "Toenail Surgery (Matrixectomy)",
    "tagline": "Help appealing denials for medically necessary toenail procedures.",
    "hero_h1": "Appeal Your Toenail Surgery Denial",
    "hero_subhead": "Don't let your insurer dismiss your painful nail condition as cosmetic.",
    "intro": "Toenail surgery, including partial or total nail removal and matrixectomy, is medically necessary for conditions like chronic ingrown toenails, fungal nail infections unresponsive to medication, and nail deformities causing pain or recurrent infections. Insurance companies often deny these procedures as cosmetic, ignoring the pain, infection risk, and functional limitations they cause.",
    "common_denial_reasons": [
      "Deemed cosmetic procedure",
      "Conservative treatment not tried",
      "Nail fungus excluded from coverage",
      "Prior authorization not obtained",
      "In-office procedure not covered",
      "Podiatrist not covered provider",
      "Frequency limits on nail procedures"
    ],
    "how_we_help": "We help you document your nail condition, pain levels, failed conservative treatments, infection history, and functional impact to prove medical necessity.",
    "cta": "Start your toenail surgery appeal — it takes about 3 minutes.",
    "faq": [
      {
        "question": "When is toenail surgery medically necessary?",
        "answer": "Surgery is medically necessary for recurrent ingrown toenails causing pain or infection, fungal nails unresponsive to oral antifungals, traumatic nail damage, or nail conditions affecting walking or causing repeated infections."
      },
      {
        "question": "What if I have diabetes?",
        "answer": "For diabetic patients, nail problems pose serious infection risks and can lead to complications. This increases medical necessity and should be emphasized in your appeal."
      },
      {
        "question": "Does my insurer have to cover nail fungus treatment?",
        "answer": "Some plans exclude onychomycosis treatment, but if the fungal nail is causing pain, secondary bacterial infections, or affecting mobility, you can argue it's medically necessary beyond cosmetic concerns."
      }
    ],
    "evidence_snippets": [
      "Chronic ingrown toenails cause significant pain and can lead to serious infections if untreated.",
      "Matrixectomy provides permanent resolution of recurrent ingrown toenails.",
      "Diabetic patients with nail disorders are at increased risk for infections and ulceration.",
      "Surgical treatment of problematic toenails improves mobility and quality of life."
    ],
    "pubmed_search_terms": [
      "ingrown toenail surgical treatment outcomes",
      "matrixectomy recurrence rates",
      "onychomycosis surgical management"
    ]
  },
  "dexa-scan-denial": {
    "slug": "dexa-scan-denial",
    "title": "Appealing DEXA Scan Denials",
    "default_procedure": "DEXA Bone Density Scan",
    "default_condition": "Osteoporosis Risk",
    "tagline": "Help appealing denials for bone density screening.",
    "hero_h1": "Appeal Your DEXA Scan Denial",
    "hero_subhead": "Don't let your insurer deny this important osteoporosis screening.",
    "intro": "DEXA (Dual-Energy X-ray Absorptiometry) scans measure bone density and are the gold standard for diagnosing osteoporosis and assessing fracture risk. Medicare covers DEXA scans every 2 years for eligible beneficiaries, and preventive guidelines recommend screening for women 65+ and younger individuals with risk factors. Insurance denials often cite timing or medical necessity.",
    "common_denial_reasons": [
      "Too soon since last scan",
      "Age does not meet screening criteria",
      "No documented risk factors",
      "Prior authorization required",
      "Facility not covered",
      "Diagnosis code issues",
      "Not preventive—diagnostic frequency limits"
    ],
    "how_we_help": "We help you document your osteoporosis risk factors, fracture history, medication use, and why screening or monitoring is medically necessary at this time.",
    "cta": "Start your DEXA scan appeal — it takes about 3 minutes.",
    "faq": [
      {
        "question": "Who should get DEXA screening?",
        "answer": "Guidelines recommend screening for women 65+, men 70+, and younger adults with risk factors such as fractures, steroid use, low body weight, family history, or conditions that affect bone health."
      },
      {
        "question": "How often should DEXA scans be done?",
        "answer": "Screening every 2 years is typical. More frequent scans may be appropriate if you're on osteoporosis treatment, have had fractures, or have conditions requiring closer monitoring."
      },
      {
        "question": "What if I need a scan sooner than 2 years?",
        "answer": "Document clinical reasons such as new fracture, starting or changing osteoporosis treatment, or new risk factors. Your doctor can support earlier scanning based on medical necessity."
      }
    ],
    "evidence_snippets": [
      "DEXA scanning is the gold standard for diagnosing osteoporosis and predicting fracture risk.",
      "Early detection of low bone density allows treatment before fractures occur.",
      "USPSTF recommends bone density screening for women 65 and older.",
      "Monitoring bone density during osteoporosis treatment helps assess therapy effectiveness."
    ],
    "pubmed_search_terms": [
      "DEXA bone density screening recommendations",
      "osteoporosis screening fracture prevention",
      "bone densitometry clinical utility"
    ],
    "advocacy_resources": [
      {
        "name": "Bone Health & Osteoporosis Foundation",
        "url": "https://www.bonehealthandosteoporosis.org/",
        "description": "40 years of commitment to preventing osteoporosis through education and advocacy."
      }
    ]
  }
}